

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number  
**WO 01/64238 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 38/17, 31/472, 31/496, 31/553, 31/7076, 48/00, A61P 19/00, 35/00**

Penzberg (DE). **BURTSCHER, Helmut** [US/US]; Am Aehrenanger 10, 82392 Habach (DE).

(21) International Application Number: **PCT/US01/06450**

(74) Agents: **QUISEL, John, Q.** et al.; Patent Group, Foley, Hoag & Eliot LLP, One Post Office Square, Boston, MA 02109 (US).

(22) International Filing Date: 28 February 2001 (28.02.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/186,058 29 February 2000 (29.02.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/186,058 (CIP)  
Filed on 29 February 2000 (29.02.2000)

Published:  
— without international search report and to be republished upon receipt of that report

(71) Applicant (for all designated States except US): **CURIS, INC.** [US/US]; 45 Moulton Street, Cambridge, MA 02138 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZEHENTNER, Barbara** [DE/DE], Bachstrasse 8, 84174 Viecht (DE). **LESER-REIFF, Ulrike** [DE/DE]; Weidenweg 6, 82377



**WO 01/64238 A2**

(54) Title: METHODS AND COMPOSITIONS FOR REGULATING ADIPOCYTES

(57) Abstract: The present application relates to a method for modulating the formation and/or maintenance of adipocyte tissue by ectopically contacting adipocyte cells, especially adipocyte stem/progenitor cells, *in vitro* or *in vivo*, with a hedgehog therapeutic or ptc therapeutic in an amount effective to alter the growth state of the treated cells, e.g., relative to the absence of administration of the hedgehog therapeutic or ptc therapeutic.

*Methods and Compositions for Regulating Adipocytes***Background of the Invention**

Adipocytes are highly specialized cells that play a critical role in energy and homeostasis. Their primary role is to store triglycerides in times of caloric excess and to mobilize this reserver during periods of nutritional deprivation. Adipocytes are derived from a multipotent stem cell of mesodermal origin that also gives rise to the adipocyte and cartilage lineages. Adipocyte differentiation is characterized by a coordinate increase in adipocyte-specific gene expression.

Recent years have seen important advances in our understanding of the molecular basis of adipocyte differentiation. (reviewed in Cornelius, P. et al. (1994) *Annu. Rev. Nutr.* 14:99-129; Tontonoz, P. et al. (1995) *Curr. Opin. Genet. Dev.* 5:571-576. A number of transcription factors are induced in fat cell differentiation (C/EBP $\alpha$ , C/EBP $\beta$  and ADD1/SREBP1) and influence this process to a certain extent (Freytag, S.O. et al. (1994) *Genes Dev.* 8:1654-63; Kim, J.B. and Spiegelman, B.M. (1996) *Genes Dev.* 10:1096-1107; Lin, F.T. and Lane, M.D. (1994) *PNAS USA* 91:8757-61; Samuelsson, L. et al. (1991) *EMBO J.* 10:3787-93; Tontonoz, P. et al. (1993) *Mol Cell Biol* 13:4753-9; Umek, R.M. et al. (1991) *Science* 251:288-92; Wu, C.L. et al. (1995) *Mol Cell Biol* 15:253646; Yeh, W.C. et al. (1995) *Genes Dev.* 9:168-81).

The peroxisome proliferator-activated receptors, or "PPAR", are members of the type II class of steroid/thyroid superfamily of receptors and which mediate the pleiotropic effects of peroxisome proliferators. Type II class of nuclear receptors includes PPAR, the thyroid hormone receptor (T<sub>3</sub>R), and the vitamin D<sub>3</sub> receptor (VD<sub>3</sub>R). Type II receptors are functionally distinct from the classical steroid receptors, such as the glucocorticoid receptor, the progesterone receptor and the estrogen receptor (reviewed in Stunnenberg, H.G. (1993) *BioEssays* Vol. 15 (5): 309-15. Three properties distinguish these two classes. Firstly, type II receptors are able to bind to their responsive elements in the absence of ligand (Damm et al. (1989) *Nature* 339:593-597; Sap et al., *Nature* 340:242-244; De The et al. (1990) *Nature* 343:177-180), whereas ligand binding is required to dissociate to the type I receptor-hsp 90 complex and hence indirectly governs DNA binding. Secondly, type II

-2-

receptors bind and transactivate through responsive elements that are composed of half-sites arranged as direct repeats, as opposed to palindromically arranged half-sites invariably separated by three nucleotides required by type I receptors. Finally, type II receptors do not bind to their respective binding site as homodimers but require an auxiliary factor, RXR

5 (e.g., RXR $\alpha$ , RXR $\beta$ , RXR $\gamma$ ) for high affinity binding (Yu et al. (1991) *Cell* 67:1251-1266; Bugge et al. (1992) *EMBO J.* 11:1409-1418; Kliewer et al. (1992) *Nature* 355:446-449; Leid et al. (1992) *Cell* 68:377-395; Marks et al. (1992) *EMBO J.* 11:1419-1435; Zhang et al. (1992) *Nature* 355:441-446). The interaction between type II receptors requires a region in the C-terminal domain (Yu et al. (1991) *Cell* 67:1251-1266; Kliewer et al. (1992)

10 *Nature* 355:446-449; Leid et al. (1992) *Cell* 68:377-395; Marks et al. (1992) *EMBO J.* 11:1419-1435). Following binding, the transcriptional activity of a target gene (i.e., a gene associated with the specific DNA sequence) is enhanced as a function of the ligand bound to the receptor heterodimer.

15 **Summary of the Invention**

One aspect of the present application relates to a method for regulating the formation and/or maintenance of adipocyte tissue by ectopically contacting adipocyte cells, especially adipocyte stem/progenitor cells, *in vitro* or *in vivo*, with a hedgehog therapeutic or ptc therapeutic in an amount effective to alter the growth state the treated cells, e.g.,

20 relative to the absence of administration of the hedgehog therapeutic or ptc therapeutic.

Wherein the subject method is carried out using a *hedgehog* therapeutic, the *hedgehog* therapeutic preferably a polypeptide including a *hedgehog* portion comprising at least a bioactive extracellular portion of a *hedgehog* protein, e.g., the *hedgehog* portion includes at least 50, 100 or 150 (contiguous) amino acid residues of an N-terminal half of a

25 *hedgehog* protein. In preferred embodiments, the *hedgehog* portion includes at least a portion of the *hedgehog* protein corresponding to a 19kd fragment of the extracellular domain of a *hedgehog* protein.

In preferred embodiments, the *hedgehog* portion has an amino acid sequence at least 60, 75, 85, or 95 percent identical with a hedgehog protein of any of SEQ ID Nos. 10-18 or

30 20, though sequences identical to those sequence listing entries are also contemplated as useful in the present method. The *hedgehog* portion can be encoded by a nucleic acid

which hybridizes under stringent conditions to a nucleic acid sequence of any of SEQ ID Nos. 1-9 or 19, e.g., the *hedgehog* portion can be encoded by a vertebrate *hedgehog* gene, especially a human *hedgehog* gene.

In other embodiments, the subject method can be carried out by administering a 5 gene activation construct, wherein the gene activation construct is designed to recombine with a genomic *hedgehog* gene of the patient to provide a heterologous transcriptional regulatory sequence operatively linked to a coding sequence of the *hedgehog* gene.

In still other embodiments, the subject method can be practiced with the 10 administration of a gene therapy construct encoding a *hedgehog* polypeptide. For instance, the gene therapy construct can be provided in a composition selected from a group 15 consisting of a recombinant viral particle, a liposome, and a poly-cationic nucleic acid binding agent,


In yet other embodiments, the subject method can be carried out using a ptc 20 therapeutic. An exemplary ptc therapeutic is a small organic molecule which binds to a *patched* protein and derepresses *patched*-mediated inhibition of mitosis, e.g., a molecule 25 which binds to *patched* and mimics *hedgehog*-mediated *patched* signal transduction, which binds to *patched* and regulates *patched*-dependent gene expression. For instance, the binding of the ptc therapeutic to *patched* may result in upregulation of *patched* and/or *gli* expression.

In a more generic sense, the ptc therapeutic can be a small organic molecule which 20 interacts with adipocyte cells to induce *hedgehog*-mediated *patched* signal transduction, such as by altering the localization, protein-protein binding and/or enzymatic activity of an 25 intracellular protein involved in a *patched* signal pathway. For instance, the ptc therapeutic may alter the level of expression of a *hedgehog* protein, a *patched* protein or a protein involved in the intracellular signal transduction pathway of *patched*.

In certain embodiments, the ptc therapeutic is an antisense construct which inhibits 30 the expression of a protein which is involved in the signal transduction pathway of *patched* and the expression of which antagonizes *hedgehog*-mediated signals. The antisense construct is preferably an oligonucleotide of about 20-30 nucleotides in length and having a GC content of at least 50 percent.

-4-

In other embodiments, the *ptc* therapeutic is an inhibitor of protein kinase A (PKA), such as a 5-isoquinolinesulfonamide. The PKA inhibitor can be a cyclic AMP analog. Exemplary PKA inhibitors include N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, 1-(5-isoquinoline-sulfonyl)-2-methylpiperazine, KT5720, 8-bromo-cAMP, dibutyryl-cAMP and PKA Heat Stable Inhibitor isoform . Another exemplary PKA inhibitor is represented in the general formula:



wherein,

R<sub>1</sub> and R<sub>2</sub> each can independently represent hydrogen, and as valence and stability permit a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-OH, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-SH, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, or

R<sub>1</sub> and R<sub>2</sub> taken together with N form a heterocycle (substituted or unsubstituted);

R<sub>3</sub> is absent or represents one or more substitutions to the isoquinoline ring such as a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-OH, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-SH, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>;

R<sub>8</sub> represents a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle; and

n and m are independently for each occurrence zero or an integer in the range of 1 to 6.

***Brief Description of the Drawings***

5 **FIG. 1.** PPAR- $\gamma$ , aP2, gli and ptc expression in C3H10T1/2 cells. The PCR fragments of the standard vector (b) and the cell mRNA (a) were separated by agarose gels. Two types of experiment were performed: samples 1 are derived from 72 h induction without serum and samples 2 from 11 d with serum. Each experiment consists of a control (0), the BMP-2 treated (1), Shh treated (2), and the combination of Shh and BMP-2 (3) 10 treated sample. The charts show the relative expression levels resulting from three independent measurements, normalized with their actin content, for BMP-2 (■), Shh (□), and BMP-2 plus Shh (△) treated cells. The bold base line at a expression level of one is equivalent to the expression level of the control sample.

15 **FIG. 2.** Oil Red O staining of C3H10T1/2 cells. Cells were cultured for 11 d with FCS and then cytologically stained with Oil Red O (see Material and Methods). Lipid filled vesicles appear red in the cytosol of adipocyte-like cells. Pictures with 10-fold magnification show the untreated cells as a control (A), cells treated with BMP-2 (B), cells treated with Shh (C), and cells treated with Shh and BMP-2 simultaneously (D).

20 ***Detailed Description of the Invention***

*I. Overview*

Skeletal tissue is composed of various types of mesenchymal cells, like osteoblasts, chondrocytes, and adipocytes. These cells originate from common pluripotent progenitors, known as mesenchymal stem cells (Bruder *et al.*, 1994). A cell system with comparable 25 multipotentiality is the mouse embryonic fibroblastic cell line C3H10T1/2, capable of *in vitro* myogenesis, osteogenesis, chondrogenesis and adipogenesis. Bone morphogenic protein-2 (BMP-2) is an important signaling protein that influences maturation of mesenchymal cells. It has been shown to cause differentiation of C3H10T1/2 cells into adipocytes, chondrocytes and osteoblasts (Ahrens *et al.*, 1993, Wang *et al.*, 1993). Bone 30 morphogenic proteins, originally isolated from bone, are part of the transforming growth

factor- $\beta$  (TGF- $\beta$ ) superfamily (Kawabata *et al.*, 1998) and consist of at least 15 molecules. Several BMPs are able to induce ectopic bone formation (Wang *et al.*, 1988).

During embryonic development BMP-2 is secreted in the mesoderm and apical ectodermal ridge of the mouse limb in response to Sonic Hedgehog (Shh) (Laufer *et al.*, 1994) pointing to BMP-2 as a downstream target of Shh. Recent results indicate that Shh is able to induce ectopic bone formation in a similar manner as BMP-2 (Kinto *et al.*, 1997). BMP-2 and Shh are able to stimulate alkaline phosphatase activity (Katagiri *et al.*, 1990, Nakamura *et al.*, 1997), a marker indicating osteogenesis, in C3H10T1/2 cells.

Since parallels between Shh and BMP-2 have only been reported for osteogenic differentiation, our aim was to investigate if Shh also influences adipogenesis like BMP-2. We determined the adipocyte-like phenotype of C3H10T1/2 cells by staining lipid vesicles in the cytosol with Oil Red O. Quantitative RT-PCR was used to monitor the expression of adipocytic marker genes, PPAR- $\gamma$  and aP2, and of the hedgehog responsive genes, gli and patched. Gli and Patched (Ptc) are important components of the hedgehog signaling pathway. Gli is the first of three identified vertebrate homologs (Gli, Gli2, Gli3) of the Drosophila zincfinger transcription factor cubitus interruptus (Ci). Gli, like Ci, is involved in the hedgehog signaling pathway and activates ptc transcription (Platt *et al.*, 1997). Patched is a hedgehog receptor and by itself a transcriptional target of hedgehog (Marigo *et al.*, 1996). Peroxisome proliferator activated receptor  $\gamma$ , PPAR- $\gamma$ , is a steroid hormone receptor expressed in adipose tissue, activated by fatty acids. PPAR- $\gamma$  is sufficient to activate the adipocyte-specific enhancer in nonadipocyte cell lines (Elbrecht *et al.*, 1996, Tontonoz *et al.*, 1994). Adipocyte protein 2 (aP2) is an intracellular lipid carrier protein and its expression indicates late stages of the adipocytic differentiation (Matarese and Bernlohr, 1988).

By measuring the expression level of these four marker genes the molecular status of the cells can be determined regarding adipocytic differentiation and stimulation of the hedgehog signaling cascade. In this study we demonstrate that BMP-2 and Shh have contrary effects regarding adipogenesis and that Shh can even counteract BMP-2 stimulation.

As described in more detail below, we monitored adipocytic differentiation in C3H10T1/2 cells by expression studies and cytological staining and demonstrated that

Sonic Hedgehog inhibits the adipogenic potential of BMP-2. BMP-2 stimulated the upregulation of two adipocyte markers, PPAR- $\gamma$  and aP2, in C3H10T1/2 cells measured as early as 72 h under serumfree conditions and as late as 11 d in the presence of 10% FCS. An induction period of 11 d was necessary for detection of a significant percentage of 5 adipocyte-like cells by Oil Red O staining. In contrast to BMP-2, Sonic hedgehog, a postulated downstream target, inhibited adipocyte-like differentiation. Shh by itself and in combination with BMP-2 did neither upregulate the expression of adipocytic marker genes nor induce the maturation into adipose cells filled with lipid vesicles stainable by Oil Red O.

10 Since serum has been reported to influence adipogenesis (Diascro *et al.*, 1998) serum and a long culture might cause adipogenesis in our cell system. However, even after only 72 h of serumfree culture BMP-2 was able to stimulate the expression of the two adipocytic marker genes PPAR- $\gamma$  and aP2. Since no fat-like cells could be detected by Oil Red O staining at this time point, an explanation could be that it takes much longer for the 15 appearance of a mature adipocyte-like cell phenotype than it takes for adipocyte specific messages to be upregulated. In order to cultivate C3H10T1/2 cells for longer than 72 h, serum supplement is mandatory and therefore a long term experiment without FCS was not feasible. The expression of adipocytic markers was slightly stimulated by serum (Figure 1A and B, samples 2.0 compared to samples 1.0). But there has been no detection of fat cells 20 by Oil Red O staining, whereas BMP-2 treatment caused the appearance of a significant amount of mature adipocytes.

Recent data of our lab showed that C3H10T1/2 cells treated with BMP-2 express a chondrocytic expression profile after 24 h, whereas the osteoblastic marker osteocalcin is induced after 72 h (Zehentner *et al.*, 1999). It can be concluded, that adipocytic genes are 25 switched on by BMP-2 simultanously with chondro- and osteoblastic markers during the first three days of treatment. Treatment for a longer period of time then leads to maturation into adipocyte like cells.

Besides monitoring the effect of BMP-2 on adipogenesis, we focused on the influence of Sonic hedgehog protein. The expression of the hedgehog downstream targets 30 gli and ptc was upregulated by Shh at each time tested pointing to functional Shh signaling in our cell system. The combination of Shh and BMP-2 also caused ptc and gli mRNA

upregulation, but interestingly gli expression was increased synergistically. BMP-2 by itself already upregulated gli expression 3-fold in the 72 h experiment. In combination with Shh the relative expression level of gli was stimulated about 6- to 10-fold. A positive feedback loop of BMP-2 to Shh signaling could be the reason for this synergistic effect.

5 After 11 d of BMP-2 treatment and the acquirement of a mature adipocyte-like cell phenotype, BMP-2 did not influence the expression of the transcription factor gli anymore. In contrast to 72 h the final commitment after 11 d to the adipocytic lineage could be a reason for a different gli response. Hence after suppression of adipocytic maturation by Shh co-treatment, BMP-2 again could cause increase of gli expression after 11 d in comparison  
10 to Shh alone (Figure C, sample 2.3).

We could demonstrate in this study that Shh suppresses the adipocytic phenotype and acts antagonistic to BMP-2. Whereas BMP-2 induces adipogenesis, co-treatment with Sonic hedgehog could inhibit the upregulation of adipocytic gene expression and the maturation into lipid vesicle filled adipose cells. Shh alone did not change the expression of  
15 adipocyte marker genes after 72 h of treatment and it even caused their downregulation in the long-term culture with FCS. The reason for this could be that FCS by itself slightly upregulates adipocytic differentiation which is in turn suppressed by Shh .

An explanation for contrary effects could be that Shh and BMP-2 are able to stimulate different transduction pathways besides their common signaling. With the use of  
20 specific signaling Shh could be able to keep cells in a more undifferentiated state preventing them from maturing towards fat cells. Closer insights into Shh and BMP-2 signaling have to be gained in order to reveal the origin for different mechanisms how to influence cell differentiation. With our work we made a first step to unravel differences between Shh and BMP-2 signaling by demonstrating their contrary effects regarding  
25 adipogenesis.

Certain aspects of the invention are directed to a preparations of hedgehog polypeptides, or other molecules which regulate *patched* or *smoothened* signalling, and their uses in regulate adipocyte growth or differentiation in mammals. In particular embodiments, the invention is directed to the use of *hedgehog* polypeptides, as well as  
30 agonist and antagonists thereof, to regulate adipocyte growth and differentiation.

As described in the appended examples, *hedgehog* proteins are implicated in the proliferation and/or differentiation of adipocytic cells and may provide early signals that regulate the differentiation of these or other precursor (stem) cells into adipose tissues. In general, the method of the present invention comprises contacting pre-adipocyte cells (e.g., 5 adipocyte stem cells), and adipocytic or other differentiated adipocyte cells, with an amount of a hedgehog therapeutic (defined *infra*) which produces a non-toxic response by the cell of either (i) inhibition of adipocyte tissue formation or maintenance of existing adipocyte tissue, or (ii) induction of adipocyte tissue formation, depending on the whether the hedgehog therapeutic is a sufficient hedgehog agonist or hedgehog antagonist. The 10 subject method can be carried out on adipocyte cells which may be either dispersed in culture or a part of an intact tissue or organ. Moreover, the method can be performed on cells which are provided in culture (*in vitro*), or on cells in a whole animal (*in vivo*).

In one aspect, the present invention provides pharmaceutical preparations and methods for controlling the formation of adipocytic-derived tissue utilizing, as an active 15 ingredient, a *hedgehog* polypeptide or a mimetic thereof. The invention also relates to methods of controlling the functional performance of an adipocyte-derived tissue by use of the pharmaceutical preparations of the invention.

The *hedgehog* formulations of the present invention may be used as part of regimens in the treatment or prevention of disorders of, or surgical or cosmetic repair of, 20 such adipocyte tissues.

In certain embodiments, the subject compositions can be used to inhibit, rather than promote, growth of adipocytic-derived tissue. For instance, certain of the compositions disclosed herein may be applied to the treatment or prevention of a variety hyperplastic or neoplastic conditions affecting adipocyte tissue. The method can find application for the 25 treatment or prophylaxis of, e.g., soft tissue tumors, especially adipose cell tumors, e.g., lipomas, fibrolipomas, lipoblastomas, lipomatosis, hibernomas, hemangiomas and/or liposarcomas.

The subject *hedgehog* treatments are effective on both human and animal subjects afflicted with these conditions. Animal subjects to which the invention is applicable extend 30 to both domestic animals and livestock, raised either as pets or for commercial purposes.

Examples are dogs, cats, cattle, horses, sheep, hogs and goats.

-10-

Still another aspect of the present invention provides a method of regulating the growth and differentiation of adipocyte cells and tissues in culture.

Without wishing to be bound by any particular theory, the effect of native hedgehog proteins on the regulation of adipocyte differentiation may be due at least in part to the 5 ability of these proteins to antagonize (directly or indirectly) *patched*-mediated regulation of gene expression and other physiological effects mediated by that protein. The *patched* gene product, a cell surface protein, is understood to signal through a pathway which causes transcriptional repression of members of the Wnt and Dpp/BMP families of morphogens, proteins which impart positional information. In development of the CNS and patterning of 10 limbs in vertebrates, the introduction of *hedgehog* relieves (derepresses) this inhibition conferred by *patched*, allowing expression of particular gene programs.

Recently, it has been reported that mutations in the human version of *patched*, a gene first identified in a fruit fly developmental pathway, cause a hereditary skin cancer and may contribute to sporadic skin cancers. See, for example, Hahn et al. (1996) *Cell* 86:841-15 851; and Johnson et al. (1996) *Science* 272:1668-1671. The demonstration that nevoid basal-cell carcinoma (NBCC) results from mutations in the human *patched* gene provided an example of the roles *patched* plays in post-embryonic development. These observations have led the art to understand one activity of *patched* to be a tumor suppressor gene, which may act by inhibiting proliferative signals from *hedgehog*. Our observations set forth 20 below reveal potential new roles for the *hedgehog/patched* pathway in maintenance of adipocyte cell proliferation and differentiation. Accordingly, the present invention contemplates the use of other agents which are capable of mimicking the effect of the *hedgehog* protein on *patched* signalling, e.g., as may be identified from the drug screening assays described below.

25

## *II. Definitions*

For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

The term "hedgehog therapeutic" refers to various forms of hedgehog polypeptides, 30 as well as peptidomimetics, which can modulate the proliferation/differentiation state of adipocyte cells by, as will be clear from the context of individual examples, mimicing or

potentiating (agonizing) or inhibiting (antagonizing) the effects of a naturally-occurring *hedgehog* protein. A *hedgehog* therapeutic which mimics or potentiates the activity of a wild-type *hedgehog* protein is a “*hedgehog* agonist”. Conversely, a *hedgehog* therapeutic which inhibits the activity of a wild-type *hedgehog* protein is a “*hedgehog* antagonist”.

5 In particular, the term “*hedgehog* polypeptide” encompasses preparations of *hedgehog* proteins and peptidyl fragments thereof, both agonist and antagonist forms as the specific context will make clear.

As used herein the term “bioactive fragment of a *hedgehog* protein” refers to a fragment of a full-length *hedgehog* polypeptide, wherein the fragment specifically agonizes 10 or antagonizes inductive events mediated by wild-type *hedgehog* proteins. The *hedgehog* bioactive fragment preferably is a soluble extracellular portion of a *hedgehog* protein, where solubility is with reference to physiologically compatible solutions. Exemplary bioactive fragments are described in PCT publications WO 95/18856 and WO 96/17924.

15 The term “ptc therapeutic” refers to agents which either (i) mimic the effect of *hedgehog* proteins on *patched* signalling, e.g., which antagonize the cell-cycle inhibitory activity of *patched*, or (ii) activate or potentiate *patched* signalling. In other embodiments, the ptc therapeutic can be a *hedgehog* antagonist. The ptc therapeutic can be, e.g., a peptide, a nucleic acid, a carbohydrate, a small organic molecule, or natural product extract (or fraction thereof).

20 A “proliferative” form of a *hedgehog* or ptc therapeutic is one which induces proliferation of adipocyte cells, particularly pre-adipocyte (stem) cells. Conversely, an “antiproliferative” form of a *hedgehog* or ptc therapeutic is one which inhibits proliferation of an adipocyte cells, preferably in a non-toxic manner, e.g., by promoting or maintaining a differentiated phenotype or otherwise promoting quiescence.

25 As used herein, “proliferating” and “proliferation” refer to cells undergoing mitosis.

As used herein, “transformed cells” refers to cells which have spontaneously converted to a state of unrestrained growth, i.e., they have acquired the ability to grow through an indefinite number of divisions in culture. Transformed cells may be characterized by such terms as neoplastic, anaplastic and/or hyperplastic, with respect to 30 their loss of growth control.

As used herein, "immortalized cells" refers to cells which have been altered via chemical and/or recombinant means such that the cells have the ability to grow through an indefinite number of divisions in culture.

5 A "patient" or "subject" to be treated by the subject method can mean either a human or non-human animal.

An "effective amount" of, e.g., a hedgehog therapeutic, with respect to the subject method of treatment, refers to an amount of, e.g., a hedgehog polypeptide in a preparation which, when applied as part of a desired dosage regimen brings about a change in the rate of cell proliferation and/or the state of differentiation of a cell so as to produce an amount 10 of adipocyte cell proliferation or differentiation according to clinically acceptable standards for the disorder to be treated or the cosmetic purpose.

The "growth state" of a cell refers to the rate of proliferation of the cell and the state of differentiation of the cell.

15 "Homology" and "identity" each refer to sequence similarity between two polypeptide sequences, with identity being a more strict comparison. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same amino acid residue, then the polypeptides can be referred to as identical at that position; when the equivalent site is occupied by the same amino acid (e.g., identical) or a 20 similar amino acid (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous at that position. A percentage of homology or identity between sequences is a function of the number of matching or homologous positions shared by the sequences. An "unrelated" or "non-homologous" sequence shares less than 40 percent identity, though preferably less than 25 percent identity, with an hedgehog sequence 25 of the present invention.

The term "corresponds to", when referring to a particular polypeptide or nucleic acid sequence is meant to indicate that the sequence of interest is identical or homologous to the reference sequence to which it is said to correspond.

30 The terms "recombinant protein", "heterologous protein" and "exogenous protein" are used interchangeably throughout the specification and refer to a polypeptide which is produced by recombinant DNA techniques, wherein generally, DNA encoding the

polypeptide is inserted into a suitable expression construct which is in turn used to transform a host cell to produce the heterologous protein. That is, the polypeptide is expressed from a heterologous nucleic acid.

A “chimeric protein” or “fusion protein” is a fusion of a first amino acid sequence 5 encoding a *hedgehog* polypeptide with a second amino acid sequence defining a domain foreign to and not substantially homologous with any domain of *hh* protein. A chimeric protein may present a foreign domain which is found (albeit in a different protein) in an organism which also expresses the first protein, or it may be an “interspecies”, “intergenic”, etc. fusion of protein structures expressed by different kinds of organisms. In general, a 10 fusion protein can be represented by the general formula (X)<sub>n</sub>-(*hh*)<sub>m</sub>-(Y)<sub>n</sub>, wherein *hh* represents all or a portion of the *hedgehog* protein, X and Y each independently represent an amino acid sequences which are not naturally found as a polypeptide chain contiguous with the *hedgehog* sequence, m is an integer greater than or equal to 1, and each occurrence of n is, independently, 0 or an integer greater than or equal to 1 (n and m are preferably no 15 greater than 5 or 10).

The term “PPAR $\gamma$ ” refers to members of the peroxisome proliferator-activated receptors family which are expressed, *inter alia*, in adipocytic and hematopoietic cells (Braissant, O. et al. *Endocrinology* 137(1): 354-66), and which function as key regulators of differentiation. Contemplated within this definition are variants thereof, as for example, 20 PPAR $\gamma$ 1 and PPAR $\gamma$ 2 which are two isoforms having a different N-terminal generated by alternate splicing of a primary RNA transcript (Tontonoz, P. et al. (1994), *Genes & Dev.* 8:1224-34; Zhu et al. (1993) *J. Biol. Chem.* 268: 26817-20).

The terms “PPAR $\gamma$ -responsive hyperproliferative cell” and “PPAR $\gamma$ -responsive neoplastic cell” are used interchangeably herein and refer to a neoplastic cell which is 25 responsive to PPAR $\gamma$  agonists. This neoplastic cell responds to PPAR $\gamma$  receptor activation by inhibiting cell proliferation and/or inducing the expression of differentiation-specific genes. This term includes tumor-derived cells that differentiate into adipocytic lineages in response to PPAR $\gamma$  ligands, e.g., human liposarcoma cells.

The term “activation of PPAR $\gamma$ ” refers to the ability of a compound to selectively 30 activate PPAR $\gamma$ -dependent gene expression, e.g., by increasing PPAR $\gamma$ -dependent transcription of a gene. Likewise, the term “inhibition of PPAR $\gamma$ ” refers to the ability of a

compound to selectively inhibit PPAR  $\gamma$ -dependent gene expression, e.g., by decreasing PPAR  $\gamma$ -dependent transcription of a gene.

The common medical meaning of the term "neoplasia" refers to "new cell growth" that results as a loss of responsiveness to normal growth controls, e.g. to neoplastic cell growth. A "hyperplasia" refers to cells undergoing an abnormally high rate of growth. 5 However, as used herein, the terms neoplasia and hyperplasia can be used interchangably, as their context will reveal, referring generally to cells experiencing abnormal cell growth rates. Neoplasias and hyperplasias include "tumors," which may be either benign, premalignant or malignant.

10 As used herein, the terms "hyperproliferative" and "neoplastic" are used interchangeably, and refer to those cells an abnormal state or condition characterized by rapid proliferation or neoplasm. The terms are meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. "Pathologic 15 hyperproliferative" cells occur in disease states characterized by malignant tumor growth.

The term "adipose cell tumor" refers to all cancers or neoplasias arising from cells of adipocytic lineage, e.g., arising from adipose or adipose precursor cells. The adipose cell tumors include both common and uncommon, benign and malignant lesions, such as lipoma, intramuscular and intermuscular lipoma, neural fibrolipoma, lipoblastoma, 20 lipomatosis, hibernoma, hemangioma and liposarcoma, as well as lesions that may mimic fat-containing soft-tissue masses.

The terms "antineoplastic agent" and "antiproliferative agent" are used interchangeably herein and refer to hedgehog or ptc therapeutic agents that have the functional property of inhibiting the proliferation of PPAR  $\gamma$ -responsive cells, e.g., 25 inhibiting the development or progression of a neoplasm having such a characteristic, particularly an adipocytic neoplasm or hematopoietic neoplasm.

### *III. Exemplary Applications of Method and Compositions*

The subject method has wide applicability to the treatment or prophylaxis of 30 disorders afflicting adipocyte tissue. In general, the method can be characterized as including a step of administering to an animal an amount of a ptc or hedgehog therapeutic

effective to alter the proliferative state of a treated adipocyte tissue. The mode of administration and dosage regimens will vary depending on the adipocyte tissue(s) which is to be treated. Likewise, as described in further detail below, the use of a particular ptc or hedgehog therapeutic, e.g., an agonist or antagonist, will depend on whether proliferation of 5 cells of the treated tissue is desired or intended to be prevented.

In one aspect, the invention is used to inhibit adipocyte differentiation in mammals. Such aspects of the present invention are thus directed to a method for inhibiting the differentiation of adipocyte precursor cells in a mammal (e.g., inhibiting differentiation of preadipocytes into adipocytes), and comprise administering to the mammal an effective 10 amount of a hedgehog polypeptide or agonist thereof. In such embodiments, the hedgehog proteins and agonists of the present invention can be used to treat (reduce the severity of or ameliorate) body weight disorders which may include, for example, inhibition of adipose cell differentiation and an inhibition of the ability of adipocytes to synthesize fat, e.g., treatment of obesity or of disorders related to abnormal proliferation of adipocytes.

15 In certain embodiments, the subject method can be used to inhibit the differentiation of preadipocytes to adipocytes, therefore limiting the possibility of cellulite appearing.

In other embodiments, the subject method can be used in livestock to repartition 20 nutrients between subcutaneous fat and other carcass components, including muscle, skin, bone and certain organs, e.g., by administration in the form of a veterinarian composition or as part of a livestock feed.

In another aspect, this invention features methods for inhibiting the proliferation of pre-adipocytes, e.g., inducing differentiation of preadipocytes into adipocytes, by inhibiting a hedgehog-mediated signal transduction pathway. The present results suggest that certain 25 adipocytic cancers may be the result of over-expression of hedgehog, or a loss-of-function of patched or a gain-of-function of smoothened, or some other mutation which mimics the proliferative activity of hedgehog on pre-adipocytes. Thus, the present invention specifically contemplates the use of the subject method for reversing the transformed phenotype of PPAR $\gamma$ -responsive hyperproliferative cells by contacting the cells with a hedgehog antagonists.

30 In general, the method includes a step of contacting pathological of PPAR $\gamma$ -responsive hyperproliferative cells with an amount of a hedgehog antagonist effective for

promoting the differentiation of the hyperproliferative cells. The present method can be performed on cells in culture, e.g., *in vitro* or *ex vivo*, or can be performed on cells present in an animal subject, e.g., as part of an *in vivo* therapeutic protocol. The therapeutic regimen can be carried out on a human or other animal subject. Induction of terminal 5 differentiation of transformed cells *in vivo* in response to hedgehog antagonists represents a promising alternative to conventional highly toxic regimens of chemotherapy.

In one embodiment, the cells to be treated are hyperproliferative cells of adipocytic lineage, e.g., arising from adipose or adipose precursor cells. For instance, the instant method can be carried out to prevent the proliferation of an adipose cell tumor. The 10 adipose tumor cells can be of a liposarcoma. The term "liposarcoma" is recognized by those skilled in the art and refers to a malignant tumor characterized by large anaplastic lipoblasts, sometimes with foci of normal fat cells. Exemplary liposarcoma types which are can be treated by the present invention include, but are not limited to, well differentiated/dedifferentiated, myxoid/round cell and pleiomorphic (reviewed in 15 Sreekantaiah, C. et al., (1994) *supra*).

Another adipose cell tumor which may be treated by the present method include lipomas, e.g., benign fatty tumors usually composed of mature fat cells. Likewise, the method of the present invention can be used in the treatment and/or prophylaxis of lipochondromas, lipofibromas and lipogranulomas. Lipochondroma are tumors composed 20 of mature lipomatous and cartilaginous elements; lipofibromas are lipomas containing areas of fibrosis; and lipogranuloma are characterized by nodules of lipid material associated with granulomatous inflammation.

The subject method can also be useful in treating malignancies of the various organ systems, such as those affecting lung, breast, lymphoid, gastrointestinal, and genito-urinary 25 tract as well as adenocarcinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus. According to the general paradigm of PPAR  $\gamma$  involvement in differentiation of transformed cells, exemplary solid tumors that can be treated according to the method of the present invention include 30 sarcomas and carcinomas with PPAR  $\gamma$ -responsive phenotypes, such as, but not limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma,

chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma,

5 adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma,

10 astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendrogioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

While the hedgehog antagonists can be utilized alone, the subject differentiation therapy can be combined with other therapeutics, e.g., such as cell cycle inhibitors, agents

15 which promote apoptosis, PPAR $\gamma$  ligands, agents which strengthen the immune response, and/or RxR agonists. Some of the co-administered therapeutics, particular those with cytotoxic effects or which lack specificity for the treated cells, may be given in smaller doses due to an additive, and sometimes synergistic effect with the hedgehog antagonist.

For instance, the subject method may involve, in addition to the use of hedgehog antagonists, one or more other anti-tumor substances. Exemplary combinatorial therapies combining with hedgehog antagonists include the use of such as agents as: mitotic inhibitors, such as vinblastine; alkylating agents, such as cisplatin, carboplatin and cyclophosphamide; antimetabolites, such as 5-fluorouracil, cytosine arabinoside, hydroxyurea or N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-

20 methylamino]-2-thenoyl]-L-glutamic acid; intercalating antibiotics, as for example adriamycin and bleomycin; enzymes, such as asparaginase; topoisomerase inhibitors, such as etoposide; biological response modifiers, e.g., to enhance anti-tumor responses, such as interferon; apoptotic agents, such as actinomycin D; and anti-hormones, for example antioestrogens such as tamoxifen or, for example antiandrogens such as 4'-cyano-3-(4-

25 fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl) propionanilide. Such

30

conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.

In another embodiment, the subject hedgehog antagonist is conjointly administered with a PPAR $\gamma$  ligand. Particular examples of a non-naturally occurring PPAR $\gamma$  ligand 5 include thiazolidine (TZD) derivatives known as thiazolidinediones, e.g., proglitazone (also known as AD-4833 and U-72107E), troglitazone (also known as CS-045) (Sankyo) and C1-991 (Parke-Davis), BRL 49653, ciglitazone, englitazone and chemical derivatives thereof. These compounds are conventionally known for the treatment of diabetes. See e.g., U.S. Patent Nos. 4,812,570; 4,775,687; 4,725,610; 4,582,839; and 4,572,912 for exemplary 10 sources of such compounds. U.S. Patents 5,521,201 and European Patent Applications 0008203, 0139421, 0155845, 0177353, 0193256, 0207581 and 0208420, and *Chem. Pharm. Bull.* 30 (10) 3580-3600 relate to thiazolidinedione derivatives, and describe commercial sources/synthetic schemes for a variety of TZD and TZD-like analogs, which may be useful in carrying out the method of the present invention. Particular examples of 15 naturally-occurring PPAR $\gamma$  ligands include arachidonic acid metabolites, e.g., prostaglandin J<sub>2</sub> (PGJ<sub>2</sub>) metabolites, e.g., 15-deoxy- $\Delta^{12,14}$ -prostaglandin J<sub>2</sub>. Prostaglandin J<sub>2</sub> dehydration and isomerization products, including  $\Delta^{12}$ -PGJ<sub>2</sub> and 15-deoxy- $\Delta^{12,14}$ -PGJ<sub>2</sub> have been shown to occur by incubation of prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) in the presence of 20 human plasma or human serum albumin (Fitzpatrick and Wyvalda (1983) *J. Biol. Chem.* 258:11713-18).  $\Delta^{12}$ -PGJ<sub>2</sub> has been shown to be a significant PGD<sub>2</sub> metabolite present in human and monkey urine, indicating that PGJ<sub>2</sub> metabolites are also found *in vivo* (Hirata et al. (1994) *PNAS USA* 91:11192-96).


Also contemplated are chemicals that stimulate the endogenous production of arachidonic acid metabolites, when administered systemically or *in vitro*. Enhanced 25 production of endogenous arachidonic acid metabolites may occur by stimulating at least one of the release of arachidonic acid from precursor glycerophospholipids, the oxygenation of free arachidonic acid by a cyclo-oxygenase enzyme, and the metabolism of prostaglandin H<sub>2</sub> to a specific biologically active prostaglandin metabolite (reviewed in Smith, W. (1989) *Biochem. J.*, 259:315-24).

In general, it will be preferable to choose a PPAR  $\alpha$  agonist which specifically activates that PPAR isoform relative to, for example, PPAR  $\gamma$  and/or PPAR  $\delta$ . According to this present invention, specificity for the PPAR  $\alpha$  isoform can reduce unwanted side effects, such as PPAR  $\gamma$ -mediated hepatocarcinogenesis. In particular, the PPAR  $\alpha$  agonist of the present method preferably activates PPAR  $\alpha$ -dependent transcription at a concentration at least 1 order of magnitude less than that which activates PPAR  $\gamma$ -dependent transcription, and even more preferably at a concentration at least 2, 3, 4 or 5 orders of magnitude less. PPAR $\gamma$  ligands useful for practicing the present invention, and methods of making these compounds are known. Examples of PPAR  $\alpha$  agonists are disclosed in PCT publications WO 91/07107; WO 92/02520; WO 94/01433; WO 89/08651; WO 95/18533; WO 95/35108; Japanese patent publication 69383/92; and U.S. Patents 5,523,314; 5,521,202; 5,510,360; 5,498,621; 5,496,621; 5,494,927; 5,480,896; 5,478,852; 5,468,762; 5,464,856; 5,457,109; 4,287,200; 4,340,605; 4,438,141; 4,444,779; 4,461,902; 4,572,912; 4,687,777; 4,703,052; 4,725,610; 4,873,255; 4,897,393; 4,897,405; 4,918,091; 4,948,900; 5,002,953; 5,061,717; 5,120,754; 5,132,317; 5,194,443; 5,223,522; 5,232,925; and 5,260,445. Exemplary PPAR  $\alpha$  agonist can be selected from amongst such compounds as 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiadiazolidine-2,4-dione: (pioglitazone); 5-[4-[(1-methylcyclohexyl)methoxy]benzyl]thiadiazolidine-2,4-dione: (ciglitazone); 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl]thiadiazoline-2,4-dione: (englitazone); 5-[(2-alkoxy-5-pyridyl)methyl]-2,4-thiazolidinedione; 5-[(substituted-3-pyridyl)methyl]-2,4-thiazolidinedione; 5-[4-(2-methyl-2-phenylpropoxy)benzyl]thiazolidine-2,4-dione; 5-[4-[3-(4-methoxyphenyl)-2-oxooxazolidin-5-yl]-methoxy]benzyl-2,4-thiazolidinedione; 5-[4-[3-(3,4-difluorophenyl)-2-oxooxazolidin-5-yl]-methoxy]benzyl-2,4-thiazolidinedione; 5-[4-[3-(4-chloro-2-fluorophenyl)-2-oxooxazolidin-5-yl]methoxy]benzyl-2,4-thiazolidinedione; 5-[4-[3-(4-trifluoromethoxyphenyl)-2-oxooxazolidin-5-yl]methoxy]benzyl-2,4-thiazolidinedione; 5-[4-[3-(4-trifluoromethylphenyl)-2-oxooxazolidin-5-yl]methoxy]benzyl-2,4-thiazolidinedione; 5-[4-[2-[3-(4-trifluoromethylphenyl)-2-oxooxazolidin-5-yl]ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-[3-(4-chloro-2-fluorophenyl)-2-oxooxazolidin-5-yl]ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[3-(4-pyridyl)-2-oxooxazolidin-5-yl]methoxy]benzyl-2,4-thiazolidinedione; 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-

thiazolidinedione: (troglitazone); 4-(2-naphthylmethyl)-1,2,3,5-oxathiadiazole-2-oxide; 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]-5-methylthiazolidine-2,4-dione; 5-[4-[2-[2,4-dioxo-5-phenylthiazolidin-3-yl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-[N-methyl-N-(phenoxy carbonyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-(2-phenoxyethoxy)benzyl]thiazolidine-2,4-dione; 5-[4-[2-(4-chlorophenyl)ethylsulfonyl]benzyl]thiazolidine-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione; 5-[4-[3-(3-hydroxy-1-methylcyclohexyl)methoxy]benzyl]thiadiazolidine-2,4-dione; 5-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxyl]benzyl]thiadiazolidine-2,4-dione; 5-[2-(2-naphthylmethyl)benzoxazol]-5-ylmethyl]thiadiazoline-2,4-dione; 5-[4-[2-(3-phenylureido)ethoxyl]benzyl]thiadiazoline-2,4-dione; 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]thiadiazoline-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiadiazoline-2,4-dione; 5-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-ylmethyl]-oxazolidine-2,4-dione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; and 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]-oxazolidine-2,4-dione.

In another embodiment, the subject methods combines the use of hedgehog antagonists in combination with one or more RxR-specific ligands. For instance, the subject method can be practiced by conjoint treatment using a hedgehog antagonist as described above and an RxR agonist such as a natural and/or synthetic retinoid. A wide variety of RxR ligands appropriate for use in the subject method are known in the art. Exemplary natural RxR ligands include all-trans-retinoic acid and phytanic acid. Exemplary synthetic RxR ligands include 9-cis-retinoic acid, LG268, AGN191701, SR11217, SR11237, SR11236, SR11246, SR11249 SR11256, LGD1069, various tricyclic retinoids, teravinyl-alkadi- or trienoic derivatives of retinoids, and phenyl-methyl heterocyclic and tetrahydro-naphthyl analogs of retinoic acid (c.f., Apfel et al. (1995) *JBC* 270:30765; Minucci et al. (1996) *PNAS* 93:1803; Hembree et al. (1996) *Cancer Res* 56:1794; Kizaki et al. (1996) *Blood* 87:1977; Lemotte et al. (1996) *Eur J Biochem* 236:328; and U.S. Patents 5,552,271; 5,466,861; 5,514,821; PCT publications WO 96/05165; WO 96/20914; WO 94/15901; WO 93/21146; and European Patent publication EP 0694301.

To further illustrate, the RxR ligand can be a compound represented in the general formula:



and U.S. Patent 5,466,861.

5 The two (or more) compounds are administered in combination according to the invention. The terms "in combination" and "conjointly" in this context means that the drugs are given substantially contemporaneously, either simultaneously or sequentially. If given sequentially, at the onset of administration of the second compound, the first of the two compounds is preferably still detectable at effective concentrations at the site of  
10 treatment.

The maintenance of tissues and organs *ex vivo* is also highly desirable. Tissue replacement therapy is well established in the treatment of human disease. There are many situations where one may wish to transplant adipocyte cells, especially adipocyte stem cells, into a recipient host where the recipient's cells are missing, damaged or dysfunctional. The  
15 subject method can be used to regulate the growth of adipocyte cells and tissue *in vitro*, as well as to accelerate the grafting of implanted adipocyte tissue to an animal host

In this regard, the present invention also concerns adipocyte cultures which have been expanded by treatment with a hedgehog or other ptc therapeutic. In an illustrative embodiment, such a method comprises obtaining a adipocyte sample, preferably one  
20 including pre-adipocytes; optionally treating the cell sample enzymically to separate the cells; culturing, in the presence of a hedgehog or ptc therapeutic.

#### *IV. Exemplary hedgehog therapeutic compounds.*

The *hedgehog* therapeutic compositions of the subject method can be generated by  
25 any of a variety of techniques, including purification of naturally occurring proteins, recombinantly produced proteins and synthetic chemistry. Polypeptide forms of the hedgehog therapeutics are preferably derived from vertebrate hedgehog proteins, e.g., have sequences corresponding to naturally occurring hedgehog proteins, or fragments thereof,

from vertebrate organisms. However, it will be appreciated that the hedgehog polypeptide can correspond to a hedgehog protein (or fragment thereof) which occurs in any metazoan organism.

The various naturally-occurring *hedgehog* proteins from which the subject 5 therapeutics can be derived are characterized by a signal peptide, a highly conserved N-terminal region, and a more divergent C-terminal domain. In addition to signal sequence cleavage in the secretory pathway (Lee, J.J. *et al.* (1992) *Cell* 71:33-50; Tabata, T. *et al.* (1992) *Genes Dev.* 2635-2645; Chang, D.E. *et al.* (1994) *Development* 120:3339-3353), *hedgehog* precursor proteins naturally undergo an internal autoproteolytic cleavage which 10 depends on conserved sequences in the C-terminal portion (Lee *et al.* (1994) *Science* 266:1528-1537; Porter *et al.* (1995) *Nature* 374:363-366). This autocleavage leads to a 19 kD N-terminal peptide and a C-terminal peptide of 26-28 kD (Lee *et al.* (1992) *supra*; Tabata *et al.* (1992) *supra*; Chang *et al.* (1994) *supra*; Lee *et al.* (1994) *supra*; Bumcrot, D.A., *et al.* (1995) *Mol. Cell. Biol.* 15:2294-2303; Porter *et al.* (1995) *supra*; Ekker, S.C. *et al.* (1995) *Curr. Biol.* 5:944-955; Lai, C.J. *et al.* (1995) *Development* 121:2349-2360). The 15 N-terminal peptide stays tightly associated with the surface of cells in which it was synthesized, while the C-terminal peptide is freely diffusible both *in vitro* and *in vivo* (Lee *et al.* (1994) *supra*; Bumcrot *et al.* (1995) *supra*; Mart', E. *et al.* (1995) *Development* 121:2537-2547; Roelink, H. *et al.* (1995) *Cell* 81:445-455). Cell surface retention of the N-terminal peptide is dependent on autocleavage, as a truncated form of *hedgehog* encoded by 20 an RNA which terminates precisely at the normal position of internal cleavage is diffusible *in vitro* (Porter *et al.* (1995) *supra*) and *in vivo* (Porter, J.A. *et al.* (1996) *Cell* 86, 21-34). Biochemical studies have shown that the autoproteolytic cleavage of the *hedgehog* 25 precursor protein proceeds through an internal thioester intermediate which subsequently is cleaved in a nucleophilic substitution. It is suggested that the nucleophile is a small lipophilic molecule, more particularly cholesterol, which becomes covalently bound to the C-terminal end of the N-peptide (Porter *et al.* (1996) *supra*), tethering it to the cell surface.

The vertebrate family of *hedgehog* genes includes at least four members, e.g., 30 paralogs of the single drosophila *hedgehog* gene (SEQ ID No. 19). Three of these members, herein referred to as Desert *hedgehog* (*Dhh*), Sonic *hedgehog* (*Shh*) and Indian *hedgehog* (*Ihh*), apparently exist in all vertebrates, including fish, birds, and mammals. A

fourth member, herein referred to as tiggie-winkle *hedgehog* (*Thh*), appears specific to fish. According to the appended sequence listing, (see also Table 1) a chicken *Shh* polypeptide is encoded by SEQ ID No:1; a mouse *Dhh* polypeptide is encoded by SEQ ID No:2; a mouse *Ihh* polypeptide is encoded by SEQ ID No:3; a mouse *Shh* polypeptide is encoded by SEQ 5 ID No:4 a zebrafish *Shh* polypeptide is encoded by SEQ ID No:5; a human *Shh* polypeptide is encoded by SEQ ID No:6; a human *Ihh* polypeptide is encoded by SEQ ID No:7; a human *Dhh* polypeptide is encoded by SEQ ID No. 8; and a zebrafish *Thh* is encoded by SEQ ID No. 9.

10

*Table 1*Guide to *hedgehog* sequences in Sequence Listing

|                      | Nucleotide    | Amino Acid    |
|----------------------|---------------|---------------|
| Chicken <i>Shh</i>   | SEQ ID No. 1  | SEQ ID No. 10 |
| Mouse <i>Dhh</i>     | SEQ ID No. 2  | SEQ ID No. 11 |
| Mouse <i>Ihh</i>     | SEQ ID No. 3  | SEQ ID No. 12 |
| Mouse <i>Shh</i>     | SEQ ID No. 4  | SEQ ID No. 13 |
| Zebrafish <i>Shh</i> | SEQ ID No. 5  | SEQ ID No. 14 |
| Human <i>Shh</i>     | SEQ ID No. 6  | SEQ ID No. 15 |
| Human <i>Ihh</i>     | SEQ ID No. 7  | SEQ ID No. 16 |
| Human <i>Dhh</i>     | SEQ ID No. 8  | SEQ ID No. 17 |
| Zebrafish <i>Thh</i> | SEQ ID No. 9  | SEQ ID No. 18 |
| Drosophila <i>HH</i> | SEQ ID No. 19 | SEQ ID No. 20 |

In addition to the sequence variation between the various *hedgehog* homologs, the *hedgehog* proteins are apparently present naturally in a number of different forms, 15 including a pro-form, a full-length mature form, and several processed fragments thereof. The pro-form includes an N-terminal signal peptide for directed secretion of the extracellular domain, while the full-length mature form lacks this signal sequence. As described above, further processing of the mature form occurs in some instances to yield biologically active fragments of the protein. For instance, *sonic hedgehog* 20 undergoes additional proteolytic processing to yield two peptides of approximately 19 kDa

and 27 kDa, the 19kDa fragment corresponding to an proteolytic N-terminal portion of the mature protein.

In addition to proteolytic fragmentation, the vertebrate *hedgehog* proteins can also be modified post-translationally, such as by glycosylation and/or addition of lipophilic 5 moieties, such as stents, fatty acids, etc., though bacterially produced (e.g. unmodified) forms of the proteins still maintain certain of the bioactivities of the native protein. Bioactive fragments of *hedgehog* polypeptides of the present invention have been generated and are described in great detail in, e.g., PCT publications WO 95/18856 and WO 96/17924.

10 There are a wide range of lipophilic moieties with which hedgehog polypeptides can be derivatived. The term "lipophilic group", in the context of being attached to a hedgehog polypeptide, refers to a group having high hydrocarbon content thereby giving the group high affinity to lipid phases. A lipophilic group can be, for example, a relatively long chain alkyl or cycloalkyl (preferably n-alkyl) group having approximately 7 to 30 carbons. The 15 alkyl group may terminate with a hydroxy or primary amine "tail". To further illustrate, lipophilic molecules include naturally-occurring and synthetic aromatic and non-aromatic moieties such as fatty acids, sterols, esters and alcohols, other lipid molecules, cage structures such as adamantane and buckminsterfullerenes, and aromatic hydrocarbons such as benzene, perylene, phenanthrene, anthracene, naphthalene, pyrene, chrysene, and 20 naphthacene.

In one embodiment, the hedgehog polypeptide is modified with one or more sterol moieties, such as cholesterol. See, for example, PCT publication WO 96/17924. In certain embodiments, the cholesterol is preferably added to the C-terminal glycine were the hedgehog polypeptide corresponds to the naturally-occurring N-terminal proteolytic 25 fragment.

In another embodiment, the hedgehog polypeptide can be modified with a fatty acid moiety, such as a myristoyl, palmitoyl, stearoyl, or arachidoyl moiety. See, e.g., Pepinsky et al. (1998) J Biol. Chem. 273: 14037.

30 In addition to those effects seen by cholesterol-addition to the C-terminus or fatty acid addition to the N-terminus of extracellular fragments of the protein, at least certain of the biological activities of the hedgehog gene products are unexpectedly potentiated by

derivatization of the protein with lipophilic moieties at other sites on the protein and/or by moieties other than cholesterol or fatty acids. Certain aspects of the invention are directed to the use of preparations of hedgehog polypeptides which are modified at sites other than N-terminal or C-terminal residues of the natural processed form of the protein, and/or 5 which are modified at such terminal residues with lipophilic moieties other than a sterol at the C-terminus or fatty acid at the N-terminus.

Particularly useful as lipophilic molecules are alicyclic hydrocarbons, saturated and unsaturated fatty acids and other lipid and phospholipid moieties, waxes, cholesterol, isoprenoids, terpenes and polycyclic hydrocarbons including adamantine and 10 buckminsterfullerenes, vitamins, polyethylene glycol or oligoethylene glycol, (C1-C18)-alkyl phosphate diesters, -O-CH<sub>2</sub>-CH(OH)-O-(C12-C18)-alkyl, and in particular conjugates with pyrene derivatives. The lipophilic moiety can be a lipophilic dye suitable for use in the invention include, but are not limited to, diphenylhexatriene, Nile Red, N-phenyl-1-naphthylamine, Prodan, Laurodan, Pyrene, Perylene, rhodamine, rhodamine B, 15 tetramethylrhodamine, Texas Red, sulforhodamine, 1,1'-didodecyl-3,3',3'tetramethylindocarbocyanine perchlorate, octadecyl rhodamine B and the BODIPY dyes available from Molecular Probes Inc.

Other exemplary lipophilic moieties include aliphatic carbonyl radical groups include 1- or 2-adamantylacetyl, 3-methyladamant-1-ylacetyl, 3-methyl-3-bromo-1-adamantylacetyl, 1-decalinacetyl, camphoracetyl, camphaneacetyl, noradamantylacetyl, norbornaneacetyl, bicyclo[2.2.2.]oct-5-eneacetyl, 1-methoxybicyclo[2.2.2.]oct-5-ene-2-carbonyl, cis-5-norbornene-endo-2,3-dicarbonyl, 5-norbornen-2-ylacetyl, (1R)-(-)-myrtentaneacetyl, 2-norbornaneacetyl, anti-3-oxo-tricyclo[2.2.1.0<2,6>]heptane-7-carbonyl, decanoyl, dodecanoyl, dodecenoyl, tetradecadienoyl, decynoyl or dodecynoyl.

25 The hedgehog polypeptide can be linked to the hydrophobic moiety in a number of ways including by chemical coupling means, or by genetic engineering.

There are a large number of chemical cross-linking agents that are known to those skilled in the art. For the present invention, the preferred cross-linking agents are heterobifunctional cross-linkers, which can be used to link the hedgehog polypeptide and 30 hydrophobic moiety in a stepwise manner. Heterobifunctional cross-linkers provide the ability to design more specific coupling methods for conjugating to proteins, thereby

reducing the occurrences of unwanted side reactions such as homo-protein polymers. A wide variety of heterobifunctional cross-linkers are known in the art. These include: succinimidyl 4-(N-maleimidomethyl) cyclohexane- 1-carboxylate (SMCC), m-  
5 Maleimidobenzoyl-N- hydroxysuccinimide ester (MBS); N-succinimidyl (4-iodoacetyl) aminobenzoate (SIAB), succinimidyl 4-(p-maleimidophenyl) butyrate (SMPB), 1-ethyl-3-  
(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC); 4-succinimidoxycarbonyl-  
a-methyl-a-(2-pyridyldithio)-tolune (SMPT), N-succinimidyl 3-(2-pyridyldithio) propionate  
10 (SPDP), succinimidyl 6-[3-(2-pyridyldithio) propionate] hexanoate (LC-SPDP). Those cross-linking agents having N-hydroxysuccinimide moieties can be obtained as the N-  
hydroxysulfosuccinimide analogs, which generally have greater water solubility. In addition, those cross-linking agents having disulfide bridges within the linking chain can be synthesized instead as the alkyl derivatives so as to reduce the amount of linker cleavage *in vivo*.

15 In addition to the heterobifunctional cross-linkers, there exists a number of other cross-linking agents including homobifunctional and photoreactive cross-linkers. Disuccinimidyl suberate (DSS), bismaleimidohexane (BMH) and dimethylpimelimide·2 HCl (DMP) are examples of useful homobifunctional cross-linking agents, and bis-[β-(4-azidosalicylamido)ethyl]disulfide (BASED) and N-succinimidyl-6(4'-azido-2'-nitrophenyl-amino)hexanoate (SANPAH) are examples of useful photoreactive cross-linkers for use in  
20 this invention. For a recent review of protein coupling techniques, see Means et al. (1990) *Bioconjugate Chemistry* 1:2-12, incorporated by reference herein.

One particularly useful class of heterobifunctional cross-linkers, included above, contain the primary amine reactive group, N-hydroxysuccinimide (NHS), or its water soluble analog N-hydroxysulfosuccinimide (sulfo-NHS). Primary amines (lysine epsilon groups) at alkaline pH's are unprotonated and react by nucleophilic attack on NHS or sulfo-NHS esters. This reaction results in the formation of an amide bond, and release of NHS or sulfo-NHS as a by-product.

Another reactive group useful as part of a heterobifunctional cross-linker is a thiol reactive group. Common thiol reactive groups include maleimides, halogens, and pyridyl disulfides. Maleimides react specifically with free sulphhydryls (cysteine residues) in minutes, under slightly acidic to neutral (pH 6.5-7.5) conditions. Halogens (iodoacetyl

functions) react with -SH groups at physiological pH's. Both of these reactive groups result in the formation of stable thioether bonds.

The third component of the heterobifunctional cross-linker is the spacer arm or bridge. The bridge is the structure that connects the two reactive ends. The most apparent 5 attribute of the bridge is its effect on steric hindrance. In some instances, a longer bridge can more easily span the distance necessary to link two complex biomolecules. For instance, SMPB has a span of 14.5 angstroms.

Preparing protein-protein conjugates using heterobifunctional reagents is a two-step process involving the amine reaction and the sulphydryl reaction. For the first step, the 10 amine reaction, the protein chosen should contain a primary amine. This can be lysine epsilon amines or a primary alpha amine found at the N-terminus of most proteins. The protein should not contain free sulphydryl groups. In cases where both proteins to be conjugated contain free sulphydryl groups, one protein can be modified so that all sulphydryls are blocked using for instance, N-ethylmaleimide (see Partis et al. (1983) J. Pro. 15 Chem. 2:263, incorporated by reference herein). Ellman's Reagent can be used to calculate the quantity of sulphydryls in a particular protein (see for example Ellman et al. (1958) Arch. Biochem. Biophys. 74:443 and Riddles et al. (1979) Anal. Biochem. 94:75, incorporated by reference herein).

The reaction buffer should be free of extraneous amines and sulphydryls. The pH of 20 the reaction buffer should be 7.0-7.5. This pH range prevents maleimide groups from reacting with amines, preserving the maleimide group for the second reaction with sulphydryls.

The NHS-ester containing cross-linkers have limited water solubility. They should be dissolved in a minimal amount of organic solvent (DMF or DMSO) before introducing 25 the cross-linker into the reaction mixture. The cross-linker/solvent forms an emulsion which will allow the reaction to occur.

The sulfo-NHS ester analogs are more water soluble, and can be added directly to the reaction buffer. Buffers of high ionic strength should be avoided, as they have a tendency to "salt out" the sulfo-NHS esters. To avoid loss of reactivity due to hydrolysis, 30 the cross-linker is added to the reaction mixture immediately after dissolving the protein solution.

The reactions can be more efficient in concentrated protein solutions. The more alkaline the pH of the reaction mixture, the faster the rate of reaction. The rate of hydrolysis of the NHS and sulfo-NHS esters will also increase with increasing pH. Higher temperatures will increase the reaction rates for both hydrolysis and acylation.

5 Once the reaction is completed, the first protein is now activated, with a sulphydryl reactive moiety. The activated protein may be isolated from the reaction mixture by simple gel filtration or dialysis. To carry out the second step of the cross-linking, the sulphydryl reaction, the lipophilic group chosen for reaction with maleimides, activated halogens, or pyridyl disulfides must contain a free sulphydryl. Alternatively, a primary amine may be  
10 modified with to add a sulphydryl

In all cases, the buffer should be degassed to prevent oxidation of sulphydryl groups. EDTA may be added to chelate any oxidizing metals that may be present in the buffer. Buffers should be free of any sulphydryl containing compounds.

Maleimides react specifically with -SH groups at slightly acidic to neutral pH ranges  
15 (6.5-7.5). A neutral pH is sufficient for reactions involving halogens and pyridyl disulfides. Under these conditions, maleimides generally react with -SH groups within a matter of minutes. Longer reaction times are required for halogens and pyridyl disulfides.

The first sulphydryl reactive-protein prepared in the amine reaction step is mixed with the sulphydryl-containing lipophilic group under the appropriate buffer conditions.  
20 The conjugates can be isolated from the reaction mixture by methods such as gel filtration or by dialysis.

Exemplary activated lipophilic moieties for conjugation include: N-(1-pyrene)maleimide; 2,5-dimethoxystilbene-4'-maleimide, eosin-5-maleimide; fluorescein-5-maleimide; N-(4-(6-dimethylamino-2-benzofuranyl)phenyl)maleimide; benzophenone-4-maleimide; 4-dimethylaminophenylazophenyl-4'-maleimide (DABMI),  
25 tetramethylrhodamine-5-maleimide, tetramethylrhodamine-6-maleimide, Rhodamine RedTM C2 maleimide, N-(5-aminopentyl)maleimide, trifluoroacetic acid salt, N-(2-aminoethyl)maleimide, trifluoroacetic acid salt, Oregon GreenTM 488 maleimide, N-(2-((2-(((4-azido-2,3,5,6-tetrafluoro)benzoyl)amino)ethyl)dithio)ethyl)maleimide (TFPAM-  
30 SS1), 2-(1-(3-dimethylaminopropyl)-indol-3-yl)-3-(indol-3-yl) maleimide (bisindolylmaleimide; GF 109203X), BODIPY® FL N-(2-aminoethyl)maleimide, N-(7-

dimethylamino- 4-methylcoumarin-3-yl)maleimide (DACM), AlexaTM 488 C5 maleimide, AlexaTM 594 C5 maleimide, sodium saltN-(1-pyrene)maleimide, 2,5-dimethoxystilbene-4'-maleimide, eosin-5-maleimide, fluorescein-5-maleimide, N-(4-(6-dimethylamino- 2-benzofuranyl)phenyl)maleimide, benzophenone-4-maleimide, 4-  
5 diimethylaminophenylazophenyl- 4'-maleimide, 1-(2-maleimidylethyl)-4-(5- (4-methoxyphenyl)oxazol-2- yl)pyridinium methanesulfonate, tetramethylrhodamine-5-maleimide, tetramethylrhodamine-6-maleimide, Rhodamine RedTM C2 maleimide, N-(5-aminopentyl)maleimide, N-(2-aminoethyl)maleimide, N-(2-((2-(((4-azido- 2,3,5,6-tetrafluoro)benzoyl) amino)ethyl)dithio)ethyl)maleimide, 2-(1-(3-dimethylaminopropyl) -  
10 indol-3-yl)-3-(indol-3-yl) maleimide, N-(7-dimethylamino- 4-methylcoumarin-3-yl)maleimide (DACM), 11H-Benzo[a]fluorene, Benzo[a]pyrene.

In one embodiment, the hedgehog polypeptide can be derivatized using pyrene maleimide, which can be purchased from Molecular Probes (Eugene, Oreg.), e.g., N-(1-pyrene)maleimide or 1-pyrenemethyl iodoacetate (PMIA ester).

15 For those embodiments wherein the hydrophobic moiety is a polypeptide, the modified hedgehog polypeptide of this invention can be constructed as a fusion protein, containing the hedgehog polypeptide and the hydrophobic moiety as one contiguous polypeptide chain.

20 In certain embodiments, the lipophilic moiety is an amphipathic polypeptide, such as magainin, cecropin, attacin, melittin, gramicidin S, alpha-toxin of *Staph. aureus*, alamethicin or a synthetic amphipathic polypeptide. Fusogenic coat proteins from viral particles can also be a convenient source of amphipathic sequences for the subject hedgehog proteins

25 Moreover, mutagenesis can be used to create modified *hh* polypeptides, e.g., for such purposes as enhancing therapeutic or prophylactic efficacy, or stability (e.g., *ex vivo* shelf life and resistance to proteolytic degradation *in vivo*). Such modified peptides can be produced, for instance, by amino acid substitution, deletion, or addition. Modified hedgehog polypeptides can also include those with altered post-translational processing relative to a naturally occurring hedgehog protein, e.g., altered glycosylation,  
30 cholesterolization, prenylation and the like.

-30-

In one embodiment, the hedgehog therapeutic is a polypeptide encodable by a nucleotide sequence that hybridizes under stringent conditions to a hedgehog coding sequence represented in one or more of SEQ ID Nos:1-9 or 19. Appropriate stringency conditions which promote DNA hybridization, for example, 6.0 x sodium chloride/sodium 5 citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C, are known to those skilled in the art or can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50°C to a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be increased from low 10 stringency conditions at room temperature, about 22°C, to high stringency conditions at about 65°C.

As described in the literature, genes for other hedgehog proteins, e.g., from other animals, can be obtained from mRNA or genomic DNA samples using techniques well known in the art. For example, a cDNA encoding a *hedgehog* protein can be obtained by 15 isolating total mRNA from a cell, e.g. a mammalian cell, e.g. a human cell, including embryonic cells. Double stranded cDNAs can then be prepared from the total mRNA, and subsequently inserted into a suitable plasmid or bacteriophage vector using any one of a number of known techniques. The gene encoding a *hedgehog* protein can also be cloned using established polymerase chain reaction techniques.

20 Preferred nucleic acids encode a *hedgehog* polypeptide comprising an amino acid sequence at least 60% homologous or identical, more preferably 70% homologous or identical, and most preferably 80% homologous or identical with an amino acid sequence selected from the group consisting of SEQ ID Nos:10-18 or 20. Nucleic acids which encode polypeptides at least about 90%, more preferably at least about 95%, and most preferably at 25 least about 98-99% homology or identity with an amino acid sequence represented in one of SEQ ID Nos:10-18 or 20 are also within the scope of the invention.

In addition to native *hedgehog* proteins, *hedgehog* polypeptides preferred by the present invention are at least 60% homologous or identical, more preferably 70% homologous or identical and most preferably 80% homologous or identical with an amino 30 acid sequence represented by any of SEQ ID Nos:10-18 or 20. Polypeptides which are at least 90%, more preferably at least 95%, and most preferably at least about 98-99%

homologous or identical with a sequence selected from the group consisting of SEQ ID Nos:10-18 or 20 are also within the scope of the invention. The only prerequisite is that the *hedgehog* polypeptide is capable of modulating the growth of adipocyte cells.

The term "recombinant protein" refers to a polypeptide of the present invention which is produced by recombinant DNA techniques, wherein generally, DNA encoding a *hedgehog* polypeptide is inserted into a suitable expression vector which is in turn used to transform a host cell to produce the heterologous protein. Moreover, the phrase "derived from", with respect to a recombinant *hedgehog* gene, is meant to include within the meaning of "recombinant protein" those proteins having an amino acid sequence of a native *hedgehog* protein, or an amino acid sequence similar thereto which is generated by mutations including substitutions and deletions (including truncation) of a naturally occurring form of the protein.

The method of the present invention can also be carried out using variant forms of the naturally occurring *hedgehog* polypeptides, e.g., mutational variants.

As is known in the art, *hedgehog* polypeptides can be produced by standard biological techniques or by chemical synthesis. For example, a host cell transfected with a nucleic acid vector directing expression of a nucleotide sequence encoding the subject polypeptides can be cultured under appropriate conditions to allow expression of the peptide to occur. The polypeptide *hedgehog* may be secreted and isolated from a mixture of cells and medium containing the recombinant *hedgehog* polypeptide. Alternatively, the peptide may be retained cytoplasmically by removing the signal peptide sequence from the recombinant *hedgehog* gene and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. The recombinant *hedgehog* polypeptide can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for such peptide. In a preferred embodiment, the recombinant *hedgehog* polypeptide is a fusion protein containing a domain which facilitates its purification, such as an *hedgehog*/GST fusion protein. The host cell may be any prokaryotic or eukaryotic cell.

Recombinant *hedgehog* genes can be produced by ligating nucleic acid encoding an *hedgehog* protein, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells, or both. Expression vectors for production of recombinant forms of the subject *hedgehog* polypeptides include plasmids and other 5 vectors. For instance, suitable vectors for the expression of a *hedgehog* polypeptide include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

A number of vectors exist for the expression of recombinant proteins in yeast. For 10 instance, YEP24, YIP5, YEP51, YEP52, pYES2, and YRP17 are cloning and expression vehicles useful in the introduction of genetic constructs into *S. cerevisiae* (see, for example, Broach *et al.* (1983) in *Experimental Manipulation of Gene Expression*, ed. M. Inouye Academic Press, p. 83, incorporated by reference herein). These vectors can replicate in *E. coli* due to the presence of the pBR322 ori, and in *S. cerevisiae* due to the replication 15 determinant of the yeast 2 micron plasmid. In addition, drug resistance markers such as ampicillin can be used. In an illustrative embodiment, an *hedgehog* polypeptide is produced recombinantly utilizing an expression vector generated by sub-cloning the coding sequence of one of the *hedgehog* genes represented in SEQ ID Nos:1-10.

The preferred mammalian expression vectors contain both prokaryotic sequences, to 20 facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The pcDNA1/amp, pcDNA1/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial 25 plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papillomavirus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. The various methods employed in the preparation of the plasmids and transformation of host organisms are well 30 known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see *Molecular Cloning A*

*Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989) Chapters 16 and 17.

In some instances, it may be desirable to express the recombinant *hedgehog* polypeptide by the use of a baculovirus expression system. Examples of such baculovirus 5 expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the  $\beta$ -gal containing pBlueBac III).

When it is desirable to express only a portion of an *hedgehog* protein, such as a 10 form lacking a portion of the N-terminus, i.e. a truncation mutant which lacks the signal peptide, it may be necessary to add a start codon (ATG) to the oligonucleotide fragment containing the desired sequence to be expressed. It is well known in the art that a 15 methionine at the N-terminal position can be enzymatically cleaved by the use of the enzyme methionine aminopeptidase (MAP). MAP has been cloned from *E. coli* (Ben-Bassat et al. (1987) *J. Bacteriol.* 169:751-757) and *Salmonella typhimurium* and its *in vitro* activity has been demonstrated on recombinant proteins (Miller et al. (1987) *PNAS* 84:2718-1722). Therefore, removal of an N-terminal methionine, if desired, can be 20 achieved either *in vivo* by expressing *hedgehog*-derived polypeptides in a host which produces MAP (e.g., *E. coli* or CM89 or *S. cerevisiae*), or *in vitro* by use of purified MAP (e.g., procedure of Miller et al., *supra*).

20 Alternatively, the coding sequences for the polypeptide can be incorporated as a part of a fusion gene including a nucleotide sequence encoding a different polypeptide. It is widely appreciated that fusion proteins can also facilitate the expression of proteins, and accordingly, can be used in the expression of the *hedgehog* polypeptides of the present invention. For example, *hedgehog* polypeptides can be generated as glutathione-S- 25 transferase (GST-fusion) proteins. Such GST-fusion proteins can enable easy purification of the *hedgehog* polypeptide, as for example by the use of glutathione-derivatized matrices (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al. (N.Y.: John Wiley & Sons, 1991)). In another embodiment, a fusion gene coding for a purification 30 leader sequence, such as a poly-(His)/enterokinase cleavage site sequence, can be used to replace the signal sequence which naturally occurs at the N-terminus of the *hedgehog* protein (e.g. of the pro-form, in order to permit purification of the poly(His)-*hedgehog*

protein by affinity chromatography using a  $\text{Ni}^{2+}$  metal resin. The purification leader sequence can then be subsequently removed by treatment with enterokinase (e.g., see Hochuli et al. (1987) *J. Chromatography* 411:177; and Janknecht et al. *PNAS* 88:8972).

Techniques for making fusion genes are known to those skilled in the art.

5 Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the

10 fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al. John Wiley &

15 Sons: 1992).

*Hedgehog* polypeptides may also be chemically modified to create *hedgehog* derivatives by forming covalent or aggregate conjugates with other chemical moieties, such as glycosyl groups, cholesterol, isoprenoids, lipids, phosphate, acetyl groups and the like. Covalent derivatives of *hedgehog* proteins can be prepared by linking the chemical moieties 20 to functional groups on amino acid sidechains of the protein or at the N-terminus or at the C-terminus of the polypeptide.

For instance, *hedgehog* proteins can be generated to include a moiety, other than sequence naturally associated with the protein, that binds a component of the extracellular matrix and enhances localization of the analog to cell surfaces. For example, sequences 25 derived from the fibronectin "type-III repeat", such as a tetrapeptide sequence R-G-D-S (Pierschbacher et al. (1984) *Nature* 309:30-3; and Kornblith et al. (1985) *EMBO* 4:1755-9) can be added to the *hedgehog* polypeptide to support attachment of the chimeric molecule to a cell through binding ECM components (Ruoslahti et al. (1987) *Science* 238:491-497; Pierschbacher et al. (1987) *J. Biol. Chem.* 262:17294-8.; Hynes (1987) *Cell* 48:549-54; and 30 Hynes (1992) *Cell* 69:11-25).

In a preferred embodiment, the *hedgehog* polypeptide is isolated from, or is otherwise substantially free of, other cellular proteins, especially other extracellular or cell surface associated proteins which may normally be associated with the *hedgehog* polypeptide, unless provided in the form of fusion protein with the *hedgehog* polypeptide.

5 The term "substantially free of other cellular or extracellular proteins" (also referred to herein as "contaminating proteins") or "substantially pure preparations" or "purified preparations" are defined as encompassing preparations of *hedgehog* polypeptides having less than 20% (by dry weight) contaminating protein, and preferably having less than 5% contaminating protein. By "purified", it is meant that the indicated molecule is present in

10 the substantial absence of other biological macromolecules, such as other proteins. The term "purified" as used herein preferably means at least 80% by dry weight, more preferably in the range of 95-99% by weight, and most preferably at least 99.8% by weight, of biological macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 5000, can be

15 present). The term "pure" as used herein preferably has the same numerical limits as "purified" immediately above.

As described above for recombinant polypeptides, isolated *hedgehog* polypeptides can include all or a portion of the amino acid sequences represented in any of SEQ ID Nos:10-18 or 20, or a homologous sequence thereto. Preferred fragments of the subject

20 *hedgehog* proteins correspond to the N-terminal and C-terminal proteolytic fragments of the mature protein. Bioactive fragments of *hedgehog* polypeptides are described in great detail in PCT publications WO 95/18856 and WO 96/17924.

With respect to bioactive fragments of *hedgehog* polypeptide, preferred *hedgehog* therapeutics include at least 50 (contiguous) amino acid residues of a *hedgehog* polypeptide, more preferably at least 100 (contiguous), and even more preferably at least 150 (contiguous) residues.

Another preferred *hedgehog* polypeptide which can be included in the *hedgehog* therapeutic is an N-terminal fragment of the mature protein having a molecular weight of approximately 19 kDa.

30 Preferred human *hedgehog* proteins include N-terminal fragments corresponding approximately to residues 24-197 of SEQ ID No. 15, 28-202 of SEQ ID No. 16, and 23-198

of SEQ ID No. 17. By "corresponding approximately" it is meant that the sequence of interest is at most 20 amino acid residues different in length to the reference sequence, though more preferably at most 5, 10 or 15 amino acid different in length.

As described above for recombinant polypeptides, isolated *hedgehog* polypeptides 5 can include all or a portion of the amino acid sequences represented in SEQ ID No:10, SEQ ID No:11, SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17, SEQ ID No:18 or SEQ ID No:20, or a homologous sequence thereto.

Preferred fragments of the subject *hedgehog* proteins correspond to the N-terminal and C-terminal proteolytic fragments of the mature protein. Bioactive fragments of hedgehog 10 polypeptides are described in great detail in PCT publications WO 95/18856 and WO 96/17924.

Still other preferred *hedgehog* polypeptides includes an amino acid sequence represented by the formula A-B wherein: (i) A represents all or the portion of the amino acid sequence designated by residues 1-168 of SEQ ID No:21; and B represents at least one 15 amino acid residue of the amino acid sequence designated by residues 169-221 of SEQ ID No:21; (ii) A represents all or the portion of the amino acid sequence designated by residues 24-193 of SEQ ID No:15; and B represents at least one amino acid residue of the amino acid sequence designated by residues 194-250 of SEQ ID No:15; (iii) A represents all or the portion of the amino acid sequence designated by residues 25-193 of SEQ ID 20 No:13; and B represents at least one amino acid residue of the amino acid sequence designated by residues 194-250 of SEQ ID No:13; (iv) A represents all or the portion of the amino acid sequence designated by residues 23-193 of SEQ ID No:11; and B represents at least one amino acid residue of the amino acid sequence designated by residues 194-250 of SEQ ID No:11; (v) A represents all or the portion of the amino acid sequence designated by residues 28-197 of SEQ ID No:12; and B represents at least one amino acid residue of the amino acid sequence designated by residues 198-250 of SEQ ID No:12; (vi) A represents all or the portion of the amino acid sequence designated by residues 29-197 of SEQ ID 25 No:16; and B represents at least one amino acid residue of the amino acid sequence designated by residues 198-250 of SEQ ID No:16; or (vii) A represents all or the portion of the amino acid sequence designated by residues 23-193 of SEQ ID No. 17, and B represents at least one amino acid residue of the amino acid sequence designated by residues 194-250 30

of SEQ ID No. 17. In certain preferred embodiments, A and B together represent a contiguous polypeptide sequence designated sequence, A represents at least 25, 50, 75, 100, 125 or 150 (contiguous) amino acids of the designated sequence, and B represents at least 5, 10, or 20 (contiguous) amino acid residues of the amino acid sequence designated by 5 corresponding entry in the sequence listing, and A and B together preferably represent a contiguous sequence corresponding to the sequence listing entry. Similar fragments from other *hedgehog* also contemplated, e.g., fragments which correspond to the preferred fragments from the sequence listing entries which are enumerated above. In preferred embodiments, the *hedgehog* polypeptide includes a C-terminal glycine (or other appropriate 10 residue) which is derivatized with a cholesterol.

Isolated peptidyl portions of *hedgehog* proteins can be obtained by screening peptides recombinantly produced from the corresponding fragment of the nucleic acid encoding such peptides. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc 15 chemistry. For example, a *hedgehog* polypeptide of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or preferably divided into overlapping fragments of a desired length. The fragments can be produced (recombinantly or by chemical synthesis) and tested to identify those peptidyl fragments which can function as either agonists or antagonists of a wild-type (e.g., 20 "authentic") *hedgehog* protein. For example, Román et al. (1994) *Eur J Biochem* 222:65-73 describe the use of competitive-binding assays using short, overlapping synthetic peptides from larger proteins to identify binding domains.

The recombinant *hedgehog* polypeptides of the present invention also include 25 homologs of the authentic *hedgehog* proteins, such as versions of those protein which are resistant to proteolytic cleavage, as for example, due to mutations which alter potential cleavage sequences or which inactivate an enzymatic activity associated with the protein. *Hedgehog* homologs of the present invention also include proteins which have been post-translationally modified in a manner different than the authentic protein. Exemplary derivatives of *hedgehog* proteins include polypeptides which lack N-glycosylation sites 30 (e.g. to produce an unglycosylated protein), which lack sites for cholesterolization, and/or which lack N-terminal and/or C-terminal sequences.

Modification of the structure of the subject *hedgehog* polypeptides can also be for such purposes as enhancing therapeutic or prophylactic efficacy, or stability (e.g., *ex vivo* shelf life and resistance to proteolytic degradation *in vivo*). Such modified peptides, when designed to retain at least one activity of the naturally-occurring form of the protein, are 5 considered functional equivalents of the *hedgehog* polypeptides described in more detail herein. Such modified peptides can be produced, for instance, by amino acid substitution, deletion, or addition.

It is well known in the art that one could reasonably expect that certain isolated 10 replacements of amino acids, e.g., replacement of an amino acid residue with another related amino acid (i.e. isosteric and/or isoelectric mutations), can be carried out without major effect on the biological activity of the resulting molecule. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are can be divided into four families: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) nonpolar = alanine, valine, 15 leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In similar fashion, the amino acid repertoire can be grouped as (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine histidine, (3) aliphatic = glycine, alanine, valine, 20 leucine, isoleucine, serine, threonine, with serine and threonine optionally be grouped separately as aliphatic-hydroxyl; (4) aromatic = phenylalanine, tyrosine, tryptophan; (5) amide = asparagine, glutamine; and (6) sulfur -containing = cysteine and methionine. (see, for example, *Biochemistry*, 2nd ed., Ed. by L. Stryer, WH Freeman and Co.: 1981).

Whether a change in the amino acid sequence of a peptide results in a functional *hedgehog* 25 homolog (e.g. functional in the sense that it acts to mimic or antagonize the wild-type form) can be readily determined by assessing the ability of the variant peptide to produce a response in cells in a fashion similar to the wild-type protein, or competitively inhibit such a response. Polypeptides in which more than one replacement has taken place can readily be tested in the same manner.

30 It is specifically contemplated that the methods of the present invention can be carried using homologs of naturally occurring hedgehog proteins. In one embodiment, the

invention contemplates using hedgehog polypeptides generated by combinatorial mutagenesis. Such methods, as are known in the art, are convenient for generating both point and truncation mutants, and can be especially useful for identifying potential variant sequences (e.g. homologs) that are functional in binding to a receptor for *hedgehog* 5 proteins. The purpose of screening such combinatorial libraries is to generate, for example, novel *hedgehog* homologs which can act as either agonists or antagonist. To illustrate, *hedgehog* homologs can be engineered by the present method to provide more efficient binding to a cognate receptor, such as *patched*, yet still retain at least a portion of an activity associated with *hedgehog*. Thus, combinatorially-derived homologs can be 10 generated to have an increased potency relative to a naturally occurring form of the protein. Likewise, *hedgehog* homologs can be generated by the present combinatorial approach to act as antagonists, in that they are able to mimic, for example, binding to other extracellular matrix components (such as receptors), yet not induce any biological response, thereby inhibiting the action of authentic *hedgehog* or *hedgehog* agonists. Moreover, manipulation 15 of certain domains of *hedgehog* by the present method can provide domains more suitable for use in fusion proteins, such as one that incorporates portions of other proteins which are derived from the extracellular matrix and/or which bind extracellular matrix components.

To further illustrate the state of the art of combinatorial mutagenesis, it is noted that the review article of Gallop et al. (1994) *J Med Chem* 37:1233 describes the general state of 20 the art of combinatorial libraries as of the earlier 1990's. In particular, Gallop et al state at page 1239 "[s]creening the analog libraries aids in determining the minimum size of the active sequence and in identifying those residues critical for binding and intolerant of substitution". In addition, the Ladner et al. PCT publication WO90/02809, the Goeddel et al. U.S. Patent 5,223,408, and the Markland et al. PCT publication WO92/15679 illustrate 25 specific techniques which one skilled in the art could utilize to generate libraries of *hedgehog* variants which can be rapidly screened to identify variants/fragments which retained a particular activity of the *hedgehog* polypeptides. These techniques are exemplary of the art and demonstrate that large libraries of related variants/truncants can be generated and assayed to isolate particular variants without undue experimentation. Gustin 30 et al. (1993) *Virology* 193:653, and Bass et al. (1990) *Proteins: Structure, Function and*

*Genetics* 8:309-314 also describe other exemplary techniques from the art which can be adapted as means for generating mutagenic variants of *hedgehog* polypeptides.

Indeed, it is plain from the combinatorial mutagenesis art that large scale mutagenesis of *hedgehog* proteins, without any preconceived ideas of which residues were 5 critical to the biological function, and generate wide arrays of variants having equivalent biological activity. Indeed, it is the ability of combinatorial techniques to screen billions of different variants by high throughout analysis that removes any requirement of *a priori* understanding or knowledge of critical residues.

To illustrate, the amino acid sequences for a population of *hedgehog* homologs or 10 other related proteins are aligned, preferably to promote the highest homology possible. Such a population of variants can include, for example, *hedgehog* homologs from one or more species. Amino acids which appear at each position of the aligned sequences are selected to create a degenerate set of combinatorial sequences. In a preferred embodiment, the variegated library of *hedgehog* variants is generated by combinatorial mutagenesis at 15 the nucleic acid level, and is encoded by a variegated gene library. For instance, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential *hedgehog* sequences are expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g. for phage display) containing the set of *hedgehog* sequences therein.

20 As illustrated in PCT publication WO 95/18856, to analyze the sequences of a population of variants, the amino acid sequences of interest can be aligned relative to sequence homology. The presence or absence of amino acids from an aligned sequence of a particular variant is relative to a chosen consensus length of a reference sequence, which can be real or artificial.

25 In an illustrative embodiment, alignment of exons 1, 2 and a portion of exon 3 encoded sequences (e.g. the N-terminal approximately 221 residues of the mature protein) of each of the *Shh* clones produces a degenerate set of *Shh* polypeptides represented by the general formula:

C-G-P-G-R-G-X(1)-G-X(2)-R-R-H-P-K-K-L-T-P-L-A-Y-K-Q-F-I-P-N-V-  
30 A-E-K-T-L-G-A-S-G-R-Y-E-G-K-I-X(3)-R-N-S-E-R-F-K-E-L-T-P-N-Y-N-  
P-D-I-I-F-K-D-E-E-N-T-G-A-D-R-L-M-T-Q-R-C-K-D-K-L-N-X(4)-L-A-I-

-41-

S-V-M-N-X(5)-W-P-G-V-X(6)-L-R-V-T-E-G-W-D-E-D-G-H-H-X(7)-E-E-  
 S-L-H-Y-E-G-R-A-V-D-I-T-T-S-D-R-D-X(8)-S-K-Y-G-X(9)-L-X(10)-R-L-  
 A-V-E-A-G-F-D-W-V-Y-Y-E-S-K-A-H-I-H-C-S-V-K-A-E-N-S-V-A-A-K-  
 S-G-G-C-F-P-G-S-A-X(11)-V-X(12)-L-X(13)-X(14)-G-G-X(15)-K-X-(16)-  
 5 V-K-D-L-X(17)-P-G-D-X(18)-V-L-A-A-D-X(19)-X(20)-G-X(21)-L-X(22)-  
     X(23)-S-D-F-X(24)-X(25)-F-X(26)-D-R (SEQ ID No: 21)

wherein each of the degenerate positions "X" can be an amino acid which occurs in that position in one of the human, mouse, chicken or zebrafish *Shh* clones, or, to expand the library, each X can also be selected from amongst amino acid residue which would be

10 conservative substitutions for the amino acids which appear naturally in each of those positions. For instance, Xaa(1) represents Gly, Ala, Val, Leu, Ile, Phe, Tyr or Trp ; Xaa(2) represents Arg, His or Lys; Xaa(3) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(4) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(5) represents Lys, Arg, His, Asn or Gln; Xaa(6) represents Lys, Arg or His; Xaa(7) represents Ser, Thr, Tyr, Trp or Phe; Xaa(8)

15 represents Lys, Arg or His; Xaa(9) represents Met, Cys, Ser or Thr; Xaa(10) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(11) represents Leu, Val, Met, Thr or Ser; Xaa(12) represents His, Phe, Tyr, Ser, Thr, Met or Cys; Xaa(13) represents Gln, Asn, Glu, or Asp; Xaa(14) represents His, Phe, Tyr, Thr, Gln, Asn, Glu or Asp; Xaa(15) represents Gln, Asn, Glu, Asp, Thr, Ser, Met or Cys; Xaa(16) represents Ala, Gly, Cys, Leu, Val or Met;

20 Xaa(17) represents Arg, Lys, Met, Ile, Asn, Asp, Glu, Gln, Ser, Thr or Cys; Xaa(18) represents Arg, Lys, Met or Ile; Xaa(19) represents Ala, Gly, Cys, Asp, Glu, Gln, Asn, Ser, Thr or Met; Xaa(20) represents Ala, Gly, Cys, Asp, Asn, Glu or Gln; Xaa(21) represents Arg, Lys, Met, Ile, Asn, Asp, Glu or Gln; Xaa(22) represent Leu, Val, Met or Ile; Xaa(23) represents Phe, Tyr, Thr, His or Trp; Xaa(24) represents Ile, Val, Leu or Met; Xaa(25)

25 represents Met, Cys, Ile, Leu, Val, Thr or Ser; Xaa(26) represents Leu, Val, Met, Thr or Ser. In an even more expansive library, each X can be selected from any amino acid.

In similar fashion, alignment of each of the human, mouse, chicken and zebrafish *hedgehog* clones, can provide a degenerate polypeptide sequence represented by the general formula:

30 C-G-P-G-R-G-X(1)-X(2)-X(3)-R-R-X(4)-X(5)-X(6)-P-K-X(7)-L-X(8)-P-L-  
     X(9)-Y-K-Q-F-X(10)-P-X(11)-X(12)-X(13)-E-X(14)-T-L-G-A-S-G-X(15)-

-42-

X(16)-E-G-X(17)-X(18)-X(19)-R-X(20)-S-E-R-F-X(21)-X(22)-L-T-P-N-Y-  
N-P-D-I-I-F-K-D-E-E-N-X(23)-G-A-D-R-L-M-T-X(24)-R-C-K-X(25)-  
X(26)-X(27)-N-X(28)-L-A-I-S-V-M-N-X(29)-W-P-G-V-X(30)-L-R-V-T-E-  
G-X(31)-D-E-D-G-H-H-X(32)-X(33)-S-L-H-Y-E-G-R-A-X(35)-D-I-  
5 T-T-S-D-R-D-X(36)-X(37)-K-Y-G-X(38)-L-X(39)-R-L-A-V-E-A-G-F-D-  
W-V-Y-Y-E-S-X(40)-X(41)-H-X(42)-H-X(43)-S-V-K-X(44)-X(45) (SEQ

IDNo:22

wherein, as above, each of the degenerate positions "X" can be an amino acid which occurs in a corresponding position in one of the wild-type clones, and may also include amino acid 10 residue which would be conservative substitutions, or each X can be any amino acid residue. In an exemplary embodiment, Xaa(1) represents Gly, Ala, Val, Leu, Ile, Pro, Phe or Tyr; Xaa(2) represents Gly, Ala, Val, Leu or Ile; Xaa(3) represents Gly, Ala, Val, Leu, Ile, Lys, His or Arg; Xaa(4) represents Lys, Arg or His; Xaa(5) represents Phe, Trp, Tyr or an amino acid gap; Xaa(6) represents Gly, Ala, Val, Leu, Ile or an amino acid gap; Xaa(7) 15 represents Asn, Gln, His, Arg or Lys; Xaa(8) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(9) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(10) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(11) represents Ser, Thr, Gln or Asn; Xaa(12) represents Met, Cys, Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(13) represents Gly, Ala, Val, Leu, Ile or Pro; Xaa(14) represents Arg, His or Lys; Xaa(15) represents Gly, Ala, Val, Leu, Ile, Pro, Arg, 20 His or Lys; Xaa(16) represents Gly, Ala, Val, Leu, Ile, Phe or Tyr; Xaa(17) represents Arg, His or Lys; Xaa(18) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(19) represents Thr or Ser; Xaa(20) represents Gly, Ala, Val, Leu, Ile, Asn or Gln; Xaa(21) represents Arg, His or Lys; Xaa(22) represents Asp or Glu; Xaa(23) represents Ser or Thr; Xaa(24) represents 25 Glu, Asp, Gln or Asn; Xaa(25) represents Glu or Asp; Xaa(26) represents Arg, His or Lys; Xaa(27) represents Gly, Ala, Val, Leu or Ile; Xaa(28) represents Gly, Ala, Val, Leu, Ile, Thr or Ser; Xaa(29) represents Met, Cys, Gln, Asn, Arg, Lys or His; Xaa(30) represents Arg, His or Lys; Xaa(31) represents Trp, Phe, Tyr, Arg, His or Lys; Xaa(32) represents Gly, Ala, Val, Leu, Ile, Ser, Thr, Tyr or Phe; Xaa(33) represents Gln, Asn, Asp or Glu; Xaa(34) represents Asp or Glu; Xaa(35) represents Gly, Ala, Val, Leu, or Ile; Xaa(36) 30 represents Arg, His or Lys; Xaa(37) represents Asn, Gln, Thr or Ser; Xaa(38) represents Gly, Ala, Val, Leu, Ile, Ser, Thr, Met or Cys; Xaa(39) represents Gly, Ala, Val, Leu, Ile,

Thr or Ser; Xaa(40) represents Arg, His or Lys; Xaa(41) represents Asn, Gln, Gly, Ala, Val, Leu or Ile; Xaa(42) represents Gly, Ala, Val, Leu or Ile; Xaa(43) represents Gly, Ala, Val, Leu, Ile, Ser, Thr or Cys; Xaa(44) represents Gly, Ala, Val, Leu, Ile, Thr or Ser; and Xaa(45) represents Asp or Glu.

5        There are many ways by which the library of potential *hedgehog* homologs can be generated from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. The purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired set of potential 10 *hedgehog* sequences. The synthesis of degenerate oligonucleotides is well known in the art (see for example, Narang, SA (1983) *Tetrahedron* 39:3; Itakura et al. (1981) *Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules*, ed. AG Walton, Amsterdam: Elsevier pp273-289; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477. Such techniques have been employed 15 in the directed evolution of other proteins (see, for example, Scott et al. (1990) *Science* 249:386-390; Roberts et al. (1992) *PNAS* 89:2429-2433; Devlin et al. (1990) *Science* 249: 404-406; Cwirla et al. (1990) *PNAS* 87: 6378-6382; as well as U.S. Patents Nos. 5,223,409, 5,198,346, and 5,096,815).

20        A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations, and for screening cDNA libraries for gene products having a certain property. Such techniques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of *hedgehog* homologs. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming 25 appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the illustrative assays described below are amenable to high through-put analysis as necessary 30 to screen large numbers of degenerate *hedgehog* sequences created by combinatorial mutagenesis techniques.

In one embodiment, the combinatorial library is designed to be secreted (e.g. the polypeptides of the library all include a signal sequence but no transmembrane or cytoplasmic domains), and is used to transfet a eukaryotic cell that can be co-cultured with pre-adipocyte (stem or progenitor) cells. A functional *hedgehog* protein secreted by the 5 cells expressing the combinatorial library will diffuse to neighboring pre-adipocyte cells and induce a particular biological response, such as proliferation or differentiation. The pattern of detection of such a change in phenotype will resemble a gradient function, and will allow the isolation (generally after several repetitive rounds of selection) of cells producing *hedgehog* homologs active as anti-adipocytic agents. Likewise, *hedgehog* 10 antagonists can be selected in similar fashion by the ability of the cell producing a functional antagonist to protect neighboring cells (e.g., to inhibit proliferation) from the effect of wild-type *hedgehog* added to the culture media.

To illustrate, target pre-adipocyte cells are cultured in 24-well microtitre plates. Other eukaryotic cells are transfected with the combinatorial *hedgehog* gene library and 15 cultured in cell culture inserts (e.g. Collaborative Biomedical Products, Catalog #40446) that are able to fit into the wells of the microtitre plate. The cell culture inserts are placed in the wells such that recombinant *hedgehog* homologs secreted by the cells in the insert can diffuse through the porous bottom of the insert and contact the target cells in the microtitre plate wells. After a period of time sufficient for functional forms of a *hedgehog* protein to 20 produce a measurable response in the target cells, such as growth state, the inserts are removed and the effect of the variant *hedgehog* proteins on the target cells determined. Cells from the inserts corresponding to wells which score positive for activity can be split and re-cultured on several inserts, the process being repeated until the active clones are identified.

25 In yet another screening assay, the candidate *hedgehog* gene products are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to associate with a *hedgehog*-binding moiety (such as the *patched* protein or other *hedgehog* receptor) via this gene product is detected in a "panning assay". Such panning steps can be carried out on cells cultured from embryos. For instance, the gene library can be cloned 30 into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991)

*Bio/Technology* 9:1370-1371; and Goward et al. (1992) *TIBS* 18:136-140). In a similar fashion, fluorescently labeled molecules which bind *hedgehog* can be used to score for potentially functional *hedgehog* homologs. Cells can be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, separated 5 by a fluorescence-activated cell sorter.

In an alternate embodiment, the gene library is expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at very high 10 concentrations, large number of phage can be screened at one time. Second, since each infectious phage displays the combinatorial gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E.coli* filamentous phages M13, fd, and f1 are most often used in phage display libraries, as either of the phage gIII or gVIII 15 coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) *J. Biol. Chem.* 267:16007-16010; Griffiths et al. (1993) *EMBO J* 12:725-734; Clackson et al. (1991) *Nature* 352:624-628; and Barbas et al. (1992) *PNAS* 89:4457-4461).

20 In an illustrative embodiment, the recombinant phage antibody system (RPAS, Pharamacia Catalog number 27-9400-01) can be easily modified for use in expressing and screening *hedgehog* combinatorial libraries. For instance, the pCANTAB 5 phagemid of the RPAS kit contains the gene which encodes the phage gIII coat protein. The *hedgehog* combinatorial gene library can be cloned into the phagemid adjacent to the gIII signal 25 sequence such that it will be expressed as a gIII fusion protein. After ligation, the phagemid is used to transform competent *E. coli* TG1 cells. Transformed cells are subsequently infected with M13KO7 helper phage to rescue the phagemid and its candidate *hedgehog* gene insert. The resulting recombinant phage contain phagemid DNA encoding a specific candidate *hedgehog*, and display one or more copies of the corresponding fusion 30 coat protein. The phage-displayed candidate *hedgehog* proteins which are capable of binding an *hedgehog* receptor are selected or enriched by panning. For instance, the phage

library can be applied to cells which express the *patched* protein and unbound phage washed away from the cells. The bound phage is then isolated, and if the recombinant phage express at least one copy of the wild type gIII coat protein, they will retain their ability to infect *E. coli*. Thus, successive rounds of reinfection of *E. coli*, and panning will 5 greatly enrich for *hedgehog* homologs, which can then be screened for further biological activities in order to differentiate agonists and antagonists.

Combinatorial mutagenesis has a potential to generate very large libraries of mutant proteins, e.g., in the order of  $10^{26}$  molecules. Combinatorial libraries of this size may be technically challenging to screen even with high throughput screening assays such as phage 10 display. To overcome this problem, a new technique has been developed recently, recursive ensemble mutagenesis (REM), which allows one to avoid the very high proportion of non-functional proteins in a random library and simply enhances the frequency of functional proteins, thus decreasing the complexity required to achieve a useful sampling of sequence space. REM is an algorithm which enhances the frequency of 15 functional mutants in a library when an appropriate selection or screening method is employed (Arkin and Yourvan, 1992, *PNAS USA* 89:7811-7815; Yourvan et al., 1992, *Parallel Problem Solving from Nature*, 2., In Maenner and Manderick, eds., Elsevier Publishing Co., Amsterdam, pp. 401-410; Delgrave et al., 1993, *Protein Engineering* 6(3):327-331).

20 The invention also provides for reduction of the *hedgehog* protein to generate mimetics, e.g. peptide or non-peptide agents, which are able to disrupt binding of a *hedgehog* polypeptide of the present invention with an *hedgehog* receptor. Thus, such mutagenic techniques as described above are also useful to map the determinants of the *hedgehog* proteins which participate in protein-protein interactions involved in, for 25 example, binding of the subject *hedgehog* polypeptide to other extracellular matrix components. To illustrate, the critical residues of a subject *hedgehog* polypeptide which are involved in molecular recognition of an *hedgehog* receptor such as *patched* can be determined and used to generate *hedgehog*-derived peptidomimetics which competitively inhibit binding of the authentic *hedgehog* protein with that moiety. By employing, for 30 example, scanning mutagenesis to map the amino acid residues of each of the subject *hedgehog* proteins which are involved in binding other extracellular proteins,

peptidomimetic compounds can be generated which mimic those residues of the *hedgehog* protein which facilitate the interaction. Such mimetics may then be used to interfere with the normal function of a *hedgehog* protein. For instance, non-hydrolyzable peptide analogs of such residues can be generated using benzodiazepine (e.g., see Freidinger et al. in 5 *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gama lactam rings (Garvey et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. 10 (1986) *J Med Chem* 29:295; and Ewenson et al. in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), -turn dipeptide cores (Nagai et al. (1985) *Tetrahedron Lett* 26:647; and Sato et al. (1986) *J Chem Soc Perkin Trans* 1:1231), and -aminoalcohols (Gordon et al. (1985) *Biochem Biophys Res Commun* 126:419; and Dann et al. (1986) *Biochem Biophys Res Commun* 134:71).

Recombinantly produced forms of the *hedgehog* proteins can be produced using, e.g, expression vectors containing a nucleic acid encoding a *hedgehog* polypeptide, operably linked to at least one transcriptional regulatory sequence. Operably linked is intended to mean that the nucleotide sequence is linked to a regulatory sequence in a 20 manner which allows expression of the nucleotide sequence. Regulatory sequences are art-recognized and are selected to direct expression of a *hedgehog* polypeptide. Accordingly, the term transcriptional regulatory sequence includes promoters, enhancers and other expression control elements. Such regulatory sequences are described in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA 25 (1990). For instance, any of a wide variety of expression control sequences, sequences that control the expression of a DNA sequence when operatively linked to it, may be used in these vectors to express DNA sequences encoding *hedgehog* polypeptide. Such useful expression control sequences, include, for example, a viral LTR, such as the LTR of the Moloney murine leukemia virus, the early and late promoters of SV40, adenovirus or 30 cytomegalovirus immediate early promoter, the lac system, the trp system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the major

operator and promoter regions of phage  $\lambda$ , the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast  $\alpha$ -mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of 5 genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other proteins encoded by the vector, such as antibiotic markers, 10 should also be considered.

In addition to providing a ready source of hedgehog polypeptides for purification, the gene constructs of the present invention can also be used as a part of a gene therapy protocol to deliver nucleic acids encoding either an agonistic or antagonistic form of a *hedgehog* polypeptide. Thus, another aspect of the invention features expression vectors 15 for *in vivo* transfection of a *hedgehog* polypeptide in particular cell types so as cause ectopic expression of a *hedgehog* polypeptide in an adipocyte tissue.

Formulations of such expression constructs may be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively delivering the recombinant gene to cells *in vivo*. Approaches include insertion of the hedgehog coding 20 sequence in viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, or recombinant bacterial or eukaryotic plasmids. Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular 25 carriers, as well as direct injection of the gene construct or CaPO<sub>4</sub> precipitation carried out *in vivo*. It will be appreciated that because transduction of appropriate target cells represents the critical first step in gene therapy, choice of the particular gene delivery system will depend on such factors as the phenotype of the intended target and the route of administration, e.g. locally or systemically. Furthermore, it will be recognized that the 30 particular gene construct provided for *in vivo* transduction of *hedgehog* expression are also

useful for *in vitro* transduction of cells, such as for use in the *ex vivo* tissue culture systems described below.

A preferred approach for *in vivo* introduction of nucleic acid into a cell is by use of a viral vector containing nucleic acid, e.g. a cDNA, encoding the particular form of the 5 *hedgehog* polypeptide desired. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.

Retrovirus vectors and adeno-associated virus vectors are generally understood to be 10 the recombinant gene delivery system of choice for the transfer of exogenous genes *in vivo*, particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. A major prerequisite for the use of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell 15 population. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D. (1990) *Blood* 76:271). Thus, recombinant retrovirus can be constructed in which part of the retroviral coding sequence 20 (*gag*, *pol*, *env*) has been replaced by nucleic acid encoding a hedgehog polypeptide and renders the retrovirus replication defective. The replication defective retrovirus is then packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in 25 Molecular Biology, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include Crip, Cre, 2 and Am. Retroviruses have been used 30 to introduce a variety of genes into many different cell types, including adipocyte cells, *in vitro* and/or *in vivo* (see for example Eglitis, et al. (1985) *Science* 230:1395-1398; Danos

and Mulligan (1988) *Proc. Natl. Acad. Sci. USA* 85:6460-6464; Wilson et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:3014-3018; Armentano et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Huber et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8039-8043; Ferry et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-8381; Chowdhury et al. (1991) *Science* 254:1802-1805; van Beusechem et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:7640-7644; Kay et al. (1992) *Human Gene Therapy* 3:641-647; Dai et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895; Hwu et al. (1993) *J. Immunol.* 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

10 Furthermore, it has been shown that it is possible to limit the infection spectrum of retroviruses and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle (see, for example PCT publications WO93/25234 and WO94/06920). For instance, strategies for the modification of the infection spectrum of retroviral vectors include: coupling antibodies specific for cell surface 15 antigens to the viral *env* protein (Roux et al. (1989) *PNAS* 86:9079-9083; Julian et al. (1992) *J. Gen Virol* 73:3251-3255; and Goud et al. (1983) *Virology* 163:251-254); or coupling cell surface receptor ligands to the viral *env* proteins (Neda et al. (1991) *J Biol Chem* 266:14143-14146). Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the *env* protein to an asialoglycoprotein), as 20 well as by generating fusion proteins (e.g. single-chain antibody/*env* fusion proteins). This technique, while useful to limit or otherwise direct the infection to certain tissue types, can also be used to convert an ecotropic vector in to an amphotropic vector.

Moreover, use of retroviral gene delivery can be further enhanced by the use of tissue- or cell-specific transcriptional regulatory sequences which control expression of the 25 *hedgehog* gene of the retroviral vector.

Another viral gene delivery system useful in the present method utilizes adenovirus-derived vectors. The genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See for example Berkner et al. (1988) *BioTechniques* 6:616; 30 Rosenfeld et al. (1991) *Science* 252:431-434; and Rosenfeld et al. (1992) *Cell* 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other

strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Recombinant adenoviruses can be advantageous in certain circumstances in that they can be used to infect a wide variety of cell types, including adipocyte cells. Furthermore, the virus particle is relatively stable and amenable to purification and concentration, and as above, 5 can be modified so as to affect the spectrum of infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the 10 adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al. cited *supra*; Haj-Ahmand and Graham (1986) *J. Virol.* 57:267). Most replication-defective adenoviral vectors currently in use and therefore favored by the present invention are deleted for all or parts of the viral E1 and E3 genes but retain as much as 80% of the adenoviral genetic material (see, e.g., Jones et al. (1979) *Cell* 15 16:683; Berkner et al., *supra*; and Graham et al. in *Methods in Molecular Biology*, E.J. Murray, Ed. (Humana, Clifton, NJ, 1991) vol. 7. pp. 109-127). Expression of the inserted *hedgehog* gene can be under control of, for example, the E1A promoter, the major late promoter (MLP) and associated leader sequences, the E3 promoter, or exogenously added promoter sequences.

20 In addition to viral transfer methods, such as those illustrated above, non-viral methods can also be employed to cause expression of a *hedgehog* polypeptide in the tissue of an animal. Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In preferred embodiments, non-viral gene delivery systems of the present invention rely on endocytic 25 pathways for the uptake of the *hedgehog* polypeptide gene by the targeted cell. Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes.

30 In clinical settings, the gene delivery systems for the therapeutic *hedgehog* gene can be introduced into a patient by any of a number of methods, each of which is familiar in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the

protein in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited with

5 introduction into the animal being quite localized. For example, the gene delivery vehicle can be introduced by catheter (see U.S. Patent 5,328,470) or by stereotactic injection (e.g. Chen et al. (1994) *PNAS* 91: 3054-3057). A *hedgehog* expression construct can be delivered in a gene therapy construct to dermal cells by; e.g., electroporation using techniques described, for example, by Dev et al. ((1994) *Cancer Treat Rev* 20:105-115).

10 The pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can comprise one or more cells which produce the gene

15 delivery system.

In yet another embodiment, the hedgehog or ptc therapeutic can be a "gene activation" construct which, by homologous recombination with a genomic DNA, alters the transcriptional regulatory sequences of an endogenous gene. For instance, the gene activation construct can replace the endogenous promoter of a *hedgehog* gene with a

20 heterologous promoter, e.g., one which causes constitutive expression of the *hedgehog* gene or which causes inducible expression of the gene under conditions different from the normal expression pattern of the gene. Other genes in the *patched* signaling pathway can be similarly targeted. A variety of different formats for the gene activation constructs are available. See, for example, the Transkaryotic Therapies, Inc PCT publications

25 WO93/09222, WO95/31560, WO96/29411, WO95/31560 and WO94/12650.

In preferred embodiments, the nucleotide sequence used as the gene activation construct can be comprised of (1) DNA from some portion of the endogenous *hedgehog* gene (exon sequence, intron sequence, promoter sequences, etc.) which direct recombination and (2) heterologous transcriptional regulatory sequence(s) which is to be

30 operably linked to the coding sequence for the genomic *hedgehog* gene upon recombination of the gene activation construct. For use in generating cultures of *hedgehog* producing cells,

the construct may further include a reporter gene to detect the presence of the knockout construct in the cell.

The gene activation construct is inserted into a cell, and integrates with the genomic DNA of the cell in such a position so as to provide the heterologous regulatory sequences in 5 operative association with the native *hedgehog* gene. Such insertion occurs by homologous recombination, i.e., recombination regions of the activation construct that are homologous to the endogenous *hedgehog* gene sequence hybridize to the genomic DNA and recombine with the genomic sequences so that the construct is incorporated into the corresponding position of the genomic DNA.

10 The terms "recombination region" or "targeting sequence" refer to a segment (i.e., a portion) of a gene activation construct having a sequence that is substantially identical to or substantially complementary to a genomic gene sequence, e.g., including 5' flanking sequences of the genomic gene, and can facilitate homologous recombination between the genomic sequence and the targeting transgene construct.

15 As used herein, the term "replacement region" refers to a portion of a activation construct which becomes integrated into an endogenous chromosomal location following homologous recombination between a recombination region and a genomic sequence.

The heterologous regulatory sequences, e.g., which are provided in the replacement region, can include one or more of a variety elements, including: promoters (such as 20 constitutive or inducible promoters), enhancers, negative regulatory elements, locus control regions, transcription factor binding sites, or combinations thereof. Promoters/enhancers which may be used to control the expression of the targeted gene *in vivo* include, but are not limited to, the cytomegalovirus (CMV) promoter/enhancer (Karasuyama et al., 1989, *J. Exp. Med.*, 169:13), the human  $\beta$ -actin promoter (Gunning et al. (1987) *PNAS* 84:4831-4835), the glucocorticoid-inducible promoter present in the mouse mammary tumor virus long terminal repeat (MMTV LTR) (Klessig et al. (1984) *Mol. Cell Biol.* 4:1354-1362), the long terminal repeat sequences of Moloney murine leukemia virus (MuLV LTR) (Weiss et al. (1985) *RNA Tumor Viruses*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York), the SV40 early or late region promoter (Bernoist et al. (1981) *Nature* 290:304-310; 25 Templeton et al. (1984) *Mol. Cell Biol.*, 4:817; and Sprague et al. (1983) *J. Virol.*, 45:773), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (RSV) 30

(Yamamoto et al., 1980, *Cell*, 22:787-797), the herpes simplex virus (HSV) thymidine kinase promoter/enhancer (Wagner et al. (1981) *PNAS* 82:3567-71), and the herpes simplex virus LAT promoter (Wolfe et al. (1992) *Nature Genetics*, 1:379-384).

5 In an exemplary embodiment, portions of the 5' flanking region of the human Shh gene are amplified using primers which add restriction sites, to generate the following fragments

5'-

gcgcgcttcgaaGCGAGGCAGCCAGCGAGGGAGAGAGCGAGCAGCGGGCGAGCCGGAGC-  
GAGGAAatcgatgcgcgc (primer 1)

10

5'-

gcgcgcagatctGGGAAAGCGCAAGAGAGAGCGCACACGCACACACCCGCCGCGCG-  
CACTCGggatccgcgcgc (primer 2)

15 As illustrated, primer 1 includes a 5' non-coding region of the human Shh gene and is flanked by an AsuII and Clal restriction sites. Primer 2 includes a portion of the 5' non-coding region immediately 3' to that present in primer 1. The hedgehog gene sequence is flanked by XhoII and BamHI restriction sites. The purified amplimers are cut with each of the enzymes as appropriate.

20 The vector pCDNA1.1 (Invitrogen) includes a CMV promoter. The plasmid is cut with AsuII, which cleaves just 3' to the CMV promoter sequence. The AsuII/Clal fragment of primer 1 is ligated to the AsuII cleavage site of the pcDNA vector. The Clal/AsuII ligation destroys the AsuII site at the 3' end of a properly inserted primer 1.

25 The vector is then cut with BamHI, and an XhoII/BamHI fragment of primer 2 is ligated to the BamHI cleavage site. As above, the BamHI/XhoII ligation destroys the BamHI site at the 5' end of a properly inserted primer 2.

30 Individual colonies are selected, cut with AsuII and BamHI, and the size of the AsuII/BamHI fragment determined. Colonies in which both the primer 1 and primer 2 sequences are correctly inserted are further amplified, and cut with AsuII and BamHI to produce the gene activation construct

-55-

cgaaggcgaggcagccagcgagggagagagcgagcggcgagccggcgaggaaATCGAAGGTTCGAATC  
CTTCCCCCACCACCATCACTTCAAAAGTCCGAAAGAATCTGCTCCCTGCTTGT  
GTGTTGGAGGTCGCTGAGTAGTGCAGAGTAAAATTAAAGCTACAACAAGGCA  
AGGCTTGACCGACAATTGCATGAAGAATCTGCTAGGGTTAGGCAGTTGCGCT  
5 GCTTCGCGATGTACGGGCCAGATATACCGCGTTGACATTGATTATTGACTAGTTA  
TTAATAGTAATCAATTACGGGTCAATTAGTCATAGCCCATATATGGAGTCCG  
CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCAACGACCCCCG  
CCCATTGACGTCAATAATGACGTATGTTCCATAGTAACGCCAATAGGGACTTT  
CCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCACTGGCAGTACA  
10 TCAAGTGTATCATATGCCAAGTACGCCCTATTGACGTCAATGACGGTAAATG  
GCCCGCCTGGCATTATGCCAGTACATGACCTTATGGGACTTCTACTTGGCA  
GTACATCTACGTATTAGTCATCGCTATTACCATGGTATGCGGTTTGGCAGTA  
CATCAATGGCGTGGATAGCGGTTGACTCACGGGATTCCAAGTCTCCACCC  
CATTGACGTCAATGGGAGTTGGCACCAAAATCAACGGACTTCCAAA  
15 ATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGCGGTAGGCGTGTACGGT  
GGGAGGTCTATATAAGCAGAGCTCTGGCTAACTAGAGAACCCACTGCTTACT  
GGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGTACCGA  
GCTCGGATCgatctggaaagcgcaagagagagcgcacacacccgccgcgcactcg  
In this construct, the flanking primer 1 and primer 2 sequences provide the recombination  
20 region which permits the insertion of the CMV promoter in front of the coding sequence for  
the human *Shh* gene. Other heterologous promoters (or other transcriptional regulatory  
sequences) can be inserted in a genomic *hedgehog* gene by a similar method.  
25 In still other embodiments, the replacement region merely deletes a negative  
transcriptional control element of the native gene, e.g., to activate expression, or ablates a  
positive control element, e.g., to inhibit expression of the targeted gene.

*V. Exemplary ptc therapeutic compounds.*

In another embodiment, the subject method is carried out using a ptc therapeutic composition. Such compositions can be generated with, for example, compounds which  
30 bind to patched and alter its signal transduction activity, compounds which alter the binding and/or enzymatic activity of a protein (e.g., intracellular) involved in patched signal

pathway, and compounds which alter the level of expression of a *hedgehog* protein, a *patched* protein or a protein involved in the intracellular signal transduction pathway of *patched*.

The availability of purified and recombinant *hedgehog* polypeptides facilitates the 5 generation of assay systems which can be used to screen for drugs, such as small organic molecules, which are either agonists or antagonists of the normal cellular function of a *hedgehog* and/or *patched* protein, particularly their role in the pathogenesis of adipocyte cell proliferation and/or differentiation. In one embodiment, the assay evaluates the ability of a compound to modulate binding between a *hedgehog* polypeptide and a *hedgehog* 10 receptor such as *patched*. In other embodiments, the assay merely scores for the ability of a test compound to alter the signal transduction acitivity of the *patched* protein. In this manner, a variety of *hedgehog* and/or *ptc* therapeutics, both proliferative and anti-proliferative in activity, can be identified. A variety of assay formats will suffice and, in light of the present disclosure, will be comprehended by skilled artisan.

15 In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as "primary" screens in that they can be generated to permit rapid development and 20 relatively easy detection of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity and/or bioavailability of the test compound can be generally ignored in the *in vitro* system, the assay instead being focused primarily on the effect of the drug on the molecular target as may be manifest in an alteration of binding affinity with receptor proteins.

25 Accordingly, in an exemplary screening assay for *ptc* therapeutics, the compound of interest is contacted with a mixture including a *hedgehog* receptor protein (e.g., a cell expressing the *patched* receptor) and a *hedgehog* protein under conditions in which it is ordinarily capable of binding the *hedgehog* protein. To the mixture is then added a composition containing a test compound. Detection and quantification of 30 receptor/*hedgehog* complexes provides a means for determining the test compound's efficacy at inhibiting (or potentiating) complex formation between the receptor protein and

the *hedgehog* polypeptide. The efficacy of the compound can be assessed by generating dose response curves from data obtained using various concentrations of the test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. In the control assay, isolated and purified *hedgehog* polypeptide is added to the receptor 5 protein, and the formation of receptor/*hedgehog* complex is quantitated in the absence of the test compound.

In other embodiments, a ptc therapeutic of the present invention is one which disrupts the association of *patched* with *smoothened*.

10 Agonist and antagonists of adipocyte cell growth can be distinguished, and the efficacy of the compound can be assessed, by subsequent testing with pre- and adipocyte cells, e.g., in culture.

15 In an illustrative embodiment, the polypeptide utilized as a *hedgehog* receptor can be generated from the *patched* protein. Accordingly, an exemplary screening assay includes all or a suitable portion of the *patched* protein which can be obtained from, for example, the human *patched* gene (GenBank U43148) or other vertebrate sources (see GenBank Accession numbers U40074 for chicken *patched* and U46155 for mouse *patched*), as well as from drosophila (GenBank Accession number M28999) or other invertebrate sources. The *patched* protein can be provided in the screening assay as a whole protein (preferably expressed on the surface of a cell), or alternatively as a fragment 20 of the full length protein which binds to *hedgehog* polypeptides, e.g., as one or both of the substantial extracellular domains (e.g. corresponding to residues Asn120-Ser438 and/or Arg770-Trp1027 of the human *patched* protein - which are also potential antagonists of *hedgehog*-dependent signal transduction). For instance, the *patched* protein can be provided in soluble form, as for example a preparation of one of the extracellular domains, 25 or a preparation of both of the extracellular domains which are covalently connected by an unstructured linker (see, for example, Huston et al. (1988) PNAS 85:4879; and U.S. Patent No. 5,091,513). In other embodiments, the protein can be provided as part of a liposomal preparation or expressed on the surface of a cell. The *patched* protein can be derived from a recombinant gene, e.g., being ectopically expressed in a heterologous cell. For instance, the 30 protein can be expressed on oocytes, mammalian cells (e.g., COS, CHO, 3T3 or the like), or yeast cell by standard recombinant DNA techniques. These recombinant cells can be used

for receptor binding, signal transduction or gene expression assays. Marigo et al. (1996) *Development* 122:1225-1233 illustrates a binding assay of human *hedgehog* to chick *patched* protein ectopically expressed in *Xenopus laevis* oocytes. The assay system of Marigo et al. can be adapted to the present drug screening assays. As illustrated in that 5 reference, *Shh* binds to the *patched* protein in a selective, saturable, dose-dependent manner, thus demonstrating that *patched* is a receptor for *Shh*.

Complex formation between the *hedgehog* polypeptide and a *hedgehog* receptor may be detected by a variety of techniques. For instance, modulation of the formation of complexes can be quantitated using, for example, detectably labelled proteins such as 10 radiolabelled, fluorescently labelled, or enzymatically labelled *hedgehog* polypeptides, by immunoassay, or by chromatographic detection.

Typically, for cell-free assays, it will be desirable to immobilize either the *hedgehog* receptor or the *hedgehog* polypeptide to facilitate separation of receptor/*hedgehog* complexes from uncomplexed forms of one of the proteins, as well as to accommodate 15 automation of the assay. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase/receptor (GST/receptor) fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the *hedgehog* polypeptide, e.g. an <sup>35</sup>S-labeled 20 *hedgehog* polypeptide, and the test compound and incubated under conditions conducive to complex formation, e.g. at physiological conditions for salt and pH, though slightly more stringent conditions may be desired. Following incubation, the beads are washed to remove any unbound *hedgehog* polypeptide, and the matrix bead-bound radiolabel determined directly (e.g. beads placed in scintillant), or in the supernatant after the receptor/*hedgehog* 25 complexes are dissociated. Alternatively, the complexes can be dissociated from the bead, separated by SDS-PAGE gel, and the level of *hedgehog* polypeptide found in the bead fraction quantitated from the gel using standard electrophoretic techniques.

Other techniques for immobilizing proteins on matrices are also available for use in the subject assay. For instance, soluble portions of the *hedgehog* receptor protein can be 30 immobilized utilizing conjugation of biotin and streptavidin. For instance, biotinylated receptor molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using

techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with the *hedgehog* receptor but which do not interfere with *hedgehog* binding can be derivatized to the wells of the plate, and the receptor trapped 5 in the wells by antibody conjugation. As above, preparations of a *hedgehog* polypeptide and a test compound are incubated in the receptor-presenting wells of the plate, and the amount of receptor/*hedgehog* complex trapped in the well can be quantitated. Exemplary methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive 10 with the *hedgehog* polypeptide, or which are reactive with the receptor protein and compete for binding with the *hedgehog* polypeptide; as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the *hedgehog* polypeptide. In the instance of the latter, the enzyme can be chemically conjugated or provided as a fusion protein with the *hedgehog* polypeptide. To illustrate, the *hedgehog* polypeptide can be chemically 15 cross-linked or genetically fused with alkaline phosphatase, and the amount of *hedgehog* polypeptide trapped in the complex can be assessed with a chromogenic substrate of the enzyme, e.g. paranitrophenylphosphate. Likewise, a fusion protein comprising the *hedgehog* polypeptide and glutathione-S-transferase can be provided, and complex formation quantitated by detecting the GST activity using 1-chloro-2,4-dinitrobenzene 20 (Habig et al (1974) *J Biol Chem* 249:7130).

For processes which rely on immunodetection for quantitating one of the proteins trapped in the complex, antibodies against the protein, such as the anti-*hedgehog* antibodies described herein, can be used. Alternatively, the protein to be detected in the complex can

Where the desired portion of the *hedgehog* receptor (or other *hedgehog* binding molecule) cannot be provided in soluble form, liposomal vesicles can be used to provide manipulatable and isolatable sources of the receptor. For example, both authentic and recombinant forms of the *patched* protein can be reconstituted in artificial lipid vesicles 5 (e.g. phosphatidylcholine liposomes) or in cell membrane-derived vesicles (see, for example, Bear et al. (1992) *Cell* 68:809-818; Newton et al. (1983) *Biochemistry* 22:6110-6117; and Reber et al. (1987) *J Biol Chem* 262:11369-11374).

In addition to cell-free assays, such as described above, the readily available source of *hedgehog* proteins provided by the art also facilitates the generation of cell-based assays 10 for identifying small molecule agonists/antagonists and the like. Analogous to the cell-based assays described above for screening combinatorial libraries, cells which are sensitive to *hedgehog* induction, e.g. *patched*-expressing cells or other adipocyte-derived cells sensitive to *hedgehog* induction, can be contacted with a *hedgehog* protein and a test agent of interest, with the assay scoring for anything from simple binding to the cell to 15 modulation in *hedgehog* inductive responses by the target cell in the presence and absence of the test agent. As with the cell-free assays, agents which produce a statistically significant change in *hedgehog* activities (either inhibition or potentiation) can be identified.

In other embodiments, the cell-based assay scores for agents which disrupt 20 association of *patched* and *smoothened* proteins, e.g., in the cell surface membrane or liposomal preparation.

In addition to characterizing cells that naturally express the *patched* protein, cells which have been genetically engineered to ectopically express *patched* can be utilized for 25 drug screening assays. As an example, cells which either express low levels or lack expression of the *patched* protein, e.g. *Xenopus laevis* oocytes, COS cells or yeast cells, can be genetically modified using standard techniques to ectopically express the *patched* protein. (see Marigo et al., *supra*).

The resulting recombinant cells, e.g., which express a functional *patched* receptor, 30 can be utilized in receptor binding assays to identify agonist or antagonists of *hedgehog* binding. Binding assays can be performed using whole cells. Furthermore, the recombinant cells of the present invention can be engineered to include other heterologous

genes encoding proteins involved in *hedgehog*-dependent signal pathways. For example, the gene products of one or more of *smoothened*, *costal-2* and/or *fused* can be co-expressed with *patched* in the reagent cell, with assays being sensitive to the functional reconstitution of the *hedgehog* signal transduction cascade.

5        Alternatively, liposomal preparations using reconstituted *patched* protein can be utilized. *Patched* protein purified from detergent extracts from both authentic and recombinant origins can be reconstituted in artificial lipid vesicles (e.g. phosphatidylcholine liposomes) or in cell membrane-derived vesicles (see, for example, Bear et al. (1992) *Cell* 68:809-818; Newton et al. (1983) *Biochemistry* 22:6110-6117; and

10      Reber et al. (1987) *J Biol Chem* 262:11369-11374). The lamellar structure and size of the resulting liposomes can be characterized using electron microscopy. External orientation of the *patched* protein in the reconstituted membranes can be demonstrated, for example, by immunoelectron microscopy. The *hedgehog* protein binding activity of liposomes containing *patched* and liposomes without the protein in the presence of candidate agents

15      can be compared in order to identify potential modulators of the *hedgehog-patched* interaction.

The *hedgehog* protein used in these cell-based assays can be provided as a purified source (natural or recombinant in origin), or in the form of cells/tissue which express the protein and which are co-cultured with the target cells. As in the cell-free assays, where

20      simple binding (rather than induction) is the hedgehog activity scored for in the assay, the protein can be labelled by any of the above-mentioned techniques, e.g., fluorescently, enzymatically or radioactively, or detected by immunoassay.

In addition to binding studies, functional assays can be used to identify modulators, i.e., agonists or antagonists, of *hedgehog* or *patched* activities. By detecting

25      changes in intracellular signals, such as alterations in second messengers or gene expression, in *patched*-expressing cells contacted with a test agent, candidate agonists and antagonists to *patched* signaling can be identified.

A number of gene products have been implicated in *patched*-mediated signal transduction, including *patched*, the transcription factor *cubitus interruptus* (ci), the

30      serine/threonine kinase *fused* (fu) and the gene products of *costal-2*, *smoothened* and *suppressor of fused*.

The interaction of a hedgehog protein with *patched* sets in motion a cascade involving the activation and inhibition of downstream effectors, the ultimate consequence of which is, in some instances, a detectable change in the transcription or translation of a gene. Potential transcriptional targets of *patched* signaling are the *patched* gene itself

5 (Hidalgo and Ingham, 1990 *Development* 110, 291-301; Marigo et al., 1996 ) and the vertebrate homologs of the drosophila cubitus interruptus gene, the *GLI* genes (Hui et al. (1994) *Dev Biol* 162:402-413). *Patched* gene expression has been shown to be induced in cells of the limb bud and the neural plate that are responsive to *Shh*. (Marigo et al. (1996) *PNAS*, in press; Marigo et al. (1996) *Development* 122:1225-1233). The *GLI* genes encode

10 putative transcription factors having zinc finger DNA binding domains (Orenic et al. (1990) *Genes & Dev* 4:1053-1067; Kinzler et al. (1990) *Mol Cell Biol* 10:634-642). Transcription of the *GLI* gene has been reported to be upregulated in response to *hedgehog* in limb buds, while transcription of the *GLI3* gene is downregulated in response to *hedgehog* induction (Marigo et al. (1996) *Development* 122:1225-1233). By selecting transcriptional regulatory

15 sequences from such target genes, e.g. from *patched* or *GLI* genes, that are responsible for the up- or down regulation of these genes in response to *patched* signalling, and operatively linking such promoters to a reporter gene, one can derive a transcription based assay which is sensitive to the ability of a specific test compound to modify *patched* signalling pathways. Expression of the reporter gene, thus, provides a valuable screening tool for the

20 development of compounds that act as agonists or antagonists of *ptc* induction of differentiation/quiescence.

Reporter gene based assays of this invention measure the end stage of the above described cascade of events, e.g., transcriptional modulation. Accordingly, in practicing one embodiment of the assay, a reporter gene construct is inserted into the reagent cell in

25 order to generate a detection signal dependent on *ptc* signaling. To identify potential regulatory elements responsive to *ptc* signaling present in the transcriptional regulatory sequence of a target gene, nested deletions of genomic clones of the target gene can be constructed using standard techniques. See, for example, Current Protocols in Molecular Biology, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989); U.S. Patent

30 5,266,488; Sato et al. (1995) *J Biol Chem* 270:10314-10322; and Kube et al. (1995) *Cytokine* 7:1-7. A nested set of DNA fragments from the gene's 5'-flanking region are

placed upstream of a reporter gene, such as the luciferase gene, and assayed for their ability to direct reporter gene expression in *patched* expressing cells. Host cells transiently transfected with reporter gene constructs can be scored for the induction of expression of the reporter gene in the presence and absence of *hedgehog* to determine regulatory sequences which are responsive to *patched*-dependent signalling.

5 In practicing one embodiment of the assay, a reporter gene construct is inserted into the reagent cell in order to generate a detection signal dependent on second messengers generated by induction with *hedgehog* protein. Typically, the reporter gene construct will include a reporter gene in operative linkage with one or more transcriptional regulatory elements responsive to the *hedgehog* activity, with the level of expression of the reporter gene providing the *hedgehog*-dependent detection signal. The amount of transcription from the reporter gene may be measured using any method known to those of skill in the art to be suitable. For example, mRNA expression from the reporter gene may be detected using RNase protection or RNA-based PCR, or the protein product of the reporter gene may be 10 identified by a characteristic stain or an intrinsic activity. The amount of expression from the reporter gene is then compared to the amount of expression in either the same cell in the absence of the test compound (or *hedgehog*) or it may be compared with the amount of transcription in a substantially identical cell that lacks the target receptor protein. Any 15 statistically or otherwise significant difference in the amount of transcription indicates that the test compound has in some manner altered the signal transduction of the *patched* protein, e.g., the test compound is a potential ptc therapeutic.

20 As described in further detail below, in preferred embodiments the gene product of the reporter is detected by an intrinsic activity associated with that product. For instance, the reporter gene may encode a gene product that, by enzymatic activity, gives rise to a detection signal based on color, fluorescence, or luminescence. In other preferred 25 embodiments, the reporter or marker gene provides a selective growth advantage, e.g., the reporter gene may enhance cell viability, relieve a cell nutritional requirement, and/or provide resistance to a drug.

Preferred reporter genes are those that are readily detectable. The reporter gene may 30 also be included in the construct in the form of a fusion gene with a gene that includes desired transcriptional regulatory sequences or exhibits other desirable properties.


Examples of reporter genes include, but are not limited to CAT (chloramphenicol acetyl transferase) (Alton and Vapnek (1979), *Nature* 282: 864-869) luciferase, and other enzyme detection systems, such as beta-galactosidase; firefly luciferase (deWet et al. (1987), *Mol. Cell. Biol.* 7:725-737); bacterial luciferase (Engebrecht and Silverman (1984), *PNAS* 1: 5 4154-4158; Baldwin et al. (1984), *Biochemistry* 23: 3663-3667); alkaline phosphatase (Toh et al. (1989) *Eur. J. Biochem.* 182: 231-238, Hall et al. (1983) *J. Mol. Appl. Gen.* 2: 101), human placental secreted alkaline phosphatase (Cullen and Malim (1992) *Methods in Enzymol.* 216:362-368).

Transcriptional control elements which may be included in a reporter gene construct 10 include, but are not limited to, promoters, enhancers, and repressor and activator binding sites. Suitable transcriptional regulatory elements may be derived from the transcriptional regulatory regions of genes whose expression is induced after modulation of a *patched* signal transduction pathway. The characteristics of preferred genes from which the transcriptional control elements are derived include, but are not limited to, low or 15 undetectable expression in quiescent cells, rapid induction at the transcriptional level within minutes of extracellular stimulation, induction that is transient and independent of new protein synthesis, subsequent shut-off of transcription requires new protein synthesis, and mRNAs transcribed from these genes have a short half-life. It is not necessary for all of these properties to be present.

20 In yet other embodiments, second messenger generation can be measured directly in the detection step, such as mobilization of intracellular calcium, phospholipid metabolism or adenylate cyclase activity are quantitated, for instance, the products of phospholipid hydrolysis IP<sub>3</sub>, DAG or cAMP could be measured. For example, recent studies have implicated protein kinase A (PKA) as a possible component of *hedgehog/patched* signaling 25 (Hammerschmidt et al. (1996) *Genes & Dev* 10:647). High PKA activity has been shown to antagonize *hedgehog* signaling in these systems. Although it is unclear whether PKA acts directly downstream or in parallel with *hedgehog* signaling, it is possible that *hedgehog* signalling occurs via inhibition of PKA activity. Thus, detection of PKA activity provides a potential readout for the instant assays.

30 In a preferred embodiment, the *ptc* therapeutic is a PKA inhibitor. A variety of PKA inhibitors are known in the art, including both peptidyl and organic compounds. For

instance, the *ptc* therapeutic can be a 5-isoquinolinesulfonamide, such as represented in the general formula:



5 wherein,

R<sub>1</sub> and R<sub>2</sub> each can independently represent hydrogen, and as valence and stability permit a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-OH, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-SH, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, or


R<sub>1</sub> and R<sub>2</sub> taken together with N form a heterocycle (substituted or unsubstituted);

15 R<sub>3</sub> is absent or represents one or more substitutions to the isoquinoline ring such as a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-OH, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-SH, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>;


20 R<sub>8</sub> represents a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle; and

n and m are independently for each occurrence zero or an integer in the range of 1 to


In a preferred embodiment, the PKA inhibitor is N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide (H-89; Calbiochem Cat. No. 371963), e.g., having the formula:



5 In another embodiment, the PKA inhibitor is 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7; Calbiochem Cat. No. 371955), e.g., having the formula:




In still other embodiments, the PKA inhibitor is KT5720 (Calbiochem Cat. No. 420315), having the structure



10

A variety of nucleoside analogs are also useful as PKA inhibitors. For example, the subject method can be carried out cyclic AMP analogs which inhibit the kinase activity of PKA, as for example, 8-bromo-cAMP or dibutyryl-cAMP



Exemplary peptidyl inhibitors of PKA activity include the PKA Heat Stable  
 5 Inhibitor (isoform ; see, for example, Calbiochem Cat. No. 539488, and Wen et al. (1995)  
*J Biol Chem* 270:2041).

Certain *hedgehog* receptors may stimulate the activity of phospholipases. Inositol lipids can be extracted and analyzed using standard lipid extraction techniques. Water soluble derivatives of all three inositol lipids (IP<sub>1</sub>, IP<sub>2</sub>, IP<sub>3</sub>) can also be quantitated using  
 10 radiolabelling techniques or HPLC.

The mobilization of intracellular calcium or the influx of calcium from outside the cell may be a response to *hedgehog* stimulation or lack thereof. Calcium flux in the reagent cell can be measured using standard techniques. The choice of the appropriate calcium indicator, fluorescent, bioluminescent, metallochromic, or Ca<sup>++</sup>-sensitive  
 15 microelectrodes depends on the cell type and the magnitude and time constant of the event under study (Borle (1990) *Environ Health Perspect* 84:45-56). As an exemplary method of Ca<sup>++</sup> detection, cells could be loaded with the Ca<sup>++</sup>sensitive fluorescent dye fura-2 or indo-1, using standard methods, and any change in Ca<sup>++</sup> measured using a fluorometer.

In certain embodiments of the assay, it may be desirable to screen for changes in  
 20 cellular phosphorylation. As an example, the drosophila gene *fused* (fu) which encodes a serine/threonine kinase has been identified as a potential downstream target in *hedgehog* signaling. (Preat et al., 1990 *Nature* 347, 87-89; Therond et al. 1993, *Mech. Dev.* 44, 65-80). The ability of compounds to modulate serine/threonine kinase activation could be screened using colony immunoblotting (Lyons and Nelson (1984) *Proc. Natl. Acad. Sci.*

USA 81:7426-7430) using antibodies against phosphorylated serine or threonine residues. Reagents for performing such assays are commercially available, for example, phosphoserine and phosphothreonine specific antibodies which measure increases in phosphorylation of those residues can be purchased from commercial sources.

5        In yet another embodiment, the *ptc* therapeutic is an antisense molecule which inhibits expression of a protein involved in a *patched*-mediated signal transduction pathway. To illustrate, by inhibiting the expression of a protein which are involved in *patched* signals, such as fused, costal-2, smoothened and/or Gli genes, the ability of the *patched* signal pathway(s) to inhibit proliferation of a cell can be altered, e.g., potentiated or  
10      repressed.

As used herein, "antisense" therapy refers to administration or *in situ* generation of oligonucleotide probes or their derivatives which specifically hybridize (e.g. bind) under cellular conditions with cellular mRNA and/or genomic DNA encoding a *hedgehog* protein, *patched*, or a protein involved in *patched*-mediated signal transduction. The hybridization  
15      should inhibit expression of that protein, e.g. by inhibiting transcription and/or translation. The binding may be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interactions in the major groove of the double helix. In general, "antisense" therapy refers to the range of techniques generally employed in the art, and includes any therapy which relies on specific binding to  
20      oligonucleotide sequences.

An antisense construct of the present invention can be delivered, for example, as an expression plasmid which, when transcribed in the cell, produces RNA which is complementary to at least a unique portion of the target cellular mRNA. Alternatively, the antisense construct is an oligonucleotide probe which is generated *ex vivo* and which, when  
25      introduced into the cell causes inhibition of expression by hybridizing with the mRNA and/or genomic sequences of a target gene. Such oligonucleotide probes are preferably modified oligonucleotide which are resistant to endogenous nucleases, e.g. exonucleases and/or endonucleases, and is therefore stable *in vivo*. Exemplary nucleic acid molecules for use as antisense oligonucleotides are phosphoramidate, phosphothioate and  
30      methylphosphonate analogs of DNA (see also U.S. Patents 5,176,996; 5,264,564; and 5,256,775). Additionally, general approaches to constructing oligomers useful in antisense

therapy have been reviewed, for example, by Van der Krol et al. (1988) *Biotechniques* 6:958-976; and Stein et al. (1988) *Cancer Res* 48:2659-2668.

Several considerations should be taken into account when constructing antisense oligonucleotides for the use in the methods of the invention: (1) oligos should have a GC content of 50% or more; (2) avoid sequences with stretches of 3 or more G's; and (3) oligonucleotides should not be longer than 25-26 mers. When testing an antisense oligonucleotide, a mismatched control can be constructed. The controls can be generated by reversing the sequence order of the corresponding antisense oligonucleotide in order to conserve the same ratio of bases.

10 In an illustrative embodiment, the *ptc* therapeutic can be an antisense construct for inhibiting the expression of *patched*, e.g., to mimic the inhibition of *patched* by *hedgehog*. Exemplary antisense constructs include:

5'-GTCCTGGCGCCGCCGCCGCCGCGCC

5'-TTCCGATGACCGGCCTTCGCGGTGA

15 5'-GTGCACGGAAAGGTGCAGGCCACACT

#### *VI. Exemplary pharmaceutical preparations of hedgehog and ptc therapeutics*

The source of the hedgehog and ptc therapeutics to be formulated will depend on the particular form of the agent. Small organic molecules and peptidyl fragments can be 20 chemically synthesized and provided in a pure form suitable for pharmaceutical/cosmetic usage. Products of natural extracts can be purified according to techniques known in the art. For example, the Cox et al. U.S. Patent 5,286,654 describes a method for purifying naturally occurring forms of a secreted protein and can be adapted for purification of hedgehog polypeptides. Recombinant sources of hedgehog polypeptides are also available. 25 For example, the gene encoding *hedgehog* polypeptides, are known, *inter alia*, from PCT publications WO 95/18856 and WO 96/17924.

Those of skill in treating adipocyte tissues can determine the effective amount of an hedgehog or ptc therapeutic to be formulated in a pharmaceutical or cosmetic preparation.

The hedgehog or ptc therapeutic formulations used in the method of the invention 30 are most preferably applied in the form of appropriate compositions. As appropriate compositions there may be cited all compositions usually employed for systemically or

topically administering drugs. The pharmaceutically acceptable carrier should be substantially inert, so as not to act with the active component. Suitable inert carriers include water, alcohol polyethylene glycol, mineral oil or petroleum gel, propylene glycol and the like.

5 To prepare the pharmaceutical compositions of this invention, an effective amount of the particular hedgehog or ptc therapeutic as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable,

10 particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders,

15 disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represents the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be

20 included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositons

25 suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.

30 In addition to the direct topical application of the preparations they can be topically administered by other methods, for example, encapsulated in a temperature and/or pressure

sensitive matrix or in film or solid carrier which is soluble in body fluids and the like for subsequent release, preferably sustained-release of the active component.

As appropriate compositions for topical application there may be cited all compositions usually employed for topically administering therapeutics, e.g., creams, 5 gellies, dressings, shampoos, tinctures, pastes, ointments, salves, powders, liquid or semiliquid formulation and the like. Application of said compositions may be by aerosol e.g. with a propellant such as nitrogen carbon dioxide, a freon, or without a propellant such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab. In particular compositions, semisolid compositions such as salves, 10 creams, pastes, gellies, ointments and the like will conveniently be used.

It is especially advantageous to formulate the subject compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to 15 produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powders packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

The pharmaceutical preparations of the present invention can be used, as stated 20 above, for the many applications which can be considered cosmetic uses. Cosmetic compositions known in the art, preferably hypoallergic and pH controlled are especially preferred, and include toilet waters, packs, lotions, skin milks or milky lotions. The preparations contain, besides the hedgehog or ptc therapeutic, components usually employed in such preparations. Examples of such components are oils, fats, waxes, 25 surfactants, humectants, thickening agents, antioxidants, viscosity stabilizers, chelating agents, buffers, preservatives, perfumes, dyestuffs, lower alkanols, and the like. If desired, further ingredients may be incorporated in the compositions, e.g. antiinflammatory agents, antibacterials, antifungals, disinfectants, vitamins, sunscreens, antibiotics, or other anti-acne agents.

30 Examples of oils comprise fats and oils such as olive oil and hydrogenated oils; waxes such as beeswax and lanolin; hydrocarbons such as liquid paraffin, ceresin, and

squalane; fatty acids such as stearic acid and oleic acid; alcohols such as cetyl alcohol, stearyl alcohol, lanolin alcohol, and hexadecanol; and esters such as isopropyl myristate, isopropyl palmitate and butyl stearate. As examples of surfactants there may be cited anionic surfactants such as sodium stearate, sodium cetyl sulfate, polyoxyethylene 5 laurylether phosphate, sodium N-acyl glutamate; cationic surfactants such as stearyldimethylbenzylammonium chloride and stearyltrimethylammonium chloride; ampholytic surfactants such as alkylaminoethylglycine hydrochloride solutions and lecithin; and nonionic surfactants such as glycerin monostearate, sorbitan monostearate, sucrose fatty acid esters, propylene glycol monostearate, polyoxyethylene oleylether, polyethylene 10 glycol monostearate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene coconut fatty acid monoethanolamide, polyoxypropylene glycol (e.g. the materials sold under the trademark "Pluronic"), polyoxyethylene castor oil, and polyoxyethylene lanolin. Examples of humectants include glycerin, 1,3-butylene glycol, and propylene glycol; examples of lower alcohols include ethanol and isopropanol; examples of thickening agents include 15 xanthan gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol and sodium carboxymethyl cellulose; examples of antioxidants comprise butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, citric acid and ethoxyquin; examples of chelating agents include disodium edetate and ethanehydroxy diphosphate; examples of buffers comprise citric acid, sodium citrate, boric acid, borax, and disodium 20 hydrogen phosphate; and examples of preservatives are methyl parahydroxybenzoate, ethyl parahydroxybenzoate, dehydroacetic acid, salicylic acid and benzoic acid.

For preparing ointments, creams, toilet waters, skin milks, and the like, typically from 0.01 to 10% in particular from 0.1 to 5% and more in particular from 0.2 to 2.5% of the active ingredient, e.g., of the hedgehog or ptc therapeutic, will be incorporated in the 25 compositions. In ointments or creams, the carrier for example consists of 1 to 20%, in particular 5 to 15% of a humectant, 0.1 to 10% in particular from 0.5 to 5% of a thickener and water; or said carrier may consist of 70 to 99%, in particular 20 to 95% of a surfactant, and 0 to 20%, in particular 2.5 to 15% of a fat; or 80 to 99.9% in particular 90 to 99% of a thickener; or 5 to 15% of a surfactant, 2-15% of a humectant, 0 to 80% of an oil, very small 30 (<2%) amounts of preservative, coloring agent and/or perfume, and water. In a toilet water, the carrier for example consists of 2 to 10% of a lower alcohol, 0.1 to 10% or in

particular 0.5 to 1% of a surfactant, 1 to 20%, in particular 3 to 7% of a humectant, 0 to 5% of a buffer, water and small amounts (< 2%) of preservative, dyestuff and/or perfume. In a skin milk, the carrier typically consists of 10-50% of oil, 1 to 10% of surfactant, 50-80% of water and 0 to 3% of preservative and/or perfume. In the aforementioned preparations, all 5 % symbols refer to weight by weight percentage.

Particular compositions for use in the method of the present invention are those wherein the hedgehog or ptc therapeutic is formulated in liposome-containing compositions. Liposomes are artificial vesicles formed by amphiphatic molecules such as polar lipids, for example, phosphatidyl cholines, ethanolamines and serines, 10 sphingomyelins, cardiolipins, plasmalogens, phosphatidic acids and cerebrosides. Liposomes are formed when suitable amphiphatic molecules are allowed to swell in water or aqueous solutions to form liquid crystals usually of multilayer structure comprised of many bilayers separated from each other by aqueous material (also referred to as coarse liposomes). Another type of liposome known to be consisting of a single bilayer 15 encapsulating aqueous material is referred to as a unilamellar vesicle. If water-soluble materials are included in the aqueous phase during the swelling of the lipids they become entrapped in the aqueous layer between the lipid bilayers.

Water-soluble active ingredients such as, for example, various salt forms of a hedgehog polypeptide, are encapsulated in the aqueous spaces between the molecular 20 layers. The lipid soluble active ingredient of hedgehog or ptc therapeutic, such as an organic mimetic, is predominantly incorporated into the lipid layers, although polar head groups may protrude from the layer into the aqueous space. The encapsulation of these compounds can be achieved by a number of methods. The method most commonly used involves casting a thin film of phospholipid onto the walls of a flask by evaporation from an 25 organic solvent. When this film is dispersed in a suitable aqueous medium, multilamellar liposomes are formed. Upon suitable sonication, the coarse liposomes form smaller similarly closed vesicles.

Water-soluble active ingredients are usually incorporated by dispersing the cast film with an aqueous solution of the compound. The unencapsulated compound is then removed 30 by centrifugation, chromatography, dialysis or other art-known suitable procedures. The lipid-soluble active ingredient is usually incorporated by dissolving it in the organic solvent

with the phospholipid prior to casting the film. If the solubility of the material in the lipid phase is not exceeded or the amount present is not in excess of that which can be bound to the lipid, liposomes prepared by the above method usually contain most of the material bound in the lipid bilayers; separation of the liposomes from unencapsulated material is not 5 required.

A particularly convenient method for preparing liposome formulated forms of hedgehog and ptc therapeutics is the method described in EP-A-253,619, incorporated herein by reference. In this method, single bilayered liposomes containing encapsulated active ingredients are prepared by dissolving the lipid component in an organic medium, 10 injecting the organic solution of the lipid component under pressure into an aqueous component while simultaneously mixing the organic and aqueous components with a high speed homogenizer or mixing means, whereupon the liposomes are formed spontaneously.

The single bilayered liposomes containing the encapsulated hedgehog or ptc therapeutic can be employed directly or they can be employed in a suitable 15 pharmaceutically acceptable carrier for topical administration. The viscosity of the liposomes can be increased by the addition of one or more suitable thickening agents such as, for example xanthan gum, hydroxypropyl cellulose, hydroxypropyl methylcellulose and mixtures thereof. The aqueous component may consist of water alone or it may contain electrolytes, buffered systems and other ingredients, such as, for example, preservatives. 20 Suitable electrolytes which can be employed include metal salts such as alkali metal and alkaline earth metal salts. The preferred metal salts are calcium chloride, sodium chloride and potassium chloride. The concentration of the electrolyte may vary from zero to 260 mM, preferably from 5 mM to 160 mM. The aqueous component is placed in a suitable vessel which can be adapted to effect homogenization by effecting great turbulence during 25 the injection of the organic component. Homogenization of the two components can be accomplished within the vessel, or, alternatively, the aqueous and organic components may be injected separately into a mixing means which is located outside the vessel. In the latter case, the liposomes are formed in the mixing means and then transferred to another vessel for collection purpose.

30 The organic component consists of a suitable non-toxic, pharmaceutically acceptable solvent such as, for example ethanol, glycerol, propylene glycol and

polyethylene glycol, and a suitable phospholipid which is soluble in the solvent. Suitable phospholipids which can be employed include lecithin, phosphatidylcholine, phosphatidylserine, phosphatidylethanol-amine, phosphatidylinositol, lysophosphatidylcholine and phosphatidyl glycerol, for example. Other lipophilic additives may be 5 employed in order to selectively modify the characteristics of the liposomes. Examples of such other additives include stearylamine, phosphatidic acid, tocopherol, cholesterol and lanolin extracts.

In addition, other ingredients which can prevent oxidation of the phospholipids may be added to the organic component. Examples of such other ingredients include tocopherol, 10 butylated hydroxyanisole, butylated hydroxytoluene, ascorbyl palmitate and ascorbyl oleate. Preservatives such as benzoic acid, methyl paraben and propyl paraben may also be added.

Apart from the above-described compositions, use may be made of covers, e.g. 15 plasters, bandages, dressings, gauze pads and the like, containing an appropriate amount of a hedgehog or ptc therapeutic. In some cases use may be made of plasters, bandages, dressings, gauze pads and the like which have been impregnated with a topical formulation containing the therapeutic formulation.

#### *Exemplification*

20 The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, which are not intended to limit the invention.

25 All enzymes, media and reagents were obtained Roche Molecular Biochemicals (Mannheim, Germany) except where noted differently.

#### *Cell Culture*

Mouse fibroblast C3H10T1/2 cells (ATCC CCL 226) were grown as monolayers in 30 DMEM with 10 % fetal calf serum (Cansera, Greiner GmbH, Frickenhausen, Germany) at 37°C in a 5% CO<sub>2</sub> atmosphere. Treatment with BMP-2, Shh or a combination of both was

done for 72 h under serumfree conditions or for 11 days in the presence of 10% FCS. The medium with inducers was changed twice a week.

BMP-2 was provided by W. Sebald, Würzburg, Germany, and used at a concentration of 500 ng/ml. Human sonic hedgehog protein was derived from baculovirus-  
5 mediated expression in insect cells and applied to cells as described previously (Zehentner *et al.*, 1999) The baculovirus supernatants containing approximately 20 µg/ml hedgehog protein were diluted 1:40 (v/v) in the assay. For RT-PCR the experiment was stopped with lysis buffer (4.5 M guanidin hydrochloride, 50 mM Tris-HCl, 30 % TritonX-100 (w/v), pH 6.6) after 72 h. The cell lysate was stored at -80°C until RNA extraction.

10

#### *Oil Red O staining*

The stock solution of Oil Red O was prepared by dissolving 4.2 g of Oil Red O (Sigma-Aldrich Chemie GmbH, Deisenhofen, Germany) in 1200 ml isopropanol. The solution was left overnight at room temperature without stirring followed by filtration. At 15 last 900 ml of water was added and solution was left overnight at 4 °C with stirring.

Cultures were fixed for 5 h with 4 % paraformaldehyde in isotonic phosphate buffer. Cells were then stained for 2 h at 4 °C by complete immersion in the working solution of Oil Red O followed by two times rinsing with water. The lipid droplets in the adipocyte-like cells were observed under a microscope with 10-fold magnification.

20

#### *RNA Isolation*

RNA was isolated using the High Pure RNA Isolation Kit (Roche Molecular Biochemicals Cat. No. 1 828 665). RNA quantity was determined by measuring absorption at 260 nm, and quality was checked in an agarose gel.

25

#### *Quantitative RT-PCR*

PPAR-γ, aP2, gli, ptc and actin mRNAs were quantitated via competitive RT-PCR using a multigene standard (Gilliland *et al.*, 1990). The following primers for standard and target amplification were used.

30 PPARγ-F 5' aat gga aga cca ctc cca c; PPARγ-R 5' tgg aga tgc agg ctc cac;  
actin-F 5' aca cct tct aca atg agc tgc g; actin-R 5' cgc tcg gtg agg atc ttc atg;

aP2-F 5' atg tgt gat gct ttt gta gg; aP2-R 5' ttt tcc atc cca ttt ctg c;  
gli-F 5' ctg ata ctc tgg gat atg gg; gli-R 5' tca agt cga gga cac tgg ct;  
ptc-F 5' gca ttg gca gga gga gtt gat tg; ptc-R 5' ggg tcg tgg ttg tga agg gaa gc.

After linearization the standard vector was transcribed with T7 RNA polymerase  
5 into standard cRNA and treated with DNase I. 0.5 µg cellular RNA and different  
concentrations of standard cRNA were combined and reverse transcribed. PCR was  
performed using Expand<sup>TM</sup> High Fidelity PCR System in a Perkin Elmer GeneAmp 9600  
thermocycler. The polymerase chain reaction conditions were one cycle: 94°C 3 min; 58°C  
1 min; 72°C 2 min followed by 45 cycles of: 94°C 20 sec; 58°C 20 sec; 72°C 1 min and  
10 completed with 5 min 72 °C. PCR products were analyzed by gel electrophoresis with  
ethidium bromide staining.

In order to quantitate the PCR products resulting from competitive RT-PCR the  
intensity of the bands in the gel was measured with the gel imaging system E.A.S.Y.  
(Herolab GmbH, Wiesloch, Germany). The relative expression level of the target gene was  
15 calculated as follows: [(standard intensity, control) x (target intensity, induced)] / [(standard  
intensity, induced) x (target intensity control)]. The relative expression level of actin was  
used to normalize the target level in each sample. Relative expression levels of four  
independent RNA isolations were used for means ± SD.

### Results

C3H10T1/2 cells were analyzed at molecular and morphological level after treatment with Shh or BMP-2 or a combination thereof. The expression profiles of adipocyte marker genes, aP2 and PPAR- $\gamma$ , were monitored by quantitative RT-PCR, as well 5 as the expression of the hedgehog response genes gli and patched (Figure 1). The results of three independent measurements, normalized with actin, were used to calculate the relative expression level, shown in figure 1. The control sample has an expression level of one corresponding to the baseline. The expression changes are demonstrated in the agarose gel of one measurement by comparing the intensity of the PCR fragments resulting from 10 cellular mRNAs to the internal standard.

The expression of the two adipocytic marker genes was significantly upregulated by BMP-2 (sample 1.1 and 2.1 of figure 1A and B). After 72 h of serumfree culture (samples 1.1) PPAR- $\gamma$  expression was increased 3.5-fold and aP2 expression 3-fold by BMP-2 in comparison to untreated cells. After 11 days of treatment (samples 2.1) PPAR- $\gamma$  expression 15 was still increased 2.5-fold and aP2 expression 2.1-fold.

In contrast to BMP-2, no upregulation of these mRNAs was detected after the treatment for 72 h or 11 days with Sonic hedgehog (samples 1.2 and 2.2). Instead, expression of the two adipocytic marker genes was downregulated by Shh to 25 % of the control level in the 11 d culture (samples 2.2).

20 Combined treatment with BMP-2 and Shh caused adipocyte specific gene expression at control levels in the 72 h experiment (sample 1.3 of A and B) and a decrease in expression down to 50 % of the control level after 11 d (sample 2.3 of A and B).

In addition to quantification of adipocyte marker genes by competitive RT-PCR, the expression of hedgehog responsive genes was analyzed. BMP-2 increased expression of the 25 transcription factor gli 3-fold, but only during the 72 h treatment in serumfree conditions (Figure 1C, sample 1.1). After 11 d BMP-2 in the presence of serum had no effect on the expression of gli (1C, sample 2.1). The mRNA of gli was significantly upregulated (6-fold) by Shh at both time points (Figure 1C, samples 1.2 and 2.2). The combination of BMP-2 and Shh increased gli expression 10-fold after 72 h in serumfree media (1C, sample 1.3) 30 and more than 7-fold after 11 days compared to the untreated control (1C, sample 2.3).

BMP-2 showed only a slight effect on expression of the hedgehog receptor patched, since the relative expression level was increased only by factor 0.5 after BMP-2 treatment for 72 h (Figure 1D, sample 1.1). There was no increase after 11 days (sample 2.1). The combination of BMP-2 and Shh resulted in ptc mRNA increase of about 3-fold at both time 5 points tested (samples 1.3 and 2.3). Patched expression was upregulated 2.5-fold by Shh alone at both time points (samples 1.2 and 2.2).

In order to confirm the molecular status of the cells, we examined the cellular phenotype by adipocyte specific cytological staining. After 11 days of BMP-2 treatment a significant amount of cells acquired the rounded shape of mature adipocytes (Figure 2B). 10 Oil Red O staining demonstrated that the cytosol of these cells contained numerous lipid-filled vesicles. Untreated control cells showed no significant Oil Red O staining after this time period (Figure 2A). Interestingly the cells treated with Shh alone (Figure 2C) and with a combination of BMP-2 and Shh showed neither lipid vesicles nor Oil Red O staining (Figure 2D). This points to a suppressing effect of Shh on BMP-2 induced adipocytic 15 differentiation. No adipocytes were visible in any of the 72 h cultures (data not shown).

#### References

AHRENS, M., ANKENBAUER, T., SCHRÖDER, D., HOLLNAGEL, A., MAYER, H. and GROSS, G. (1993). Expression of human bone morphogenetic protein-2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct 20 mesenchymal cell lineages. *DNA Cell. Biol.* **12**, 871-880.

BENNETT, J.H., JOYNER, C.J., TRIFFITT, J.T. and OWEN, M.E. (1991). Adipocytic cells cultured from marrow have osteogenic potential. *J. Cell. Sci.* **99**, 131-139.

BERESFORD, J.N., BENNETT, J.H., DEVLIN, C., LEBOY, P.S. and OWEN, M.E. (1992). Evidence for an inverse relationship between the differentiation of adipocytic and 25 osteogenic cells in rat marrow stromal cell cultures. *J. Cell. Sci.* **102**, 341-351.

BRUDER, S.P., FINK, D.J. and CAPLAN, A.I. (1994). Mesenchymal Stem Cells in Bone Development, Bone Repair, and Skeletal Regeneration Therapy. *J. Cell. Biochem.* **56**, 283 - 294.

DIASCRO, D.D., VOGEL, R.L., JOHNSON, T.E., WITHERUP, K.M., 30 PITZENBERGER, S.M., RUTLEDGE, S.J., PRESCOTT, D.J., RODAN, G.A. and

SCHMIDT, A. (1998). High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. *J. Bone Miner. Res.* **13**, 96-106.

ELBRECHT, A., CHEN, Y., CULLINAN, C.A., HAYES, N., LEIBOWITZ, M.D., MOLLER, D.E. and BERGER, J. (1996). Molecular Cloning, Expression and 5 Characterization of Human Peroxisome Proliferator Activated Receptors y1 and y2. *Biochem. Biophys. Res. Com.* **224**, 431-437.

GILLILAND, G., PERRIN, S., BLANCHARD, K. and BUNN, H.F. (1990). Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. *Proc. Natl. Acad. Sci. USA* **87**, 2725 - 2729.

10 KATAGIRI, T., YAMAGUCHI, A., IKEDA, T., YOSHIKI, S., WOZNEY, J.M., ROSEN, V., WANG, E.A., TANAKA, H., OMURA, S. and SUDA, T. (1990). The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. *Biochem. Biophys. Res. Commun.* **172**, 295-299.

15 KAWABATA, M., IMAMURA, T. and MIYAZONO, K. (1998). Signal transduction by bone morphogenetic proteins. *Cytokine Growth Factor Rev.* **9**, 49-61.

KINTO, N., IWAMOTO, M., ENOMOTO-IWAMOTO, M., NOJI, S., OHUCHI, H., YOSHIOKA, H., KATAOKA, H., WADA, Y., YUHAO, G., TAKAHASHI, H.E., YOSHIKI, S. and YAMAGUCHI, A. (1997). Fibroblasts expressing Sonic hedgehog 20 induce osteoblast differentiation and ectopic bone formation. *FEBS Lett* **404**, 319-323.

LAUFER, E., NELSON, C.E., JOHNSON, R.L., MARGAN, B.A. and TABIN, C. (1994). Sonic hedgehog and Fgf-4 act through a signaling cascade and feedback loop to integrate growth and patterning of the developing limb bud. *Cell* **79**, 993-1003.

MARIGO, V., DAVEY, R.A., ZUO, Y., CUNNINGHAM, J.M. and TABIN, C.J. 25 (1996). Biochemical evidence that Patched is the Hedgehog receptor. *Nature* **384**, 176-179.

MATARESE, V. and BERNLOHR, D.A. (1988). Purification of murine adipocyte lipid-binding protein. *J. Biol. Chem.* **263**, 14544-14551.

NAKAMURA, T., AIKAWA, T., IWAMOTO-ENOMOTO, M., IWAMOTO, M., HIGUCHI, Y., PACIFICI, M., KINTO, N., YAMAGUCHI, A., NOJI, S., KURISU, K. and 30 MATSUYA, T. (1997). Induction of osteogenic differentiation by hedgehog proteins. *Biochem. Biophys. Res. Commun.* **237**, 465-469.

-81-

PLATT, K.A., MICHAUD, J. and JOYNER, A.L. (1997). Expression of the mouse Gli and Ptc genes is adjacent to embryonic sources of hedgehog signals suggesting a conservation of pathways between flies and mice. *Mech. Dev.* **62**, 121-135.

5 TONTONOZ, P., HU, E., GRAVES, R.A., BUDAVERI, A.I. and SPIEGELMAN, B.M. (1994). mPPAR $\gamma$ 2: tissue-specific regulator of an adipocyte enhancer. *Genes Dev.* **8**, 1224-1234.

WANG, E.A., ISRAEL, D.I., KELLY, S. and LUXENBERG, D.P. (1993). Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. *Growth Factors* **9**, 57-71.

10 WANG, E.A., ROSEN, V., CORDES, P., HEWICK, R.M., KRIZ, M.J., LUXENBERG, D.P., SIBLEY, B.S. and WOZNEY, J.M. (1988). Purification and characterization of other distinct bone-inducing factors. *Proc. Natl. Acad. Sci. USA* **85**, 9484-9488.

15 ZEHENTNER, B.K., DONY, C. and BURTSCHER, H. (1999). The transcription factor Sox9 is involved in BMP-2 signaling. *J. Bone Miner. Res.* **14**, 1733-1740.

All of the above-cited references and publications are hereby incorporated by reference.

20 ***Equivalents***

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.


25 We claim:

1. A method for regulating formation and/or maintenance of adipocyte tissue comprising contacting pre-adipocyte or adipocyte cells with a hedgehog polypeptide or a *ptc* therapeutic.  
5
2. The method of claim 1, wherein the hedgehog polypeptide is modified with one or more lipophilic moieties.
3. The method of claim 2, wherein the hedgehog polypeptide is modified with one or  
10 more sterol moieties.
4. The method of claim 2, wherein the sterol moiety is cholesterol.
5. The method of claim 2, wherein the hedgehog polypeptide is modified with one or  
15 more fatty acid moieties.
6. The method of claim 5, wherein each fatty acid moiety is independently selected from the group consisting of myristoyl, palmitoyl, stearoyl, and arachidoyl.
- 20 7. The method of claim 2, wherein the hedgehog polypeptide is modified with one or more aromatic hydrocarbons.
8. The method of claim 1, wherein the *ptc* therapeutic binds to *patched* and mimics *hedgehog*-mediated *patched* signal transduction.
- 25 9. The method of claim 8, wherein the *ptc* therapeutic is a small organic molecule.
10. The method of claim 8, wherein the binding of the *ptc* therapeutic to *patched* results in upregulation of *patched* and/or *gli* expression.

11. The method of claim 1, wherein the *ptc* therapeutic is a small organic molecule which interacts with neuronal cells to mimic *hedgehog*-mediated *patched* signal transduction.
- 5 12. The method of claim 1, wherein the *ptc* therapeutic mimics *hedgehog*-mediated *patched* signal transduction by altering the localization, protein-protein binding and/or enzymatic activity of an intracellular protein involved in a *patched* signal pathway.
- 10 13. The method of claim 1, wherein the *ptc* therapeutic alters the level of expression of a *hedgehog* protein, a *patched* protein or a protein involved in the intracellular signal transduction pathway of *patched*.
- 15 14. The method of claim 13, wherein the *ptc* therapeutic is an antisense construct which inhibits the expression of a protein which is involved in the signal transduction pathway of *patched* and the expression of which antagonizes *hedgehog*-mediated signals.
- 20 15. The method of claim 14, wherein the antisense construct is an oligonucleotide of about 20-30 nucleotides in length and having a GC content of at least 50 percent.
16. The method of claim 15, wherein the antisense oligonucleotide is selected from the group consisting of: 5'-GTCCTGGCGCCGCCGCCGCGTCGCC; 5'-TTCCGATGACCGGCCTTCGCGGTGA; and 5'-GTGCACGGAAAGGTGCAGGCCACACT
- 25 17. The method of claims 13, wherein the *ptc* therapeutic is a small organic molecule which binds to *patched* and regulates *patched*-dependent gene expression.
18. The method of claim 12, wherein the *ptc* therapeutic is an inhibitor of protein kinase A.

19. The method of claim 18, wherein the PKA inhibitor is a 5-isoquinolinesulfonamide

20. The method of claim 19, wherein the PKA inhibitor is represented in the general formula:



5

wherein,

R<sub>1</sub> and R<sub>2</sub> each can independently represent hydrogen, and as valence and stability permit a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-OH, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-SH, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, or

R<sub>1</sub> and R<sub>2</sub> taken together with N form a heterocycle (substituted or unsubstituted);

15 R<sub>3</sub> is absent or represents one or more substitutions to the isoquinoline ring such as a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-OH, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-O-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, -(CH<sub>2</sub>)<sub>m</sub>-SH, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkyl, -(CH<sub>2</sub>)<sub>m</sub>-S-lower alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>;

20 R<sub>8</sub> represents a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle; and

n and m are independently for each occurrence zero or an integer in the range of 1 to

25 6.

21. The method of claim 18, wherein the PKA inhibitor is cyclic AMP analog.
22. The method of claim 18, wherein the PKA inhibitor is selected from the group consisting of N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, 1-(5-  
5 isoquinoline-sulfonyl)-2-methylpiperazine, KT5720, 8-bromo-cAMP, dibutyryl-  
cAMP and PKA Heat Stable Inhibitor isoform
23. The method of claim 1, wherein patient is being treated prophylactically.
- 10 24. A therapeutic preparation of a small molecule antagonist of *patched*, which *patched*  
antagonist is provided in a pharmaceutically acceptable carrier and in an amount  
sufficient to regulate growth and/or maintenance of adipocyte cells.
- 15 25. A method for regulating the growth state of a adipocyte stem/progenitor cell  
comprising contacting the cell with a hedgehog polypeptide or a *ptc* therapeutic.
26. A method for treatment or prevention of disorders of, or surgical or cosmetic repair  
of, such adipocyte tissues, comprising administering to the patient a hedgehog  
polypeptide or a *ptc* therapeutic.

1/2




Figure 1

.2/2




**A****B****C****D**

Figure 2

- 1 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANTS: CURIS, Inc. et al.  
45 Moulton Street  
Cambridge, Massachusetts 02138  
United States of America

(ii) TITLE OF INVENTION: Methods and Compositions for Regulating Adipocytes

(iii) NUMBER OF SEQUENCES: 22

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Foley, Hoag & Eliot LLP  
(B) STREET: One Post Office Square  
(C) CITY: Boston  
(D) STATE: MA  
(E) COUNTRY: USA  
(F) ZIP: 02109

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: AscII DOS (text)

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:  
(B) FILING DATE: 28-FEB-2000  
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Quisel, John D.  
(B) REGISTRATION NUMBER: P-47,874  
(C) REFERENCE/DOCKET NUMBER: CUV-083.25

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 832-1000  
(B) TELEFAX: (617) 832-7000

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1277 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: both

- 2 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1275

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

|   |     |
|---|-----|
| ATG GTC GAA ATG CTG CTG TTG ACA AGA ATT CTC TTG GTG GGC TTC ATC | 48  |
| Met Val Glu Met Leu Leu Leu Thr Arg Ile Leu Leu Val Gly Phe Ile |     |
| 1 5 10 15   |     |
| TGC GCT CTT TTA GTC TCC TCT GGG CTG ACT TGT GGA CCA GGC AGG GGC | 96  |
| Cys Ala Leu Leu Val Ser Ser Gly Leu Thr Cys Gly Pro Gly Arg Gly |     |
| 20 25 30  |     |
| ATT GGA AAA AGG AGG CAC CCC AAA AAG CTG ACC CCG TTA GCC TAT AAG | 144 |
| Ile Gly Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys |     |
| 35 40 45  |     |
| CAG TTT ATT CCC AAT GTG GCA GAG AAG ACC CTA GGG GCC AGT GGA AGA | 192 |
| Gln Phe Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg |     |
| 50 55 60  |     |
| TAT GAA GGG AAG ATC ACA AGA AAC TCC GAG AGA TTT AAA GAA CTA ACC | 240 |
| Tyr Glu Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr |     |
| 65 70 75 80   |     |
| CCA AAT TAC AAC CCT GAC ATT ATT TTT AAG GAT GAA GAG AAC ACG GGA | 288 |
| Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly |     |
| 85 90 95  |     |
| GCT GAC AGA CTG ATG ACT CAG CGC TGC AAG GAC AAG CTG AAT GCC CTG | 336 |
| Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu |     |
| 100 105 110   |     |
| GCG ATC TCG GTG ATG AAC CAG TGG CCC GGG GTG AAG CTG CGG GTG ACC | 384 |
| Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr |     |
| 115 120 125   |     |
| GAG GGC TGG GAC GAG GAT GGC CAT CAC TCC GAG GAA TCG CTG CAC TAC | 432 |
| Glu Gly Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr |     |
| 130 135 140   |     |
| GAG GGT CGC GCC GTG GAC ATC ACC ACG TCG GAT CGG GAC CGC AGC AAG | 480 |
| Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys |     |
| 145 150 155 160   |     |
| TAC GGA ATG CTG GCC CGC CTC GCC GTC GAG GGC TTC GAC TGG GTC     | 528 |
| Tyr Gly Met Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val |     |

- 3 -

|   |     |     |      |
|---|-----|-----|------|
| 165   | 170 | 175 |      |
| TAC TAC GAG TCC AAG GCG CAC ATC CAC TGC TCC GTC AAA GCA GAA AAC |     |     | 576  |
| Tyr Tyr Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn |     |     |      |
| 180   | 185 | 190 |      |
| TCA GTG GCA GCG AAA TCA GGA GGC TGC TTC CCT GGC TCA GCC ACA GTG |     |     | 624  |
| Ser Val Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val |     |     |      |
| 195   | 200 | 205 |      |
| CAC CTG GAG CAT GGA GGC ACC AAG CTG GTG AAG GAC CTG AGC CCT GGG |     |     | 672  |
| His Leu Glu His Gly Gly Thr Lys Leu Val Lys Asp Leu Ser Pro Gly |     |     |      |
| 210   | 215 | 220 |      |
| GAC CGC GTG CTG GCT GCT GAC GCG GAC GGC CGG CTG CTC TAC AGT GAC |     |     | 720  |
| Asp Arg Val Leu Ala Ala Asp Ala Asp Gly Arg Leu Leu Tyr Ser Asp |     |     |      |
| 225   | 230 | 235 | 240  |
| TTC CTC ACC TTC CTC GAC CGG ATG GAC AGC TCC CGA AAG CTC TTC TAC |     |     | 768  |
| Phe Leu Thr Phe Leu Asp Arg Met Asp Ser Ser Arg Lys Leu Phe Tyr |     |     |      |
| 245   | 250 | 255 |      |
| GTC ATC GAG ACG CGG CAG CCC CGG GCC CGG CTG CTA CTG ACG GCG GCC |     |     | 816  |
| Val Ile Glu Thr Arg Gln Pro Arg Ala Arg Leu Leu Leu Thr Ala Ala |     |     |      |
| 260   | 265 | 270 |      |
| CAC CTG CTC TTT GTG GCC CCC CAG CAC AAC CAG TCG GAG GCC ACA GGG |     |     | 864  |
| His Leu Leu Phe Val Ala Pro Gln His Asn Gln Ser Glu Ala Thr Gly |     |     |      |
| 275   | 280 | 285 |      |
| TCC ACC AGT GGC CAG GCG CTC TTC GCC AGC AAC GTG AAG CCT GGC CAA |     |     | 912  |
| Ser Thr Ser Gly Gln Ala Leu Phe Ala Ser Asn Val Lys Pro Gly Gln |     |     |      |
| 290   | 295 | 300 |      |
| CGT GTC TAT GTG CTG GGC GAG GGC GGG CAG CAG CTG CTG CCG GCG TCT |     |     | 960  |
| Arg Val Tyr Val Leu Gly Glu Gly Gly Gln Gln Leu Leu Pro Ala Ser |     |     |      |
| 305   | 310 | 315 | 320  |
| GTC CAC AGC GTC TCA TTG CGG GAG GAG GCG TCC GGA GCC TAC GCC CCA |     |     | 1008 |
| Val His Ser Val Ser Leu Arg Glu Glu Ala Ser Gly Ala Tyr Ala Pro |     |     |      |
| 325   | 330 | 335 |      |
| CTC ACC GCC CAG GGC ACC ATC CTC ATC AAC CGG GTG TTG GCC TCC TGC |     |     | 1056 |
| Leu Thr Ala Gln Gly Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys |     |     |      |
| 340   | 345 | 350 |      |
| TAC GCC GTC ATC GAG GAG CAC AGT TGG GCC CAT TGG GCC TTC GCA CCA |     |     | 1104 |
| Tyr Ala Val Ile Glu Glu His Ser Trp Ala His Trp Ala Phe Ala Pro |     |     |      |
| 355   | 360 | 365 |      |
| TTC CGC TTG GCT CAG GGG CTG CTG GCC GCC CTC TGC CCA GAT GGG GCC |     |     | 1152 |

- 4 -

Phe Arg Leu Ala Gln Gly Leu Leu Ala Ala Leu Cys Pro Asp Gly Ala  
 370 375 380  
 ATC CCT ACT GCC GCC ACC ACC ACC ACT GGC ATC CAT TGG TAC TCA CGG 1200  
 Ile Pro Thr Ala Ala Thr Thr Thr Gly Ile His Trp Tyr Ser Arg  
 385 390 395 400  
 CTC CTC TAC CGC ATC GGC AGC TGG GTG CTG GAT GGT GAC GCG CTG CAT 1248  
 Leu Leu Tyr Arg Ile Gly Ser Trp Val Leu Asp Gly Asp Ala Leu His  
 405 410 415  
 CCG CTG GGC ATG GTG GCA CCG GCC AGC TG 1277  
 Pro Leu Gly Met Val Ala Pro Ala Ser  
 420 425

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1190 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1191

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATG GCT CTG CCG GCC AGT CTG TTG CCC CTG TGC TGC TTG GCA CTC TTG 48  
 Met Ala Leu Pro Ala Ser Leu Leu Pro Leu Cys Cys Leu Ala Leu Leu  
 1 5 10 15  
 GCA CTA TCT GCC CAG AGC TGC GGG CCG GGC CGA GGA CCG GTT GGC CGG 96  
 Ala Leu Ser Ala Gln Ser Cys Gly Pro Gly Arg Gly Pro Val Gly Arg  
 20 25 30  
 CGG CGT TAT GTG CGC AAG CAA CTT GTG CCT CTG CTA TAC AAG CAG TTT 144  
 Arg Arg Tyr Val Arg Lys Gln Leu Val Pro Leu Leu Tyr Lys Gln Phe  
 35 40 45  
 GTG CCC AGT ATG CCC GAG CGG ACC CTG GGC GCG AGT GGG CCA GCG GAG 192  
 Val Pro Ser Met Pro Glu Arg Thr Leu Gly Ala Ser Gly Pro Ala Glu  
 50 55 60  
 GGG AGG GTA ACA AGG GGG TCG GAG CGC TTC CGG GAC CTC GTA CCC AAC 240  
 Gly Arg Val Thr Arg Gly Ser Glu Arg Phe Arg Asp Leu Val Pro Asn  
 65 70 75 80  
 TAC AAC CCC GAC ATA ATC TTC AAG GAT GAG GAG AAC AGC GGC GCA GAC 288

- 5 -

Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Ser Gly Ala Asp  
 85 90 95  
 CGC CTG ATG ACA GAG CGT TGC AAA GAG CGG GTG AAC GCT CTA GCC ATC 336  
 Arg Leu Met Thr Glu Arg Cys Lys Glu Arg Val Asn Ala Leu Ala Ile  
 100 105 110  
 GCG GTG ATG AAC ATG TGG CCC GGA GTA CGC CTA CGT GTG ACT GAA GGC 384  
 Ala Val Met Asn Met Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly  
 115 120 125  
 TGG GAC GAG GAC GGC CAC CAC GCA CAG GAT TCA CTC CAC TAC GAA GGC 432  
 Trp Asp Glu Asp Gly His His Ala Gln Asp Ser Leu His Tyr Glu Gly  
 130 135 140  
 CGT GCC TTG GAC ATC ACC ACG TCT GAC CGT GAC CGT AAT AAG TAT GGT 480  
 Arg Ala Leu Asp Ile Thr Thr Ser Asp Arg Asp Arg Asn Lys Tyr Gly  
 145 150 155 160  
 TTG TTG GCG CGC CTA GCT GTG GAA GCC GGA TTC GAC TGG GTC TAC TAC 528  
 Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr  
 165 170 175  
 GAG TCC CGC AAC CAC ATC CAC GTC TCG GTC AAA GCT GAT AAC TCA CTG 576  
 Glu Ser Arg Asn His Ile His Val Ser Val Lys Ala Asp Asn Ser Leu  
 180 185 190  
 GCG GTC CGA GCC GGA GGC TGC TTT CCG GGA AAT GCC ACG GTG CGC TTG 624  
 Ala Val Arg Ala Gly Gly Cys Phe Pro Gly Asn Ala Thr Val Arg Leu  
 195 200 205  
 CGG AGC GGC GAA CGG AAG GGG CTG AGG GAA CTA CAT CGT GGT GAC TGG 672  
 Arg Ser Gly Glu Arg Lys Gly Leu Arg Glu Leu His Arg Gly Asp Trp  
 210 215 220  
 GTA CTG GCC GCT GAT GCA GCG GGC CGA GTG GTA CCC ACG CCA GTG CTG 720  
 Val Leu Ala Ala Asp Ala Ala Gly Arg Val Val Pro Thr Pro Val Leu  
 225 230 235 240  
 CTC TTC CTG GAC CGG GAT CTG CAG CGC CGC GCC TCG TTC GTG GCT GTG 768  
 Leu Phe Leu Asp Arg Asp Leu Gln Arg Arg Ala Ser Phe Val Ala Val  
 245 250 255  
 GAG ACC GAG CGG CCT CCG CGC AAA CTG TTG CTC ACA CCC TGG CAT CTG 816  
 Glu Thr Glu Arg Pro Pro Arg Lys Leu Leu Leu Thr Pro Trp His Leu  
 260 265 270  
 GTG TTC GCT GCT CGC GGG CCA GCG CCT GCT CCA GGT GAC TTT GCA CCG 864  
 Val Phe Ala Ala Arg Gly Pro Ala Pro Ala Pro Gly Asp Phe Ala Pro  
 275 280 285

- 6 -

GTG TTC GCG CGC CGC TTA CGT GCT GGC GAC TCG GTG CTG GCT CCC GGC 912  
 Val Phe Ala Arg Arg Leu Arg Ala Gly Asp Ser Val Leu Ala Pro Gly  
 290 295 300  
 GGG GAC GCG CTC CAG CCG GCG CGC GTA GCC CGC GTG GCG CGC GAG GAA 960  
 Gly Asp Ala Leu Gln Pro Ala Arg Val Ala Arg Val Ala Arg Glu Glu  
 305 310 315 320  
 GCC GTG GGC GTG TTC GCA CCG CTC ACT GCG CAC GGG ACG CTG CTG GTC 1008  
 Ala Val Gly Val Phe Ala Pro Leu Thr Ala His Gly Thr Leu Leu Val  
 325 330 335  
 AAC GAC GTC CTC GCC TCC TGC TAC GCG GTT CTA GAG AGT CAC CAG TGG 1056  
 Asn Asp Val Leu Ala Ser Cys Tyr Ala Val Leu Glu Ser His Gln Trp  
 340 345 350  
 GCC CAC CGC GCC TTC GCC CCT TTG CGG CTG CTG CAC GCG CTC GGG GCT 1104  
 Ala His Arg Ala Phe Ala Pro Leu Arg Leu Leu His Ala Leu Gly Ala  
 355 360 365  
 CTG CTC CCT GGG GGT GCA GTC CAG CCG ACT GGC ATG CAT TGG TAC TCT 1152  
 Leu Leu Pro Gly Gly Ala Val Gln Pro Thr Gly Met His Trp Tyr Ser  
 370 375 380  
 CGC CTC CTT TAC CGC TTG GCC GAG GAG TTA ATG GGC TG 1190  
 Arg Leu Leu Tyr Arg Leu Ala Glu Glu Leu Met Gly  
 385 390 395

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1281 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1233

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG TCT CCC GCC TGG CTC CCG CCC CGA CTG CGG TTC TGT CTG TTC CTG 48  
 Met Ser Pro Ala Trp Leu Arg Pro Arg Leu Arg Phe Cys Leu Phe Leu  
 1 5 10 15  
 CTG CTG CTG CTT CTG GTG CCG GCG GCG CGG GGC TGC GGG CCG GGC CGG 96  
 Leu Leu Leu Leu Val Pro Ala Ala Arg Gly Cys Gly Pro Gly Arg  
 20 25 30

- 7 -

GTG GTG GGC AGC CGC CGG AGG CCG CCT CGC AAG CTC GTG CCT CTT GCC 144  
 Val Val Gly Ser Arg Arg Arg Pro Pro Arg Lys Leu Val Pro Leu Ala  
     35       40       45  
 TAC AAG CAG TTC AGC CCC AAC GTG CCG GAG AAG ACC CTG GGC GCC AGC 192  
 Tyr Lys Gln Phe Ser Pro Asn Val Pro Glu Lys Thr Leu Gly Ala Ser  
     50       55       60  
 GGG CGC TAC GAA GGC AAG ATC GCG CGC AGC TCT GAG CGC TTC AAA GAG 240  
 Gly Arg Tyr Glu Gly Lys Ile Ala Arg Ser Ser Glu Arg Phe Lys Glu  
     65       70       75       80  
 CTC ACC CCC AAC TAC AAT CCC GAC ATC ATC TTC AAG GAC GAG GAG AAC 288  
 Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn  
     85       90       95  
 ACG GGT GCC GAC CGC CTC ATG ACC CAG CGC TGC AAG GAC CGT CTG AAC 336  
 Thr Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Arg Leu Asn  
     100      105      110  
 TCA CTG GCC ATC TCT GTC ATG AAC CAG TGG CCT GGT GTG AAA CTG CGG 384  
 Ser Leu Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg  
     115      120      125  
 GTG ACC GAA GGC CGG GAT GAA GAT GGC CAT CAC TCA GAG GAG TCT TTA 432  
 Val Thr Glu Gly Arg Asp Glu Asp Gly His His Ser Glu Glu Ser Leu  
     130      135      140  
 CAC TAT GAG GGC CGC GCG GTG GAT ATC ACC ACC TCA GAC CGT GAC CGA 480  
 His Tyr Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg  
     145      150      155      160  
 AAT AAG TAT GGA CTG CTG GCG CGC TTA GCA GTG GAG GCC GGC TTC GAC 528  
 Asn Lys Tyr Glu Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp  
     165      170      175  
 TGG GTG TAT TAC GAG TCC AAG GCC CAC GTG CAT TGC TCT GTC AAG TCT 576  
 Trp Val Tyr Tyr Glu Ser Lys Ala His Val His Cys Ser Val Lys Ser  
     180      185      190  
 GAG CAT TCG GCC GCT GCC AAG ACA GGT GGC TGC TTT CCT GCC GGA GCC 624  
 Glu His Ser Ala Ala Lys Thr Gly Gly Cys Phe Pro Ala Gly Ala  
     195      200      205  
 CAG GTG CGC CTA GAG AAC GGG GAG CGT GTG GCC CTG TCA GCT GTA AAG 672  
 Gln Val Arg Leu Glu Asn Gly Glu Arg Val Ala Leu Ser Ala Val Lys  
     210      215      220  
 CCA GGA GAC CGG GTG CTG GCC ATG GGG GAG GAT GGG ACC CCC ACC TTC 720  
 Pro Gly Asp Arg Val Leu Ala Met Gly Glu Asp Gly Thr Pro Thr Phe

- 8 -

|   |     |     |     |      |
|---|-----|-----|-----|------|
| 225   | 230 | 235 | 240 |      |
| AGT GAT GTG CTT ATT TTC CTG GAC CGC GAG CCA AAC CGG CTG AGA GCT   |     |     |     | 768  |
| Ser Asp Val Leu Ile Phe Leu Asp Arg Glu Pro Asn Arg Leu Arg Ala   |     |     |     |      |
| 245   | 250 | 255 |     |      |
| TTC CAG GTC ATC GAG ACT CAG GAT CCT CCG CGT CGG CTG GCG CTC ACG   |     |     |     | 816  |
| Phe Gln Val Ile Glu Thr Gln Asp Pro Pro Arg Arg Leu Ala Leu Thr   |     |     |     |      |
| 260   | 265 | 270 |     |      |
| CCT GCC CAC CTG CTC TTC ATT GCG GAC AAT CAT ACA GAA CCA GCA GCC   |     |     |     | 864  |
| Pro Ala His Leu Leu Phe Ile Ala Asp Asn His Thr Glu Pro Ala Ala   |     |     |     |      |
| 275   | 280 | 285 |     |      |
| CAC TTC CCG GCC ACA TTT GCC AGC CAT GTG CAA CCA GGC CAA TAT GTG   |     |     |     | 912  |
| His Phe Arg Ala Thr Phe Ala Ser His Val Gln Pro Gly Gln Tyr Val   |     |     |     |      |
| 290   | 295 | 300 |     |      |
| CTG GTA TCA GGG GTA CCA GGC CTC CAG CCT GCT CGG GTG GCA GCT GTC   |     |     |     | 960  |
| Leu Val Ser Gly Val Pro Gly Leu Gln Pro Ala Arg Val Ala Ala Val   |     |     |     |      |
| 305   | 310 | 315 | 320 |      |
| TCC ACC CAC GTG GCC CTT GGG TCC TAT GCT CCT CTC ACA AGG CAT GGG   |     |     |     | 1008 |
| Ser Thr His Val Ala Leu Gly Ser Tyr Ala Pro Leu Thr Arg His Gly   |     |     |     |      |
| 325   | 330 | 335 |     |      |
| ACA CTT GTG GTG GAG GAT GTG GTG GCC TCC TGC TTT GCA GCT GTG GCT   |     |     |     | 1056 |
| Thr Leu Val Val Glu Asp Val Val Ala Ser Cys Phe Ala Ala Val Ala   |     |     |     |      |
| 340   | 345 | 350 |     |      |
| GAC CAC CAT CTG GCT CAG TTG GCC TTC TGG CCC CTG CGA CTG TTT CCC   |     |     |     | 1104 |
| Asp His His Leu Ala Gln Leu Ala Phe Trp Pro Leu Arg Leu Phe Pro   |     |     |     |      |
| 355   | 360 | 365 |     |      |
| AGT TTG GCA TGG GGC AGC TGG ACC CCA AGT GAG GGT GTT CAC TCC TAC   |     |     |     | 1152 |
| Ser Leu Ala Trp Gly Ser Trp Thr Pro Ser Glu Gly Val His Ser Tyr   |     |     |     |      |
| 370   | 375 | 380 |     |      |
| CCT CAG ATG CTC TAC CGC CTG GGG CGT CTC TTG CTA GAA GAG AGC ACC   |     |     |     | 1200 |
| Pro Gln Met Leu Tyr Arg Leu Gly Arg Leu Leu Leu Glu Glu Ser Thr   |     |     |     |      |
| 385   | 390 | 395 | 400 |      |
| TTC CAT CCA CTG GGC ATG TCT GGG GCA GGA AGC TGAAGGGACT CTAACCACTG |     |     |     | 1253 |
| Phe His Pro Leu Gly Met Ser Gly Ala Gly Ser                       |     |     |     |      |
| 405   | 410 |     |     |      |
| CCCTCCTGGA ACTGCTGTGC GTGGATCC                                    |     |     |     | 1281 |

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1313 base pairs

- 9 -

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1314

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

|   |     |
|---|-----|
| ATG CTG CTG CTG CTG GCC AGA TGT TTT CTG GTG ATC CTT GCT TCC TCG | 48  |
| Met Leu Leu Leu Leu Ala Arg Cys Phe Leu Val Ile Leu Ala Ser Ser |     |
| 1 5 10 15   |     |
| CTG CTG GTG TGC CCC GGG CTG GCC TGT GGG CCC GGC AGG GGG TTT GGA | 96  |
| Leu Leu Val Cys Pro Gly Leu Ala Cys Gly Pro Gly Arg Gly Phe Gly |     |
| 20 25 30  |     |
| AAG AGG CGG CAC CCC AAA AAG CTG ACC CCT TTA GCC TAC AAG CAG TTT | 144 |
| Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe |     |
| 35 40 45  |     |
| ATT CCC AAC GTA GCC GAG AAG ACC CTA GGG GCC AGC GGC AGA TAT GAA | 192 |
| Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu |     |
| 50 55 60  |     |
| GGG AAG ATC ACA AGA AAC TCC GAA CGA TTT AAG GAA CTC ACC CCC AAT | 240 |
| Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn |     |
| 65 70 75 80   |     |
| TAC AAC CCC GAC ATC ATA TTT AAG GAT GAG GAA AAC ACG GGA GCA GAC | 288 |
| Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp |     |
| 85 90 95  |     |
| CGG CTG ATG ACT CAG AGG TGC AAA GAC AAG TTA AAT GCC TTG GCC ATC | 336 |
| Arg Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu Ala Ile |     |
| 100 105 110   |     |
| TCT GTG ATG AAC CAG TGG CCT GGA GTG AGG CTG CGA GTG ACC GAG GGC | 384 |
| Ser Val Met Asn Gln Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly |     |
| 115 120 125   |     |
| TGG GAT GAG GAC GGC CAT CAT TCA GAG GAG TCT CTA CAC TAT GAG GGT | 432 |
| Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr Glu Gly |     |
| 130 135 140   |     |
| CGA GCA GTG GAC ATC ACC ACG TCC GAC CGG GAC CGC AGC AAG TAC GGC | 480 |
| Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys Tyr Gly |     |

- 10 -

|   |     |     |     |      |
|---|-----|-----|-----|------|
| 145   | 150 | 155 | 160 |      |
| ATG CTG GCT CGC CTG GCT GTG GAA GCA GGT TTC GAC TGG GTC TAC TAT |     |     |     | 528  |
| Met Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr |     |     |     |      |
| 165   | 170 | 175 |     |      |
| GAA TCC AAA GCT CAC ATC CAC TGT TCT GTG AAA GCA GAG AAC TCC GTG |     |     |     | 576  |
| Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val |     |     |     |      |
| 180   | 185 | 190 |     |      |
| GCG GCC AAA TCC GGC GGC TGT TTC CCG GGA TCC GCC ACC GTG CAC CTG |     |     |     | 624  |
| Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val His Leu |     |     |     |      |
| 195   | 200 | 205 |     |      |
| GAG CAG GGC GGC ACC AAG CTG GTG AAG GAC TTA CGT CCC GGA GAC CGC |     |     |     | 672  |
| Glu Gln Gly Gly Thr Lys Leu Val Lys Asp Leu Arg Pro Gly Asp Arg |     |     |     |      |
| 210   | 215 | 220 |     |      |
| GTG CTG GCG GCT GAC GAC CAG GGC CGG CTG CTG TAC AGC GAC TTC CTC |     |     |     | 720  |
| Val Leu Ala Ala Asp Asp Gln Gly Arg Leu Leu Tyr Ser Asp Phe Leu |     |     |     |      |
| 225   | 230 | 235 | 240 |      |
| ACC TTC CTG GAC CGC GAC GAA GGC GCC AAG AAG GTC TTC TAC GTG ATC |     |     |     | 768  |
| Thr Phe Leu Asp Arg Asp Glu Gly Ala Lys Lys Val Phe Tyr Val Ile |     |     |     |      |
| 245   | 250 | 255 |     |      |
| GAG ACG CTG GAG CCG CGC GAG CGC CTG CTG CTC ACC GCC GCG CAC CTG |     |     |     | 816  |
| Glu Thr Leu Glu Pro Arg Glu Arg Leu Leu Leu Thr Ala Ala His Leu |     |     |     |      |
| 260   | 265 | 270 |     |      |
| CTC TTC GTG GCG CCG CAC AAC GAC TCG GGG CCC ACG CCC GGG CCA AGC |     |     |     | 864  |
| Leu Phe Val Ala Pro His Asn Asp Ser Gly Pro Thr Pro Gly Pro Ser |     |     |     |      |
| 275   | 280 | 285 |     |      |
| GCG CTC TTT GCC AGC CGC GTG CGC CCC GGG CAG CGC GTG TAC GTG GTG |     |     |     | 912  |
| Ala Leu Phe Ala Ser Arg Val Arg Pro Gly Gln Arg Val Tyr Val Val |     |     |     |      |
| 290   | 295 | 300 |     |      |
| GCT GAA CGC GGC GGG GAC CGC CGG CTG CTG CCC GCC GCG GTG CAC AGC |     |     |     | 960  |
| Ala Glu Arg Gly Gly Asp Arg Arg Leu Leu Pro Ala Ala Val His Ser |     |     |     |      |
| 305   | 310 | 315 | 320 |      |
| GTG ACG CTG CGA GAG GAG GAG GCG GGC GCG TAC GCG CCG CTC ACG GCG |     |     |     | 1008 |
| Val Thr Leu Arg Glu Glu Ala Gly Ala Tyr Ala Pro Leu Thr Ala     |     |     |     |      |
| 325   | 330 | 335 |     |      |
| CAC GGC ACC ATT CTC ATC AAC CGG GTG CTC GCC TCG TGC TAC GCT GTC |     |     |     | 1056 |
| His Gly Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys Tyr Ala Val |     |     |     |      |
| 340   | 345 | 350 |     |      |
| ATC GAG GAG CAC AGC TGG GCA CAC CGG GCC TTC GCG CCT TTC CGC CTG |     |     |     | 1104 |

- 11 -

Ile Glu Glu His Ser Trp Ala His Arg Ala Phe Ala Pro Phe Arg Leu  
 355 360 365  
 GCG CAC GCG CTG CTG GCC GCG CTG GCA CCC GCC CGC ACG GAC GGC GGG 1152  
 Ala His Ala Leu Leu Ala Ala Leu Ala Pro Ala Arg Thr Asp Gly Gly  
 370 375 380  
 GGC GGG GGC AGC ATC CCT GCA GCG CAA TCT GCA ACG GAA GCG AGG GGC 1200  
 Gly Gly Gly Ser Ile Pro Ala Ala Gln Ser Ala Thr Glu Ala Arg Gly  
 385 390 395 400  
 GCG GAG CCG ACT GCG GGC ATC CAC TGG TAC TCG CAG CTG CTC TAC CAC 1248  
 Ala Glu Pro Thr Ala Gly Ile His Trp Tyr Ser Gln Leu Leu Tyr His  
 405 410 415  
 ATT GGC ACC TGG CTG TTG GAC AGC GAG ACC ATG CAT CCC TTG GGA ATG 1296  
 Ile Gly Thr Trp Leu Leu Asp Ser Glu Thr Met His Pro Leu Gly Met  
 420 425 430  
 GCG GTC AAG TCC AGC TG 1313  
 Ala Val Lys Ser Ser  
 435

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1256 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1257

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATG CGG CTT TTG ACG AGA GTG CTG CTG GTG TCT CTT CTC ACT CTG TCC 48  
 Met Arg Leu Leu Thr Arg Val Leu Leu Val Ser Leu Leu Thr Leu Ser  
 1 5 10 15  
 TTG GTG GTG TCC GGA CTG GCC TGC GGT CCT GGC AGA GGC TAC GGC AGA 96  
 Leu Val Val Ser Gly Leu Ala Cys Gly Pro Gly Arg Gly Tyr Gly Arg  
 20 25 30  
 AGA AGA CAT CCG AAG AAG CTG ACA CCT CTC GCC TAC AAG CAG TTC ATA 144  
 Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe Ile  
 35 40 45  
 CCT AAT GTC GCG GAG AAG ACC TTA GGG GCC AGC GGC AGA TAC GAG GGC 192

- 12 -

Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu Gly  
 50 55 60  
 AAG ATA ACG CGC AAT TCG GAG AGA TTT AAA GAA CTT ACT CCA AAT TAC 240  
 Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn Tyr  
 65 70 75 80  
 AAT CCC GAC ATT ATC TTT AAG GAT GAG GAG AAC ACG GGA GCG GAC AGG 288  
 Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp Arg  
 85 90 95  
 CTC ATG ACA CAG AGA TGC AAA GAC AAG CTG AAC TCG CTG GCC ATC TCT 336  
 Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ser Leu Ala Ile Ser  
 100 105 110  
 GTA ATG AAC CAC TGG CCA GGG GTT AAG CTG CGT GTG ACA GAG GGC TGG 384  
 Val Met Asn His Trp Pro Gly Val Lys Leu Arg Val Thr Glu Gly Trp  
 115 120 125  
 GAT GAG GAC GGT CAC CAT TTT GAA GAA TCA CTC CAC TAC GAG GGA AGA 432  
 Asp Glu Asp Gly His His Phe Glu Ser Leu His Tyr Glu Gly Arg  
 130 135 140  
 GCT GTT GAT ATT ACC ACC TCT GAC CGA GAC AAG AGC AAA TAC GGG ACA 480  
 Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Lys Ser Lys Tyr Gly Thr  
 145 150 155 160  
 CTG TCT CGC CTA GCT GTG GAG GCT GGA TTT GAC TGG GTC TAT TAC GAG 528  
 Leu Ser Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu  
 165 170 175  
 TCC AAA GCC CAC ATT CAT TGC TCT GTC AAA GCA GAA AAT TCG GTT GCT 576  
 Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val Ala  
 180 185 190  
 GCG AAA TCT GGG GGC TGT TTC CCA GGT TCG GCT CTG GTC TCG CTC CAG 624  
 Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Leu Val Ser Leu Gln  
 195 200 205  
 GAC GGA GGA CAG AAG GCC GTG AAG GAC CTG AAC CCC GGA GAC AAG GTG 672  
 Asp Gly Gly Gln Lys Ala Val Lys Asp Leu Asn Pro Gly Asp Lys Val  
 210 215 220  
 CTG GCG GCA GAC AGC GCG GGA AAC CTG GTG TTC AGC GAC TTC ATC ATG 720  
 Leu Ala Ala Asp Ser Ala Gly Asn Leu Val Phe Ser Asp Phe Ile Met  
 225 230 235 240  
 TTC ACA GAC CGA GAC TCC ACG ACG CGA CGT GTG TTT TAC GTC ATA GAA 768  
 Phe Thr Asp Arg Asp Ser Thr Thr Arg Arg Val Phe Tyr Val Ile Glu  
 245 250 255

- 13 -

ACG CAA GAA CCC GTT GAA AAG ATC ACC CTC ACC GCC GCT CAC CTC CTT 816  
 Thr Gln Glu Pro Val Glu Lys Ile Thr Leu Thr Ala Ala His Leu Leu  
 260 265 270  
 TTT GTC CTC GAC AAC TCA ACG GAA GAT CTC CAC ACC ATG ACC GCC GCG 864  
 Phe Val Leu Asp Asn Ser Thr Glu Asp Leu His Thr Met Thr Ala Ala  
 275 280 285  
 TAT GCC AGC AGT GTC AGA GCC GGA CAA AAG GTG ATG GTT GTT GAT GAT 912  
 Tyr Ala Ser Ser Val Arg Ala Gly Gln Lys Val Met Val Val Asp Asp  
 290 295 300  
 AGC GGT CAG CTT AAA TCT GTC ATC GTG CAG CGG ATA TAC ACG GAG GAG 960  
 Ser Gly Gln Leu Lys Ser Val Ile Val Gln Arg Ile Tyr Thr Glu Glu  
 305 310 315 320  
 CAG CGG GGC TCG TTC GCA CCA GTG ACT GCA CAT GGG ACC ATT GTG GTC 1008  
 Gln Arg Gly Ser Phe Ala Pro Val Thr Ala His Gly Thr Ile Val Val  
 325 330 335  
 GAC AGA ATA CTG GCG TCC TGT TAC GCC GTA ATA GAG GAC CAG GGG CTT 1056  
 Asp Arg Ile Leu Ala Ser Cys Tyr Ala Val Ile Glu Asp Gln Gly Leu  
 340 345 350  
 GCG CAT TTG GCC TTC GCG CCC GCC AGG CTC TAT TAC GTG TCA TCA 1104  
 Ala His Leu Ala Phe Ala Pro Ala Arg Leu Tyr Tyr Val Ser Ser  
 355 360 365  
 TTC CTG TCC CCC AAA ACT CCA GCA GTC GGT CCA ATG CGA CTT TAC AAC 1152  
 Phe Leu Ser Pro Lys Thr Pro Ala Val Gly Pro Met Arg Leu Tyr Asn  
 370 375 380  
 AGG AGG GGG TCC ACT GGT ACT CCA GGC TCC TGT CAT CAA ATG GGA ACG 1200  
 Arg Arg Gly Ser Thr Gly Thr Pro Gly Ser Cys His Gln Met Gly Thr  
 385 390 395 400  
 TGG CTT TTG GAC AGC AAC ATG CTT CAT CCT TTG GGG ATG TCA GTA AAC 1248  
 Trp Leu Leu Asp Ser Asn Met Leu His Pro Leu Gly Met Ser Val Asn  
 405 410 415  
 TCA AGC TG 1256  
 Ser Ser

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1425 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

- 14 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1425

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

|   |     |
|---|-----|
| ATG CTG CTG CTG GCG AGA TGT CTG CTG CTA GTC CTC GTC TCC TCG CTG | 48  |
| Met Leu Leu Leu Ala Arg Cys Leu Leu Leu Val Leu Val Ser Ser Leu |     |
| 1 5 10 15   |     |
| CTG GTA TGC TCG GGA CTG GCG TGC GGA CCG GGC AGG GGG TTC GGG AAG | 96  |
| Leu Val Cys Ser Gly Leu Ala Cys Gly Pro Gly Arg Gly Phe Gly Lys |     |
| 20 25 30  |     |
| AGG AGG CAC CCC AAA AAG CTG ACC CCT TTA GCC TAC AAG CAG TTT ATC | 144 |
| Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe Ile |     |
| 35 40 45  |     |
| CCC AAT GTG GCC GAG AAG ACC CTA GGC GCC AGC GGA AGG TAT GAA GGG | 192 |
| Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu Gly |     |
| 50 55 60  |     |
| AAG ATC TCC AGA AAC TCC GAG CGA TTT AAG GAA CTC ACC CCC AAT TAC | 240 |
| Lys Ile Ser Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn Tyr |     |
| 65 70 75 80   |     |
| AAC CCC GAC ATC ATA TTT AAG GAT GAA GAA AAC ACC GGA GCG GAC AGG | 288 |
| Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp Arg |     |
| 85 90 95  |     |
| CTG ATG ACT CAG AGG TGT AAG GAC AAG TTG AAC GCT TTG GCC ATC TCG | 336 |
| Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu Ala Ile Ser |     |
| 100 105 110   |     |
| GTG ATG AAC CAG TGG CCA GGA GTG AAA CTG CGG GTG ACC GAG GGC TGG | 384 |
| Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr Glu Gly Trp |     |
| 115 120 125   |     |
| GAC GAA GAT GGC CAC CAC TCA GAG GAG TCT CTG CAC TAC GAG GGC CGC | 432 |
| Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr Glu Gly Arg |     |
| 130 135 140   |     |
| GCA GTG GAC ATC ACC ACG TCT GAC CGC GAC CGC AGC AAG TAC GGC ATG | 480 |
| Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys Tyr Gly Met |     |
| 145 150 155 160   |     |
| CTG GCC CGC CTG GCG GTG GAG GCC GGC TTC GAC TGG GTG TAC TAC GAG | 528 |
| Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu |     |

- 15 -

|   |     |     |      |
|---|-----|-----|------|
| 165   | 170 | 175 |      |
| TCC AAG GCA CAT ATC CAC TGC TCG GTG AAA GCA GAG AAC TCG GTG GCG |     |     | 576  |
| Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val Ala |     |     |      |
| 180   | 185 | 190 |      |
| GCC AAA TCG GGA GGC TGC TTC CCG GGC TCG GCC ACG GTG CAC CTG GAG |     |     | 624  |
| Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val His Leu Glu |     |     |      |
| 195   | 200 | 205 |      |
| CAG GGC GGC ACC AAG CTG GTG AAG GAC CTG AGC CCC GGG GAC CGC GTG |     |     | 672  |
| Gln Gly Gly Thr Lys Leu Val Lys Asp Leu Ser Pro Gly Asp Arg Val |     |     |      |
| 210   | 215 | 220 |      |
| CTG GCG GCG GAC GAC CAG GGC CGG CTG CTC TAC AGC GAC TTC CTC ACT |     |     | 720  |
| Leu Ala Ala Asp Asp Gln Gly Arg Leu Leu Tyr Ser Asp Phe Leu Thr |     |     |      |
| 225   | 230 | 235 | 240  |
| TTC CTG GAC CGC GAC GAC GGC GCC AAG AAG GTC TTC TAC GTG ATC GAG |     |     | 768  |
| Phe Leu Asp Arg Asp Asp Gly Ala Lys Lys Val Phe Tyr Val Ile Glu |     |     |      |
| 245   | 250 | 255 |      |
| ACG CGG GAG CCG CGC GAG CGC CTG CTG CTC ACC GCC GCG CAC CTG CTC |     |     | 816  |
| Thr Arg Glu Pro Arg Glu Arg Leu Leu Leu Thr Ala Ala His Leu Leu |     |     |      |
| 260   | 265 | 270 |      |
| TTT GTG GCG CCG CAC AAC GAC TCG GCC ACC GGG GAG CCC GAG GCG TCC |     |     | 864  |
| Phe Val Ala Pro His Asn Asp Ser Ala Thr Gly Glu Pro Glu Ala Ser |     |     |      |
| 275   | 280 | 285 |      |
| TCG GGC TCG GGG CCG CCT TCC GGG GGC GCA CTG GGG CCT CGG GCG CTG |     |     | 912  |
| Ser Gly Ser Gly Pro Pro Ser Gly Gly Ala Leu Gly Pro Arg Ala Leu |     |     |      |
| 290   | 295 | 300 |      |
| TTC GCC AGC CGC GTG CGC CCG GGC CAG CGC GTG TAC GTG GTG GCC GAG |     |     | 960  |
| Phe Ala Ser Arg Val Arg Pro Gly Gln Arg Val Tyr Val Val Ala Glu |     |     |      |
| 305   | 310 | 315 | 320  |
| CGT GAC GGG GAC CGC CGG CTC CTG CCC GCC GCT GTG CAC AGC GTG ACC |     |     | 1008 |
| Arg Asp Gly Asp Arg Arg Leu Leu Pro Ala Ala Val His Ser Val Thr |     |     |      |
| 325   | 330 | 335 |      |
| CTA AGC GAG GAG GCC GCG GGC GCC TAC GCG CCG CTC ACG GCC CAG GGC |     |     | 1056 |
| Leu Ser Glu Glu Ala Ala Gly Ala Tyr Ala Pro Leu Thr Ala Gln Gly |     |     |      |
| 340   | 345 | 350 |      |
| ACC ATT CTC ATC AAC CGG GTG CTG GCC TCG TGC TAC GCG GTC ATC GAG |     |     | 1104 |
| Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys Tyr Ala Val Ile Glu |     |     |      |
| 355   | 360 | 365 |      |
| GAG CAC AGC TGG GCG CAC CGG GCC TTC GCG CCC TTC CGC CTG GCG CAC |     |     | 1152 |

- 16 -

Glu His Ser Trp Ala His Arg Ala Phe Ala Pro Phe Arg Leu Ala His  
 370 375 380  
 GCG CTC CTG GCT GCA CTG GCG CCC GCG CGC ACG GAC CGC GGC GGG GAC 1200  
 Ala Leu Leu Ala Ala Leu Ala Pro Ala Arg Thr Asp Arg Gly Gly Asp  
 385 390 395 400  
 AGC GGC GGC GGG GAC CGC GGG GGC GGC GGC AGA GTA GCC CTA ACC 1248  
 Ser Gly Gly Asp Arg Gly Gly Gly Arg Val Ala Leu Thr  
 405 410 415  
 GCT CCA GGT GCT GCC GAC GCT CCG GGT GCG GGG GCC ACC GCG GGC ATC 1296  
 Ala Pro Gly Ala Ala Asp Ala Pro Gly Ala Gly Ala Thr Ala Gly Ile  
 420 425 430  
 CAC TGG TAC TCG CAG CTG CTC TAC CAA ATA GGC ACC TGG CTC CTG GAC 1344  
 His Trp Tyr Ser Gln Leu Leu Tyr Gln Ile Gly Thr Trp Leu Leu Asp  
 435 440 445  
 AGC GAG GCC CTG CAC CCG CTG GGC ATG GCG GTC AAG TCC AGC NNN AGC 1392  
 Ser Glu Ala Leu His Pro Leu Gly Met Ala Val Lys Ser Ser Xaa Ser  
 450 455 460  
 CGG GGG GCC GGG GGA GGG GCG CGG GAG GGG GCC 1425  
 Arg Gly Ala Gly Gly Ala Arg Glu Gly Ala  
 465 470 475  
 (2) INFORMATION FOR SEQ ID NO:7:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1622 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: both  
 (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: cDNA  
 (ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 51..1283  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:  
 CATCAGCCCCA CCAGGAGACC TCGCCCGCCG CTCCCCCGGG CTCCCCGGCC ATG TCT 56

Met Ser

1

CCC GCC CGG CTC CGG CCC CGA CTG CAC TTC TGC CTG GTC CTG TTG CTG 104  
 Pro Ala Arg Leu Arg Pro Arg Leu His Phe Cys Leu Val Leu Leu  
 5 10 15  
 CTG CTG GTG GTG CCC GCG GCA TGG GGC TGC GGG CCG GGT CGG GTG GTG 152

- 17 -

Leu Leu Val Val Pro Ala Ala Trp Gly Cys Gly Pro Gly Arg Val Val  
 20 25 30  
 GGC AGC CGC CGG CGA CCG CCA CGC AAA CTC GTG CCG CTC GCC TAC AAG 200  
 Gly Ser Arg Arg Arg Pro Pro Arg Lys Leu Val Pro Leu Ala Tyr Lys  
 35 40 45 50  
 CAG TTC AGC CCC AAT GTG CCC GAG AAG ACC CTG GGC GCC AGC GGA CGC 248  
 Gln Phe Ser Pro Asn Val Pro Glu Lys Thr Leu Gly Ala Ser Gly Arg  
 55 60 65  
 TAT GAA GGC AAG ATC GCT CGC AGC TCC GAG CGC TTC AAG GAG CTC ACC 296  
 Tyr Glu Gly Lys Ile Ala Arg Ser Ser Glu Arg Phe Lys Glu Leu Thr  
 70 75 80  
 CCC AAT TAC AAT CCA GAC ATC ATC TTC AAG GAC GAG GAG AAC ACA GGC 344  
 Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly  
 85 90 95  
 GCC GAC CGC CTC ATG ACC CAG CGC TGC AAG GAC CGC CTG AAC TCG CTG 392  
 Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Arg Leu Asn Ser Leu  
 100 105 110  
 GCT ATC TCG GTG ATG AAC CAG TGG CCC GGT GTG AAG CTG CGG GTG ACC 440  
 Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr  
 115 120 125 130  
 GAG GGC TGG GAC GAG GAC GGC CAC CAC TCA GAG GAG TCC CTG CAT TAT 488  
 Glu Gly Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr  
 135 140 145  
 GAG GGC CGC GCG GTG GAC ATC ACC ACA TCA GAC CGC GAC CGC AAT AAG 536  
 Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Asn Lys  
 150 155 160  
 TAT GGA CTG CTG GCG CGC TTG GCA GTG GAG GCC GGC TTT GAC TGG GTG 584  
 Tyr Gly Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val  
 165 170 175  
 TAT TAC GAG TCA AAG GCC CAC GTG CAT TGC TCC GTC AAG TCC GAG CAC 632  
 Tyr Tyr Glu Ser Lys Ala His Val His Cys Ser Val Lys Ser Glu His  
 180 185 190  
 TCG GCC GCA GCC AAG ACG GGC GGC TGC TTC CCT GCC GGA GCC CAG GTA 680  
 Ser Ala Ala Ala Lys Thr Gly Gly Cys Phe Pro Ala Gly Ala Gln Val  
 195 200 205 210  
 CGC CTG GAG AGT GGG GCG CGT GTG GCC TTG TCA GCC GTG AGG CCG GGA 728  
 Arg Leu Glu Ser Gly Ala Arg Val Ala Leu Ser Ala Val Arg Pro Gly  
 215 220 225

- 18 -

GAC CGT GTG CTG GCC ATG GGG GAG GAT GGG AGC CCC ACC TTC AGC GAT 776  
 Asp Arg Val Leu Ala Met Gly Glu Asp Gly Ser Pro Thr Phe Ser Asp  
 230 235 240  
 GTG CTC ATT TTC CTG GAC CGC GAG CCC CAC AGG CTG AGA GCC TTC CAG 824  
 Val Leu Ile Phe Leu Asp Arg Glu Pro His Arg Leu Arg Ala Phe Gln  
 245 250 255  
 GTC ATC GAG ACT CAG GAC CCC CCA CGC CGC CTG GCA CTC ACA CCC GCT 872  
 Val Ile Glu Thr Gln Asp Pro Pro Arg Arg Leu Ala Leu Thr Pro Ala  
 260 265 270  
 CAC CTG CTC TTT ACG GCT GAC AAT CAC ACG GAG CCG GCA GCC CGC TTC 920  
 His Leu Leu Phe Thr Ala Asp Asn His Thr Glu Pro Ala Ala Arg Phe  
 275 280 285 290  
 CGG GCC ACA TTT GCC AGC CAC GTG CAG CCT GGC CAG TAC GTG CTG GTG 968  
 Arg Ala Thr Phe Ala Ser His Val Gln Pro Gly Gln Tyr Val Leu Val  
 295 300 305  
 GCT GGG GTG CCA GGC CTG CAG CCT GCC CGC GTG GCA GCT GTC TCT ACA 1016  
 Ala Gly Val Pro Gly Leu Gln Pro Ala Arg Val Ala Ala Val Ser Thr  
 310 315 320  
 CAC GTG GCC CTC GGG GCC TAC GCC CCG CTC ACA AAG CAT GGG ACA CTG 1064  
 His Val Ala Leu Gly Ala Tyr Ala Pro Leu Thr Lys His Gly Thr Leu  
 325 330 335  
 GTG GTG GAG GAT GTG GTG GCA TCC TGC TTC GCG GCC GTG GCT GAC CAC 1112  
 Val Val Glu Asp Val Val Ala Ser Cys Phe Ala Ala Val Ala Asp His  
 340 345 350  
 CAC CTG GCT CAG TTG GCC TTC TGG CCC CTG AGA CTC TTT CAC AGC TTG 1160  
 His Leu Ala Gln Leu Ala Phe Trp Pro Leu Arg Leu Phe His Ser Leu  
 355 360 365 370  
 GCA TGG GGC AGC TGG ACC CCG GGG GAG GGT GTG CAT TGG TAC CCC CAG 1208  
 Ala Trp Gly Ser Trp Thr Pro Gly Glu Gly Val His Trp Tyr Pro Gln  
 375 380 385  
 CTG CTC TAC CGC CTG GGG CGT CTC CTG CTA GAA GAG GGC AGC TTC CAC 1256  
 Leu Leu Tyr Arg Leu Gly Arg Leu Leu Leu Glu Glu Gly Ser Phe His  
 390 395 400  
 CCA CTG GGC ATG TCC GGG GCA GGG AGC TGAAAGGACT CCACCGCTGC 1303  
 Pro Leu Gly Met Ser Gly Ala Gly Ser  
 405 410  
 CCTCCTGGAA CTGCTGTACT GGGTCCAGAA GCCTCTCAGC CAGGAGGGAG CTGGCCCTGG  
 1363

- 19 -

AAGGGACCTG AGCTGGGGGA CACTGGCTCC TGCCATCTCC TCTGCCATGA AGATACACCA  
1423

TTGAGACTTG ACTGGGCAAC ACCAGCGTCC CCCACCCGCG TCGTGGTGT A GTCATAGAGC  
1483

TGCAAGCTGA GCTGGCGAGG GGATGGTTGT TGACCCCTCT CTCCTAGAGA CCTTGAGGCT  
1543

GGCACGGCGA CTCCCAACTC AGCCTGCTCT CACTACGAGT TTTCATACTC TGCCTCCCC  
1603

ATTGGGAGGG CCCATTCCC 1622

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1191 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1191

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ATG GCT CTC CTG ACC AAT CTA CTG CCC TTG TGC TGC TTG GCA CTT CTG 48

Met Ala Leu Leu Thr Asn Leu Leu Pro Leu Cys Cys Leu Ala Leu Leu

1 5 10 15

GCG CTG CCA GCC CAG AGC TGC GGG CCG GGC CGG GGG CCG GTT GGC CGG 96

Ala Leu Pro Ala Gln Ser Cys Gly Pro Gly Arg Gly Pro Val Gly Arg

20 25 30

CGC CGC TAT GCG CGC AAG CAG CTC GTG CCG CTA CTC TAC AAG CAA TTT 144

Arg Arg Tyr Ala Arg Lys Gln Leu Val Pro Leu Leu Tyr Lys Gln Phe

35 40 45

G TG CCC GGC GTG CCA GAG CGG ACC CTG GGC GCC AGT GGG CCA GCG GAG 192

Val Pro Gly Val Pro Glu Arg Thr Leu Gly Ala Ser Gly Pro Ala Glu

50 55 60

GGG AGG GTG GCA AGG GGC TCC GAG CGC TTC CGG GAC CTC GTG CCC AAC 240

Gly Arg Val Ala Arg Gly Ser Glu Arg Phe Arg Asp Leu Val Pro Asn

65 70 75 80

TAC AAC CCC GAC ATC ATC TTC AAG GAT GAG GAG AAC AGT GGA GCC GAC 288

Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Ser Gly Ala Asp

85 90 95

- 20 -

CGC CTG ATG ACC GAG CGT TGC AAG GAG AGG GTG AAC GCT TTG GCC ATT 336  
 Arg Leu Met Thr Glu Arg Cys Lys Glu Arg Val Asn Ala Leu Ala Ile  
 100 105 110  
 GCC GTG ATG AAC ATG TGG CCC GGA GTG CGC CTA CGA GTG ACT GAG GGC 384  
 Ala Val Met Asn Met Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly  
 115 120 125  
 TGG GAC GAG GAC GGC CAC CAC GCT CAG GAT TCA CTC CAC TAC GAA GGC 432  
 Trp Asp Glu Asp Gly His His Ala Gln Asp Ser Leu His Tyr Glu Gly  
 130 135 140  
 CGT GCT TTG GAC ATC ACT ACG TCT GAC CGC GAC CGC AAC AAG TAT GGG 480  
 Arg Ala Leu Asp Ile Thr Thr Ser Asp Arg Asp Arg Asn Lys Tyr Gly  
 145 150 155 160  
 TTG CTG GCG CGC CTC GCA GTG GAA GCC GGC TTC GAC TGG GTC TAC TAC 528  
 Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr  
 165 170 175  
 GAG TCC CGC AAC CAC GTC CAC GTG TCG GTC AAA GCT GAT AAC TCA CTG 576  
 Glu Ser Arg Asn His Val His Val Ser Val Lys Ala Asp Asn Ser Leu  
 180 185 190  
 GCG GTC CGG GCG GGC GGC TGC TTT CCG GGA AAT GCA ACT GTG CGC CTG 624  
 Ala Val Arg Ala Gly Gly Cys Phe Pro Gly Asn Ala Thr Val Arg Leu  
 195 200 205  
 TGG AGC GGC GAG CGG AAA GGG CTG CGG GAA CTG CAC CGC GGA GAC TGG 672  
 Trp Ser Gly Glu Arg Lys Gly Leu Arg Glu Leu His Arg Gly Asp Trp  
 210 215 220  
 GTT TTG GCG GCC GAT GCG TCA GGC CGG GTG GTG CCC ACG CCG GTG CTG 720  
 Val Leu Ala Ala Asp Ala Ser Gly Arg Val Val Pro Thr Pro Val Leu  
 225 230 235 240  
 CTC TTC CTG GAC CGG GAC TTG CAG CGC CGG GCT TCA TTT GTG GCT GTG 768  
 Leu Phe Leu Asp Arg Asp Leu Gln Arg Arg Ala Ser Phe Val Ala Val  
 245 250 255  
 GAG ACC GAG TGG CCT CCA CGC AAA CTG TTG CTC ACG CCC TGG CAC CTG 816  
 Glu Thr Glu Trp Pro Pro Arg Lys Leu Leu Leu Thr Pro Trp His Leu  
 260 265 270  
 GTG TTT GCC GCT CGA GGG CCG GCG CCC GCG CCA GGC GAC TTT GCA CCG 864  
 Val Phe Ala Ala Arg Gly Pro Ala Pro Ala Pro Gly Asp Phe Ala Pro  
 275 280 285  
 GTG TTC GCG CGC CGG CTA CGC GCT GGG GAC TCG GTG CTG GCG CCC GGC 912  
 Val Phe Ala Arg Arg Leu Arg Ala Gly Asp Ser Val Leu Ala Pro Gly

- 21 -

|   |     |     |     |      |
|---|-----|-----|-----|------|
| 290   | 295 | 300 |     |      |
| GGG GAT GCG CTT CGG CCA GCG CGC GTG GCC CGT GTG GCG CGG GAG GAA |     |     |     | 960  |
| Gly Asp Ala Leu Arg Pro Ala Arg Val Ala Arg Val Ala Arg Glu Glu |     |     |     |      |
| 305   | 310 | 315 | 320 |      |
| GCC GTG GGC GTG TTC GCG CCG CTC ACC GCG CAC GGG ACG CTG CTG GTG |     |     |     | 1008 |
| Ala Val Gly Val Phe Ala Pro Leu Thr Ala His Gly Thr Leu Leu Val |     |     |     |      |
| 325   | 330 | 335 |     |      |
| AAC GAT GTC CTG GCC TCT TGC TAC GCG GTT CTG GAG AGT CAC CAG TGG |     |     |     | 1056 |
| Asn Asp Val Leu Ala Ser Cys Tyr Ala Val Leu Glu Ser His Gln Trp |     |     |     |      |
| 340   | 345 | 350 |     |      |
| GCG CAC CGC GCT TTT GCC CCC TTG AGA CTG CTG CAC GCG CTA GGG GCG |     |     |     | 1104 |
| Ala His Arg Ala Phe Ala Pro Leu Arg Leu Leu His Ala Leu Gly Ala |     |     |     |      |
| 355   | 360 | 365 |     |      |
| CTG CTC CCC GGC GGG GCC GTC CAG CCG ACT GGC ATG CAT TGG TAC TCT |     |     |     | 1152 |
| Leu Leu Pro Gly Gly Ala Val Gln Pro Thr Gly Met His Trp Tyr Ser |     |     |     |      |
| 370   | 375 | 380 |     |      |
| CGG CTC CTC TAC CGC TTA GCG GAG GAG CTA CTG GGC TGA             |     |     |     | 1191 |
| Arg Leu Leu Tyr Arg Leu Ala Glu Glu Leu Leu Gly                 |     |     |     |      |
| 385   | 390 | 395 |     |      |
| (2) INFORMATION FOR SEQ ID NO:9:                                |     |     |     |      |
| (i) SEQUENCE CHARACTERISTICS:                                   |     |     |     |      |
| (A) LENGTH: 1251 base pairs                                     |     |     |     |      |
| (B) TYPE: nucleic acid  |     |     |     |      |
| (C) STRANDEDNESS: both  |     |     |     |      |
| (D) TOPOLOGY: linear  |     |     |     |      |
| (ii) MOLECULE TYPE: cDNA  |     |     |     |      |
| (ix) FEATURE:   |     |     |     |      |
| (A) NAME/KEY: CDS   |     |     |     |      |
| (B) LOCATION: 1..1248   |     |     |     |      |
| (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:                         |     |     |     |      |
| ATG GAC GTA AGG CTG CAT CTG AAG CAA TTT GCT TTA CTG TGT TTT ATC |     |     |     | 48   |
| Met Asp Val Arg Leu His Leu Lys Gln Phe Ala Leu Leu Cys Phe Ile |     |     |     |      |
| 1   | 5   | 10  | 15  |      |
| AGC TTG CTT CTG ACG CCT TGT GGA TTA GCC TGT GGT CCT GGT AGA GGT |     |     |     | 96   |
| Ser Leu Leu Leu Thr Pro Cys Gly Leu Ala Cys Gly Pro Gly Arg Gly |     |     |     |      |
| 20  | 25  | 30  |     |      |
| TAT GGA AAA CGA AGA CAC CCA AAG AAA TTA ACC CCG TTG GCT TAC AAG |     |     |     | 144  |
| Tyr Gly Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys |     |     |     |      |

- 22 -

|   |     |     |     |
|---|-----|-----|-----|
| 35  | 40  | 45  |     |
| CAA TTC ATC CCC AAC GTT GCT GAG AAA ACG CTT GGA GCC AGC GGC AAA |     |     | 192 |
| Gln Phe Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Lys |     |     |     |
| 50  | 55  | 60  |     |
| TAC GAA GGC AAA ATC ACA AGG AAT TCA GAG AGA TTT AAA GAG CTG ATT |     |     | 240 |
| Tyr Glu Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Ile |     |     |     |
| 65  | 70  | 75  | 80  |
| CCG AAT TAT AAT CCC GAT ATC ATC TTT AAG GAC GAG GAA AAC ACA AAC |     |     | 288 |
| Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Asn |     |     |     |
| 85  | 90  | 95  |     |
| GCT GAC AGG CTG ATG ACC AAG CGC TGT AAG GAC AAG TTA AAT TCG TTG |     |     | 336 |
| Ala Asp Arg Leu Met Thr Lys Arg Cys Lys Asp Lys Leu Asn Ser Leu |     |     |     |
| 100   | 105 | 110 |     |
| GCC ATA TCC GTC ATG AAC CAC TGG CCC GGC GTG AAA CTG CGC GTC ACT |     |     | 384 |
| Ala Ile Ser Val Met Asn His Trp Pro Gly Val Lys Leu Arg Val Thr |     |     |     |
| 115   | 120 | 125 |     |
| GAA GGC TGG GAT GAG GAT GGT CAC CAT TTA GAA GAA TCT TTG CAC TAT |     |     | 432 |
| Glu Gly Trp Asp Glu Asp Gly His His Leu Glu Glu Ser Leu His Tyr |     |     |     |
| 130   | 135 | 140 |     |
| GAG GGA CGG GCA GTG GAC ATC ACT ACC TCA GAC AGG GAT AAA AGC AAG |     |     | 480 |
| Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Lys Ser Lys |     |     |     |
| 145   | 150 | 155 | 160 |
| TAT GGG ATG CTA TCC AGG CTT GCA GTG GAG GCA GGA TTC GAC TGG GTC |     |     | 528 |
| Tyr Gly Met Leu Ser Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val |     |     |     |
| 165   | 170 | 175 |     |
| TAT TAT GAA TCT AAA GCC CAC ATA CAC TGC TCT GTC AAA GCA GAA AAT |     |     | 576 |
| Tyr Tyr Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn |     |     |     |
| 180   | 185 | 190 |     |
| TCA GTG GCT GCT AAA TCA GGA GGA TGT TTT CCT GGG TCT GGG ACG GTG |     |     | 624 |
| Ser Val Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Gly Thr Val |     |     |     |
| 195   | 200 | 205 |     |
| ACA CTT GGT GAT GGG ACG AGG AAA CCC ATC AAA GAT CTT AAA GTG GGC |     |     | 672 |
| Thr Leu Gly Asp Gly Thr Arg Lys Pro Ile Lys Asp Leu Lys Val Gly |     |     |     |
| 210   | 215 | 220 |     |
| GAC CGG GTT TTG GCT GCA GAC GAG AAG GGA AAT GTC TTA ATA AGC GAC |     |     | 720 |
| Asp Arg Val Leu Ala Ala Asp Glu Lys Gly Asn Val Leu Ile Ser Asp |     |     |     |
| 225   | 230 | 235 | 240 |
| TTT ATT ATG TTT ATA GAC CAC GAT CCG ACA ACG AGA AGG CAA TTC ATC |     |     | 768 |

- 23 -

Phe Ile Met Phe Ile Asp His Asp Pro Thr Thr Arg Arg Gln Phe Ile  
 245 250 255  
 GTC ATC GAG ACG TCA GAA CCT TTC ACC AAG CTC ACC CTC ACT GCC GCG 816  
 Val Ile Glu Thr Ser Glu Pro Phe Thr Lys Leu Thr Leu Thr Ala Ala  
 260 265 270  
 CAC CTA GTT TTC GTT GGA AAC TCT TCA GCA GCT TCG GGT ATA ACA GCA 864  
 His Leu Val Phe Val Gly Asn Ser Ser Ala Ala Ser Gly Ile Thr Ala  
 275 280 285  
 ACA TTT GCC AGC AAC GTG AAG CCT GGA GAT ACA GTT TTA GTG TGG GAA 912  
 Thr Phe Ala Ser Asn Val Lys Pro Gly Asp Thr Val Leu Val Trp Glu  
 290 295 300  
 GAC ACA TGC GAG AGC CTC AAG AGC GTT ACA GTG AAA AGG ATT TAC ACT 960  
 Asp Thr Cys Glu Ser Leu Lys Ser Val Thr Val Lys Arg Ile Tyr Thr  
 305 310 315 320  
 GAG GAG CAC GAG GGC TCT TTT GCG CCA GTC ACC GCG CAC GGA ACC ATA 1008  
 Glu Glu His Glu Gly Ser Phe Ala Pro Val Thr Ala His Gly Thr Ile  
 325 330 335  
 ATA GTG GAT CAG GTG TTG GCA TCG TGC TAC GCG GTC ATT GAG AAC CAC 1056  
 Ile Val Asp Gln Val Leu Ala Ser Cys Tyr Ala Val Ile Glu Asn His  
 340 345 350  
 AAA TGG GCA CAT TGG GCT TTT GCG CCG GTC AGG TTG TGT CAC AAG CTG 1104  
 Lys Trp Ala His Trp Ala Phe Ala Pro Val Arg Leu Cys His Lys Leu  
 355 360 365  
 ATG ACG TGG CTT TTT CCG GCT CGT GAA TCA AAC GTC AAT TTT CAG GAG 1152  
 Met Thr Trp Leu Phe Pro Ala Arg Glu Ser Asn Val Asn Phe Gln Glu  
 370 375 380  
 GAT GGT ATC CAC TGG TAC TCA AAT ATG CTG TTT CAC ATC GGC TCT TGG 1200  
 Asp Gly Ile His Trp Tyr Ser Asn Met Leu Phe His Ile Gly Ser Trp  
 385 390 395 400  
 CTG CTG GAC AGA GAC TCT TTC CAT CCA CTC GGG ATT TTA CAC TTA AGT 1248  
 Leu Leu Asp Arg Asp Ser Phe His Pro Leu Gly Ile Leu His Leu Ser  
 405 410 415  
 TGA 1251

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 425 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

- 24 -

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Val Glu Met Leu Leu Leu Thr Arg Ile Leu Leu Val Gly Phe Ile  
1 5 10 15  
Cys Ala Leu Leu Val Ser Ser Gly Leu Thr Cys Gly Pro Gly Arg Gly  
20 25 30  
Ile Gly Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys  
35 40 45  
Gln Phe Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg  
50 55 60  
Tyr Glu Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr  
65 70 75 80  
Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly  
85 90 95  
Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu  
100 105 110  
Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr  
115 120 125  
Glu Gly Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr  
130 135 140  
Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys  
145 150 155 160  
Tyr Gly Met Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val  
165 170 175  
Tyr Tyr Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn  
180 185 190  
Ser Val Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val  
195 200 205  
His Leu Glu His Gly Gly Thr Lys Leu Val Lys Asp Leu Ser Pro Gly  
210 215 220  
Asp Arg Val Leu Ala Ala Asp Ala Asp Gly Arg Leu Leu Tyr Ser Asp  
225 230 235 240  
Phe Leu Thr Phe Leu Asp Arg Met Asp Ser Ser Arg Lys Leu Phe Tyr  
245 250 255  
Val Ile Glu Thr Arg Gln Pro Arg Ala Arg Leu Leu Leu Thr Ala Ala  
260 265 270  
His Leu Leu Phe Val Ala Pro Gln His Asn Gln Ser Glu Ala Thr Gly  
275 280 285

- 25 -

Ser Thr Ser Gly Gln Ala Leu Phe Ala Ser Asn Val Lys Pro Gly Gln  
 290            295            300  
 Arg Val Tyr Val Leu Gly Glu Gly Gly Gln Leu Leu Pro Ala Ser  
 305            310            315            320  
 Val His Ser Val Ser Leu Arg Glu Glu Ala Ser Gly Ala Tyr Ala Pro  
 325            330            335  
 Leu Thr Ala Gln Gly Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys  
 340            345            350  
 Tyr Ala Val Ile Glu Glu His Ser Trp Ala His Trp Ala Phe Ala Pro  
 355            360            365  
 Phe Arg Leu Ala Gln Gly Leu Leu Ala Ala Leu Cys Pro Asp Gly Ala  
 370            375            380  
 Ile Pro Thr Ala Ala Thr Thr Thr Gly Ile His Trp Tyr Ser Arg  
 385            390            395            400  
 Leu Leu Tyr Arg Ile Gly Ser Trp Val Leu Asp Gly Asp Ala Leu His  
 405            410            415  
 Pro Leu Gly Met Val Ala Pro Ala Ser  
 420            425

**(2) INFORMATION FOR SEQ ID NO:11:**

**(i) SEQUENCE CHARACTERISTICS:**

- (A) LENGTH: 396 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

**(ii) MOLECULE TYPE: protein**

**(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:**

Met Ala Leu Pro Ala Ser Leu Leu Pro Leu Cys Cys Leu Ala Leu Leu  
 1            5            10            15  
 Ala Leu Ser Ala Gln Ser Cys Gly Pro Gly Arg Gly Pro Val Gly Arg  
 20            25            30  
 Arg Arg Tyr Val Arg Lys Gln Leu Val Pro Leu Leu Tyr Lys Gln Phe  
 35            40            45  
 Val Pro Ser Met Pro Glu Arg Thr Leu Gly Ala Ser Gly Pro Ala Glu  
 50            55            60  
 Gly Arg Val Thr Arg Gly Ser Glu Arg Phe Arg Asp Leu Val Pro Asn  
 65            70            75            80  
 Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Ser Gly Ala Asp  
 85            90            95  
 Arg Leu Met Thr Glu Arg Cys Lys Glu Arg Val Asn Ala Leu Ala Ile

- 26 -

|   |     |     |     |
|---|-----|-----|-----|
| 100   | 105 | 110 |     |
| Ala Val Met Asn Met Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly |     |     |     |
| 115   | 120 | 125 |     |
| Trp Asp Glu Asp Gly His His Ala Gln Asp Ser Leu His Tyr Glu Gly |     |     |     |
| 130   | 135 | 140 |     |
| Arg Ala Leu Asp Ile Thr Thr Ser Asp Arg Asp Arg Asn Lys Tyr Gly |     |     |     |
| 145   | 150 | 155 | 160 |
| Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr |     |     |     |
| 165   | 170 | 175 |     |
| Glu Ser Arg Asn His Ile His Val Ser Val Lys Ala Asp Asn Ser Leu |     |     |     |
| 180   | 185 | 190 |     |
| Ala Val Arg Ala Gly Gly Cys Phe Pro Gly Asn Ala Thr Val Arg Leu |     |     |     |
| 195   | 200 | 205 |     |
| Arg Ser Gly Glu Arg Lys Gly Leu Arg Glu Leu His Arg Gly Asp Trp |     |     |     |
| 210   | 215 | 220 |     |
| Val Leu Ala Ala Asp Ala Ala Gly Arg Val Val Pro Thr Pro Val Leu |     |     |     |
| 225   | 230 | 235 | 240 |
| Leu Phe Leu Asp Arg Asp Leu Gln Arg Arg Ala Ser Phe Val Ala Val |     |     |     |
| 245   | 250 | 255 |     |
| Glu Thr Glu Arg Pro Pro Arg Lys Leu Leu Leu Thr Pro Trp His Leu |     |     |     |
| 260   | 265 | 270 |     |
| Val Phe Ala Ala Arg Gly Pro Ala Pro Ala Pro Gly Asp Phe Ala Pro |     |     |     |
| 275   | 280 | 285 |     |
| Val Phe Ala Arg Arg Leu Arg Ala Gly Asp Ser Val Leu Ala Pro Gly |     |     |     |
| 290   | 295 | 300 |     |
| Gly Asp Ala Leu Gln Pro Ala Arg Val Ala Arg Val Ala Arg Glu Glu |     |     |     |
| 305   | 310 | 315 | 320 |
| Ala Val Gly Val Phe Ala Pro Leu Thr Ala His Gly Thr Leu Leu Val |     |     |     |
| 325   | 330 | 335 |     |
| Asn Asp Val Leu Ala Ser Cys Tyr Ala Val Leu Glu Ser His Gln Trp |     |     |     |
| 340   | 345 | 350 |     |
| Ala His Arg Ala Phe Ala Pro Leu Arg Leu Leu His Ala Leu Gly Ala |     |     |     |
| 355   | 360 | 365 |     |
| Leu Leu Pro Gly Gly Ala Val Gln Pro Thr Gly Met His Trp Tyr Ser |     |     |     |
| 370   | 375 | 380 |     |
| Arg Leu Leu Tyr Arg Leu Ala Glu Glu Leu Met Gly                 |     |     |     |
| 385   | 390 | 395 |     |

(2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Ser Pro Ala Trp Leu Arg Pro Arg Leu Arg Phe Cys Leu Phe Leu  
 1 5 10 15

Leu Leu Leu Leu Leu Val Pro Ala Ala Arg Gly Cys Gly Pro Gly Arg  
 20 25 30

Val Val Gly Ser Arg Arg Arg Pro Pro Arg Lys Leu Val Pro Leu Ala  
 35 40 45

Tyr Lys Gln Phe Ser Pro Asn Val Pro Glu Lys Thr Leu Gly Ala Ser  
 50 55 60

Gly Arg Tyr Glu Gly Lys Ile Ala Arg Ser Ser Glu Arg Phe Lys Glu  
 65 70 75 80

Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn  
 85 90 95

Thr Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Arg Leu Asn  
 100 105 110

Ser Leu Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg  
 115 120 125

Val Thr Glu Gly Arg Asp Glu Asp Gly His His Ser Glu Glu Ser Leu  
 130 135 140

His Tyr Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg  
 145 150 155 160

Asn Lys Tyr Gly Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp  
 165 170 175

Trp Val Tyr Tyr Glu Ser Lys Ala His Val His Cys Ser Val Lys Ser  
 180 185 190

Glu His Ser Ala Ala Ala Lys Thr Gly Gly Cys Phe Pro Ala Gly Ala  
 195 200 205

Gln Val Arg Leu Glu Asn Gly Glu Arg Val Ala Leu Ser Ala Val Lys  
 210 215 220

Pro Gly Asp Arg Val Leu Ala Met Gly Glu Asp Gly Thr Pro Thr Phe  
 225 230 235 240

Ser Asp Val Leu Ile Phe Leu Asp Arg Glu Pro Asn Arg Leu Arg Ala  
 245 250 255

- 28 -

Phe Gln Val Ile Glu Thr Gln Asp Pro Pro Arg Arg Leu Ala Leu Thr  
 260 265 270  
 Pro Ala His Leu Leu Phe Ile Ala Asp Asn His Thr Glu Pro Ala Ala  
 275 280 285  
 His Phe Arg Ala Thr Phe Ala Ser His Val Gln Pro Gly Gln Tyr Val  
 290 295 300  
 Leu Val Ser Gly Val Pro Gly Leu Gln Pro Ala Arg Val Ala Ala Val  
 305 310 315 320  
 Ser Thr His Val Ala Leu Gly Ser Tyr Ala Pro Leu Thr Arg His Gly  
 325 330 335  
 Thr Leu Val Val Glu Asp Val Val Ala Ser Cys Phe Ala Ala Val Ala  
 340 345 350  
 Asp His His Leu Ala Gln Leu Ala Phe Trp Pro Leu Arg Leu Phe Pro  
 355 360 365  
 Ser Leu Ala Trp Gly Ser Trp Thr Pro Ser Glu Gly Val His Ser Tyr  
 370 375 380  
 Pro Gln Met Leu Tyr Arg Leu Gly Arg Leu Leu Leu Glu Ser Thr  
 385 390 395 400  
 Phe His Pro Leu Gly Met Ser Gly Ala Gly Ser  
 405 410

**(2) INFORMATION FOR SEQ ID NO:13:**

**(i) SEQUENCE CHARACTERISTICS:**

- (A) LENGTH: 437 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

**(ii) MOLECULE TYPE: protein**

**(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:**

Met Leu Leu Leu Leu Ala Arg Cys Phe Leu Val Ile Leu Ala Ser Ser  
 1 5 10 15  
 Leu Leu Val Cys Pro Gly Leu Ala Cys Gly Pro Gly Arg Gly Phe Gly  
 20 25 30  
 Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe  
 35 40 45  
 Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu  
 50 55 60  
 Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn  
 65 70 75 80  
 Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp

|   |     |     |
|---|-----|-----|
| 85  | 90  | 95  |
| Arg Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu Ala Ile |     |     |
| 100   | 105 | 110 |
| Ser Val Met Asn Gln Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly |     |     |
| 115   | 120 | 125 |
| Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr Glu Gly |     |     |
| 130   | 135 | 140 |
| Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys Tyr Gly |     |     |
| 145   | 150 | 155 |
| 160   |     |     |
| Met Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr |     |     |
| 165   | 170 | 175 |
| Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val |     |     |
| 180   | 185 | 190 |
| Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val His Leu |     |     |
| 195   | 200 | 205 |
| Glu Gln Gly Gly Thr Lys Leu Val Lys Asp Leu Arg Pro Gly Asp Arg |     |     |
| 210   | 215 | 220 |
| Val Leu Ala Ala Asp Asp Gln Gly Arg Leu Leu Tyr Ser Asp Phe Leu |     |     |
| 225   | 230 | 235 |
| 240   |     |     |
| Thr Phe Leu Asp Arg Asp Glu Gly Ala Lys Lys Val Phe Tyr Val Ile |     |     |
| 245   | 250 | 255 |
| Glu Thr Leu Glu Pro Arg Glu Arg Leu Leu Leu Thr Ala Ala His Leu |     |     |
| 260   | 265 | 270 |
| Leu Phe Val Ala Pro His Asn Asp Ser Gly Pro Thr Pro Gly Pro Ser |     |     |
| 275   | 280 | 285 |
| Ala Leu Phe Ala Ser Arg Val Arg Pro Gly Gln Arg Val Tyr Val Val |     |     |
| 290   | 295 | 300 |
| Ala Glu Arg Gly Gly Asp Arg Arg Leu Leu Pro Ala Ala Val His Ser |     |     |
| 305   | 310 | 315 |
| 320   |     |     |
| Val Thr Leu Arg Glu Glu Glu Ala Gly Ala Tyr Ala Pro Leu Thr Ala |     |     |
| 325   | 330 | 335 |
| His Gly Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys Tyr Ala Val |     |     |
| 340   | 345 | 350 |
| Ile Glu Glu His Ser Trp Ala His Arg Ala Phe Ala Pro Phe Arg Leu |     |     |
| 355   | 360 | 365 |
| Ala His Ala Leu Leu Ala Ala Leu Ala Pro Ala Arg Thr Asp Gly Gly |     |     |
| 370   | 375 | 380 |
| Gly Gly Gly Ser Ile Pro Ala Ala Gln Ser Ala Thr Glu Ala Arg Gly |     |     |

- 30 -

|   |     |     |     |
|---|-----|-----|-----|
| 385   | 390 | 395 | 400 |
| Ala Glu Pro Thr Ala Gly Ile His Trp Tyr Ser Gln Leu Leu Tyr His |     |     |     |
| 405   | 410 | 415 |     |
| Ile Gly Thr Trp Leu Leu Asp Ser Glu Thr Met His Pro Leu Gly Met |     |     |     |
| 420   | 425 | 430 |     |
| Ala Val Lys Ser Ser   |     |     |     |

(2) INFORMATION FOR SEO ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 418 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Arg Leu Leu Thr Arg Val Leu Leu Val Ser Leu Leu Thr Leu Ser  
 1 5 10 15  
 Leu Val Val Ser Gly Leu Ala Cys Gly Pro Gly Arg Gly Tyr Gly Arg  
 20 25 30  
 Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe Ile  
 35 40 45  
 Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu Gly  
 50 55 60  
 Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn Tyr  
 65 70 75 80  
 Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp Arg  
 85 90 95  
 Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ser Leu Ala Ile Ser  
 100 105 110  
 Val Met Asn His Trp Pro Gly Val Lys Leu Arg Val Thr Glu Gly Trp  
 115 120 125  
 Asp Glu Asp Gly His His Phe Glu Glu Ser Leu His Tyr Glu Gly Arg  
 130 135 140  
 Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Lys Ser Lys Tyr Gly Thr  
 145 150 155 160  
 Leu Ser Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu  
 165 170 175  
 Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val Ala  
 180 185 190

- 31 -

Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Leu Val Ser Leu Gln  
 195 200 205  
 Asp Gly Gly Gln Lys Ala Val Lys Asp Leu Asn Pro Gly Asp Lys Val  
 210 215 220  
 Leu Ala Ala Asp Ser Ala Gly Asn Leu Val Phe Ser Asp Phe Ile Met  
 225 230 235 240  
 Phe Thr Asp Arg Asp Ser Thr Thr Arg Arg Val Phe Tyr Val Ile Glu  
 245 250 255  
 Thr Gln Glu Pro Val Glu Lys Ile Thr Leu Thr Ala Ala His Leu Leu  
 260 265 270  
 Phe Val Leu Asp Asn Ser Thr Glu Asp Leu His Thr Met Thr Ala Ala  
 275 280 285  
 Tyr Ala Ser Ser Val Arg Ala Gly Gln Lys Val Met Val Val Asp Asp  
 290 295 300  
 Ser Gly Gln Leu Lys Ser Val Ile Val Gln Arg Ile Tyr Thr Glu Glu  
 305 310 315 320  
 Gln Arg Gly Ser Phe Ala Pro Val Thr Ala His Gly Thr Ile Val Val  
 325 330 335  
 Asp Arg Ile Leu Ala Ser Cys Tyr Ala Val Ile Glu Asp Gln Gly Leu  
 340 345 350  
 Ala His Leu Ala Phe Ala Pro Ala Arg Leu Tyr Tyr Val Ser Ser  
 355 360 365  
 Phe Leu Ser Pro Lys Thr Pro Ala Val Gly Pro Met Arg Leu Tyr Asn  
 370 375 380  
 Arg Arg Gly Ser Thr Gly Thr Pro Gly Ser Cys His Gln Met Gly Thr  
 385 390 395 400  
 Trp Leu Leu Asp Ser Asn Met Leu His Pro Leu Gly Met Ser Val Asn  
 405 410 415  
 Ser Ser

**(2) INFORMATION FOR SEQ ID NO:15:**

**(i) SEQUENCE CHARACTERISTICS:**

- (A) LENGTH: 475 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

**(ii) MOLECULE TYPE: protein**

**(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:**

Met Leu Leu Leu Ala Arg Cys Leu Leu Leu Val Leu Val Ser Ser Leu

- 32 -

1 5 10 15  
Leu Val Cys Ser Gly Leu Ala Cys Gly Pro Gly Arg Gly Phe Gly Lys  
20 25 30  
Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe Ile  
35 40 45  
Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu Gly  
50 55 60  
Lys Ile Ser Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn Tyr  
65 70 75 80  
Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp Arg  
85 90 95  
Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu Ala Ile Ser  
100 105 110  
Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr Glu Gly Trp  
115 120 125  
Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr Glu Gly Arg  
130 135 140  
Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys Tyr Gly Met  
145 150 155 160  
Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu  
165 170 175  
Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val Ala  
180 185 190  
Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val His Leu Glu  
195 200 205  
Gln Gly Gly Thr Lys Leu Val Lys Asp Leu Ser Pro Gly Asp Arg Val  
210 215 220  
Leu Ala Ala Asp Asp Gln Gly Arg Leu Leu Tyr Ser Asp Phe Leu Thr  
225 230 235 240  
Phe Leu Asp Arg Asp Asp Gly Ala Lys Lys Val Phe Tyr Val Ile Glu  
245 250 255  
Thr Arg Glu Pro Arg Glu Arg Leu Leu Leu Thr Ala Ala His Leu Leu  
260 265 270  
Phe Val Ala Pro His Asn Asp Ser Ala Thr Gly Glu Pro Glu Ala Ser  
275 280 285  
Ser Gly Ser Gly Pro Pro Ser Gly Gly Ala Leu Gly Pro Arg Ala Leu  
290 295 300  
Phe Ala Ser Arg Val Arg Pro Gly Gln Arg Val Tyr Val Val Ala Glu

- 33 -

|   |     |     |     |  |
|---|-----|-----|-----|--|
| 305   | 310 | 315 | 320 |  |
| Arg Asp Gly Asp Arg Arg Leu Leu Pro Ala Ala Val His Ser Val Thr |     |     |     |  |
| 325   | 330 | 335 |     |  |
| Leu Ser Glu Glu Ala Ala Gly Ala Tyr Ala Pro Leu Thr Ala Gln Gly |     |     |     |  |
| 340   | 345 | 350 |     |  |
| Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys Tyr Ala Val Ile Glu |     |     |     |  |
| 355   | 360 | 365 |     |  |
| Glu His Ser Trp Ala His Arg Ala Phe Ala Pro Phe Arg Leu Ala His |     |     |     |  |
| 370   | 375 | 380 |     |  |
| Ala Leu Leu Ala Ala Leu Ala Pro Ala Arg Thr Asp Arg Gly Gly Asp |     |     |     |  |
| 385   | 390 | 395 | 400 |  |
| Ser Gly Gly Asp Arg Gly Gly Gly Gly Arg Val Ala Leu Thr         |     |     |     |  |
| 405   | 410 | 415 |     |  |
| Ala Pro Gly Ala Ala Asp Ala Pro Gly Ala Gly Ala Thr Ala Gly Ile |     |     |     |  |
| 420   | 425 | 430 |     |  |
| His Trp Tyr Ser Gln Leu Leu Tyr Gln Ile Gly Thr Trp Leu Leu Asp |     |     |     |  |
| 435   | 440 | 445 |     |  |
| Ser Glu Ala Leu His Pro Leu Gly Met Ala Val Lys Ser Ser Xaa Ser |     |     |     |  |
| 450   | 455 | 460 |     |  |
| Arg Gly Ala Gly Gly Ala Arg Glu Gly Ala                         |     |     |     |  |
| 465   | 470 | 475 |     |  |

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 411 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

|   |    |    |    |  |
|---|----|----|----|--|
| 1   | 5  | 10 | 15 |  |
| Met Ser Pro Ala Arg Leu Arg Pro Arg Leu His Phe Cys Leu Val Leu |    |    |    |  |
| 20  | 25 | 30 |    |  |
| Leu Leu Leu Leu Val Val Pro Ala Ala Trp Gly Cys Gly Pro Gly Arg |    |    |    |  |
| 35  | 40 | 45 |    |  |
| Val Val Gly Ser Arg Arg Arg Pro Pro Arg Lys Leu Val Pro Leu Ala |    |    |    |  |
| 50  | 55 | 60 |    |  |
| Tyr Lys Gln Phe Ser Pro Asn Val Pro Glu Lys Thr Leu Gly Ala Ser |    |    |    |  |
| 65  | 70 | 75 | 80 |  |
| Gly Arg Tyr Glu Gly Lys Ile Ala Arg Ser Ser Glu Arg Phe Lys Glu |    |    |    |  |

Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn  
 85 90 95  
 Thr Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Arg Leu Asn  
 100 105 110  
 Ser Leu Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg  
 115 120 125  
 Val Thr Glu Gly Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu  
 130 135 140  
 His Tyr Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg  
 145 150 155 160  
 Asn Lys Tyr Gly Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp  
 165 170 175  
 Trp Val Tyr Tyr Glu Ser Lys Ala His Val His Cys Ser Val Lys Ser  
 180 185 190  
 Glu His Ser Ala Ala Lys Thr Gly Gly Cys Phe Pro Ala Gly Ala  
 195 200 205  
 Gln Val Arg Leu Glu Ser Gly Ala Arg Val Ala Leu Ser Ala Val Arg  
 210 215 220  
 Pro Gly Asp Arg Val Leu Ala Met Gly Glu Asp Gly Ser Pro Thr Phe  
 225 230 235 240  
 Ser Asp Val Leu Ile Phe Leu Asp Arg Glu Pro His Arg Leu Arg Ala  
 245 250 255  
 Phe Gln Val Ile Glu Thr Gln Asp Pro Pro Arg Arg Leu Ala Leu Thr  
 260 265 270  
 Pro Ala His Leu Leu Phe Thr Ala Asp Asn His Thr Glu Pro Ala Ala  
 275 280 285  
 Arg Phe Arg Ala Thr Phe Ala Ser His Val Gln Pro Gly Gln Tyr Val  
 290 295 300  
 Leu Val Ala Gly Val Pro Gly Leu Gln Pro Ala Arg Val Ala Ala Val  
 305 310 315 320  
 Ser Thr His Val Ala Leu Gly Ala Tyr Ala Pro Leu Thr Lys His Gly  
 325 330 335  
 Thr Leu Val Val Glu Asp Val Val Ala Ser Cys Phe Ala Ala Val Ala  
 340 345 350  
 Asp His His Leu Ala Gln Leu Ala Phe Trp Pro Leu Arg Leu Phe His  
 355 360 365  
 Ser Leu Ala Trp Gly Ser Trp Thr Pro Gly Glu Gly Val His Trp Tyr  
 370 375 380

- 35 -

Pro Gln Leu Leu Tyr Arg Leu Gly Arg Leu Leu Leu Glu Glu Gly Ser  
 385            390            395            400  
 Phe His Pro Leu Gly Met Ser Gly Ala Gly Ser  
 405            410

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 396 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Met Ala Leu Leu Thr Asn Leu Leu Pro Leu Cys Cys Leu Ala Leu Leu  
 1            5            10            15  
 Ala Leu Pro Ala Gln Ser Cys Gly Pro Gly Arg Gly Pro Val Gly Arg  
 20            25            30  
 Arg Arg Tyr Ala Arg Lys Gln Leu Val Pro Leu Leu Tyr Lys Gln Phe  
 35            40            45  
 Val Pro Gly Val Pro Glu Arg Thr Leu Gly Ala Ser Gly Pro Ala Glu  
 50            55            60  
 Gly Arg Val Ala Arg Gly Ser Glu Arg Phe Arg Asp Leu Val Pro Asn  
 65            70            75            80  
 Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Ser Gly Ala Asp  
 85            90            95  
 Arg Leu Met Thr Glu Arg Cys Lys Glu Arg Val Asn Ala Leu Ala Ile  
 100            105            110  
 Ala Val Met Asn Met Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly  
 115            120            125  
 Trp Asp Glu Asp Gly His His Ala Gln Asp Ser Leu His Tyr Glu Gly  
 130            135            140  
 Arg Ala Leu Asp Ile Thr Thr Ser Asp Arg Asp Arg Asn Lys Tyr Gly  
 145            150            155            160  
 Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr  
 165            170            175  
 Glu Ser Arg Asn His Val His Val Ser Val Lys Ala Asp Asn Ser Leu  
 180            185            190  
 Ala Val Arg Ala Gly Gly Cys Phe Pro Gly Asn Ala Thr Val Arg Leu  
 195            200            205  
 Trp Ser Gly Glu Arg Lys Gly Leu Arg Glu Leu His Arg Gly Asp Trp

- 36 -

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 210 | 215 | 220 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Val | Leu | Ala | Ala | Asp | Ala | Ser | Gly | Arg | Val | Val | Pro | Thr | Pro | Val | Leu |
| 225 | 230 | 235 | 240 |     |     |     |     |     |     |     |     |     |     |     |     |
| Leu | Phe | Leu | Asp | Arg | Asp | Leu | Gln | Arg | Arg | Ala | Ser | Phe | Val | Ala | Va  |
| 245 | 250 | 255 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Glu | Thr | Glu | Trp | Pro | Pro | Arg | Lys | Leu | Leu | Leu | Thr | Pro | Trp | His | Leu |
| 260 | 265 | 270 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Val | Phe | Ala | Ala | Arg | Gly | Pro | Ala | Pro | Ala | Pro | Gly | Asp | Phe | Ala | Pro |
| 275 | 280 | 285 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Val | Phe | Ala | Arg | Arg | Leu | Arg | Ala | Gly | Asp | Ser | Val | Leu | Ala | Pro | Gly |
| 290 | 295 | 300 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Gly | Asp | Ala | Leu | Arg | Pro | Ala | Arg | Val | Ala | Arg | Val | Ala | Arg | Glu | Gl  |
| 305 | 310 | 315 | 320 |     |     |     |     |     |     |     |     |     |     |     |     |
| Ala | Val | Gly | Val | Phe | Ala | Pro | Leu | Thr | Ala | His | Gly | Thr | Leu | Leu | Val |
| 325 | 330 | 335 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Asn | Asp | Val | Leu | Ala | Ser | Cys | Tyr | Ala | Val | Leu | Glu | Ser | His | Gln | Trp |
| 340 | 345 | 350 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Ala | His | Arg | Ala | Phe | Ala | Pro | Leu | Arg | Leu | Leu | His | Ala | Leu | Gly | Ala |
| 355 | 360 | 365 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Leu | Leu | Pro | Gly | Gly | Ala | Val | Gln | Pro | Thr | Gly | Met | His | Trp | Tyr | Ser |
| 370 | 375 | 380 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Arg | Leu | Leu | Tyr | Arg | Leu | Ala | Glu | Glu | Leu | Leu | Gly |     |     |     |     |
| 385 | 390 | 395 |     |     |     |     |     |     |     |     |     |     |     |     |     |

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 416 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

- 37 -

Tyr Glu Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Ile  
 65            70            75            80  
 Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Asn  
 85            90            95  
 Ala Asp Arg Leu Met Thr Lys Arg Cys Lys Asp Lys Leu Asn Ser Leu  
 100           105           110  
 Ala Ile Ser Val Met Asn His Trp Pro Gly Val Lys Leu Arg Val Thr  
 115           120           125  
 Glu Gly Trp Asp Glu Asp Gly His His Leu Glu Glu Ser Leu His Tyr  
 130           135           140  
 Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Lys Ser Lys  
 145           150           155           160  
 Tyr Gly Met Leu Ser Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val  
 165           170           175  
 Tyr Tyr Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn  
 180           185           190  
 Ser Val Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Gly Thr Val  
 195           200           205  
 Thr Leu Gly Asp Gly Thr Arg Lys Pro Ile Lys Asp Leu Lys Val Gly  
 210           215           220  
 Asp Arg Val Leu Ala Ala Asp Glu Lys Gly Asn Val Leu Ile Ser Asp  
 225           230           235           240  
 Phe Ile Met Phe Ile Asp His Asp Pro Thr Thr Arg Arg Gln Phe Ile  
 245           250           255  
 Val Ile Glu Thr Ser Glu Pro Phe Thr Lys Leu Thr Leu Thr Ala Ala  
 260           265           270  
 His Leu Val Phe Val Gly Asn Ser Ser Ala Ala Ser Gly Ile Thr Ala  
 275           280           285  
 Thr Phe Ala Ser Asn Val Lys Pro Gly Asp Thr Val Leu Val Trp Glu  
 290           295           300  
 Asp Thr Cys Glu Ser Leu Lys Ser Val Thr Val Lys Arg Ile Tyr Thr  
 305           310           315           320  
 Glu Glu His Glu Gly Ser Phe Ala Pro Val Thr Ala His Gly Thr Ile  
 325           330           335  
 Ile Val Asp Gln Val Leu Ala Ser Cys Tyr Ala Val Ile Glu Asn His  
 340           345           350  
 Lys Trp Ala His Trp Ala Phe Ala Pro Val Arg Leu Cys His Lys Leu  
 355           360           365

- 38 -

Met Thr Trp Leu Phe Pro Ala Arg Glu Ser Asn Val Asn Phe Gln Glu  
 370            375            380  
 Asp Gly Ile His Trp Tyr Ser Asn Met Leu Phe His Ile Gly Ser Trp  
 385            390            395            400  
 Leu Leu Asp Arg Asp Ser Phe His Pro Leu Gly Ile Leu His Leu Ser  
 405            410            415

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1416 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1413

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

|   |     |
|---|-----|
| ATG GAT AAC CAC AGC TCA GTG CCT TGG GCC AGT GCC GCC AGT GTC ACC | 48  |
| Met Asp Asn His Ser Ser Val Pro Trp Ala Ser Ala Ala Ser Val Thr |     |
| 1            5            10            15                      |     |
| TGT CTC TCC CTG GGA TGC CAA ATG CCA CAG TTC CAG TTC CAG CAG     | 96  |
| Cys Leu Ser Leu Gly Cys Gln Met Pro Gln Phe Gln Phe Gln Phe Gln |     |
| 20            25            30                                  |     |
| CTC CAA ATC CGC AGC GAG CTC CAT CTC CGC AAG CCC GCA AGA AGA ACG | 144 |
| Leu Gln Ile Arg Ser Glu Leu His Leu Arg Lys Pro Ala Arg Arg Thr |     |
| 35            40            45                                  |     |
| CAA ACG ATG CGC CAC ATT GCG CAT ACG CAG CGT TGC CTC AGC AGG CTG | 192 |
| Gln Thr Met Arg His Ile Ala His Thr Gln Arg Cys Leu Ser Arg Leu |     |
| 50            55            60                                  |     |
| ACC TCT CTG GTG GCC CTG CTG ATC GTC TTG CCG ATG GTC TTT AGC     | 240 |
| Thr Ser Leu Val Ala Leu Leu Ile Val Leu Pro Met Val Phe Ser     |     |
| 65            70            75            80                    |     |
| CCG GCT CAC AGC TGC GGT CCT GGC CGA GGA TTG GGT CGT CAT AGG GCG | 288 |
| Pro Ala His Ser Cys Gly Pro Gly Arg Gly Leu Gly Arg His Arg Ala |     |
| 85            90            95                                  |     |
| CGC AAC CTG TAT CCG CTG GTC CTC AAG CAG ACA ATT CCC AAT CTA TCC | 336 |
| Arg Asn Leu Tyr Pro Leu Val Leu Lys Gln Thr Ile Pro Asn Leu Ser |     |
| 100            105            110                               |     |

GAG TAC ACG AAC AGC GCC TCC GGA CCT CTG GAG GGT GTG ATC CGT CGG 384  
 Glu Tyr Thr Asn Ser Ala Ser Gly Pro Leu Glu Gly Val Ile Arg Arg  
 115 120 125  
 GAT TCG CCC AAA TTC AAG GAC CTC GTG CCC AAC TAC AAC AGG GAC ATC 432  
 Asp Ser Pro Lys Phe Lys Asp Leu Val Pro Asn Tyr Asn Arg Asp Ile  
 130 135 140  
 CTT TTC CGT GAC GAG GAA GGC ACC GGA GCG GAT GGC TTG ATG AGC AAG 480  
 Leu Phe Arg Asp Glu Glu Gly Thr Gly Ala Asp Gly Leu Met Ser Lys  
 145 150 155 160  
 CGC TGC AAG GAG AAG CTA AAC GTG CTG GCC TAC TCG GTG ATG AAC GAA 528  
 Arg Cys Lys Glu Lys Leu Asn Val Leu Ala Tyr Ser Val Met Asn Glu  
 165 170 175  
 TGG CCC GGC ATC CGG CTG CTG GTC ACC GAG AGC TGG GAC GAG GAC TAC 576  
 Trp Pro Gly Ile Arg Leu Leu Val Thr Glu Ser Trp Asp Glu Asp Tyr  
 180 185 190  
 CAT CAC GGC CAG GAG TCG CTC CAC TAC GAG GGC CGA GCG GTG ACC ATT 624  
 His His Gly Gln Glu Ser Leu His Tyr Glu Gly Arg Ala Val Thr Ile  
 195 200 205  
 GCC ACC TCC GAT CGC GAC CAG TCC AAA TAC GGC ATG CTC GCT CGC CTG 672  
 Ala Thr Ser Asp Arg Asp Gln Ser Lys Tyr Gly Met Leu Ala Arg Leu  
 210 215 220  
 GCC GTC GAG GCT GGA TTC GAT TGG GTC TCC TAC GTC AGC AGG CGC CAC 720  
 Ala Val Glu Ala Gly Phe Asp Trp Val Ser Tyr Val Ser Arg Arg His  
 225 230 235 240  
 ATC TAC TGC TCC GTC AAG TCA GAT TCG TCG ATC AGT TCC CAC GTG CAC 768  
 Ile Tyr Cys Ser Val Lys Ser Asp Ser Ser Ile Ser Ser His Val His  
 245 250 255  
 GGC TGC TTC ACG CCG GAG AGC ACA GCG CTG CTG GAG AGT GGA GTC CGG 816  
 Gly Cys Phe Thr Pro Glu Ser Thr Ala Leu Leu Glu Ser Gly Val Arg  
 260 265 270  
 AAG CCG CTC GGC GAG CTC TCT ATC GGA GAT CGT GTT TTG AGC ATG ACC 864  
 Lys Pro Leu Gly Glu Leu Ser Ile Gly Asp Arg Val Leu Ser Met Thr  
 275 280 285  
 GCC AAC GGA CAG GCC GTC TAC AGC GAA GTG ATC CTC TTC ATG GAC CGC 912  
 Ala Asn Gly Gln Ala Val Tyr Ser Glu Val Ile Leu Phe Met Asp Arg  
 290 295 300  
 AAC CTC GAG CAG ATG CAA AAC TTT GTG CAG CTG CAC ACG GAC GGT GGA 960  
 Asn Leu Glu Gln Met Gln Asn Phe Val Gln Leu His Thr Asp Gly Gly

- 40 -

|   |     |     |     |      |
|---|-----|-----|-----|------|
| 305   | 310 | 315 | 320 |      |
| GCA GTG CTC ACG GTG ACG CCG GCT CAC CTG GTT AGC GTT TGG CAG CCG |     |     |     | 1008 |
| Ala Val Leu Thr Val Thr Pro Ala His Leu Val Ser Val Trp Gln Pro |     |     |     |      |
| 325   | 330 | 335 |     |      |
| GAG AGC CAG AAG CTC ACG TTT GTG TTT GCG CAT CGC ATC GAG GAG AAG |     |     |     | 1056 |
| Glu Ser Gln Lys Leu Thr Phe Val Phe Ala His Arg Ile Glu Glu Lys |     |     |     |      |
| 340   | 345 | 350 |     |      |
| AAC CAG GTG CTC GTA CGG GAT GTG GAG ACG GGC GAG CTG AGG CCC CAG |     |     |     | 1104 |
| Asn Gln Val Leu Val Arg Asp Val Glu Thr Gly Glu Leu Arg Pro Gln |     |     |     |      |
| 355   | 360 | 365 |     |      |
| CGA GTG GTC AAG TTG GGC AGT GTG CGC AGT AAG GGC GTG GTC GCG CCG |     |     |     | 1152 |
| Arg Val Val Lys Leu Gly Ser Val Arg Ser Lys Gly Val Val Ala Pro |     |     |     |      |
| 370   | 375 | 380 |     |      |
| CTG ACC CGC GAG GGC ACC ATT GTG GTC AAC TCG GTG GCC GCC AGT TGC |     |     |     | 1200 |
| Leu Thr Arg Glu Gly Thr Ile Val Val Asn Ser Val Ala Ala Ser Cys |     |     |     |      |
| 385   | 390 | 395 | 400 |      |
| TAT GCG GTG ATC AAC AGT CAG TCG CTG GCC CAC TGG GGA CTG GCT CCC |     |     |     | 1248 |
| Tyr Ala Val Ile Asn Ser Gln Ser Leu Ala His Trp Gly Leu Ala Pro |     |     |     |      |
| 405   | 410 | 415 |     |      |
| ATG CGC CTG CTG TCC ACG CTG GAG GCG TGG CTG CCC GCC AAG GAG CAG |     |     |     | 1296 |
| Met Arg Leu Leu Ser Thr Leu Glu Ala Trp Leu Pro Ala Lys Glu Gln |     |     |     |      |
| 420   | 425 | 430 |     |      |
| TTG CAC AGT TCG CCG AAG GTG GTG AGC TCG GCG CAG CAG CAG AAT GGC |     |     |     | 1344 |
| Leu His Ser Ser Pro Lys Val Val Ser Ser Ala Gln Gln Gln Asn Gly |     |     |     |      |
| 435   | 440 | 445 |     |      |
| ATC CAT TGG TAT GCC AAT GCG CTC TAC AAG GTC AAG GAC TAC GTG CTG |     |     |     | 1392 |
| Ile His Trp Tyr Ala Asn Ala Leu Tyr Lys Val Lys Asp Tyr Val Leu |     |     |     |      |
| 450   | 455 | 460 |     |      |
| CCG CAG AGC TGG CGC CAC GAT TGA                                 |     |     |     | 1416 |
| Pro Gln Ser Trp Arg His Asp                                     |     |     |     |      |
| 465   | 470 |     |     |      |

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 471 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

- 41 -

Met Asp Asn His Ser Ser Val Pro Trp Ala Ser Ala Ala Ser Val Thr  
1 5 10 15  
Cys Leu Ser Leu Gly Cys Gln Met Pro Gln Phe Gln Phe Gln Phe Gln  
20 25 30  
Leu Gln Ile Arg Ser Glu Leu His Leu Arg Lys Pro Ala Arg Arg Thr  
35 40 45  
Gln Thr Met Arg His Ile Ala His Thr Gln Arg Cys Leu Ser Arg Leu  
50 55 60  
Thr Ser Leu Val Ala Leu Leu Ile Val Leu Pro Met Val Phe Ser  
65 70 75 80  
Pro Ala His Ser Cys Gly Pro Gly Arg Gly Leu Gly Arg His Arg Ala  
85 90 95  
Arg Asn Leu Tyr Pro Leu Val Leu Lys Gln Thr Ile Pro Asn Leu Ser  
100 105 110  
Glu Tyr Thr Asn Ser Ala Ser Gly Pro Leu Glu Gly Val Ile Arg Arg  
115 120 125  
Asp Ser Pro Lys Phe Lys Asp Leu Val Pro Asn Tyr Asn Arg Asp Ile  
130 135 140  
Leu Phe Arg Asp Glu Glu Gly Thr Gly Ala Asp Gly Leu Met Ser Lys  
145 150 155 160  
Arg Cys Lys Glu Lys Leu Asn Val Leu Ala Tyr Ser Val Met Asn Glu  
165 170 175  
Trp Pro Gly Ile Arg Leu Leu Val Thr Glu Ser Trp Asp Glu Asp Tyr  
180 185 190  
His His Gly Gln Glu Ser Leu His Tyr Glu Gly Arg Ala Val Thr Ile  
195 200 205  
Ala Thr Ser Asp Arg Asp Gln Ser Lys Tyr Gly Met Leu Ala Arg Leu  
210 215 220  
Ala Val Glu Ala Gly Phe Asp Trp Val Ser Tyr Val Ser Arg Arg His  
225 230 235 240  
Ile Tyr Cys Ser Val Lys Ser Asp Ser Ser Ile Ser Ser His Val His  
245 250 255  
Gly Cys Phe Thr Pro Glu Ser Thr Ala Leu Leu Glu Ser Gly Val Arg  
260 265 270  
Lys Pro Leu Gly Glu Leu Ser Ile Gly Asp Arg Val Leu Ser Met Thr  
275 280 285  
Ala Asn Gly Gln Ala Val Tyr Ser Glu Val Ile Leu Phe Met Asp Arg  
290 295 300

- 42 -

Asn Leu Glu Gln Met Gln Asn Phe Val Gln Leu His Thr Asp Gly Gly  
 305            310            315            320  
 Ala Val Leu Thr Val Thr Pro Ala His Leu Val Ser Val Trp Gln Pro  
 325            330            335  
 Glu Ser Gln Lys Leu Thr Phe Val Phe Ala His Arg Ile Glu Glu Lys  
 340            345            350  
 Asn Gln Val Leu Val Arg Asp Val Glu Thr Gly Glu Leu Arg Pro Gln  
 355            360            365  
 Arg Val Val Lys Leu Gly Ser Val Arg Ser Lys Gly Val Val Ala Pro  
 370            375            380  
 Leu Thr Arg Glu Gly Thr Ile Val Val Asn Ser Val Ala Ala Ser Cys  
 385            390            395            400  
 Tyr Ala Val Ile Asn Ser Gln Ser Leu Ala His Trp Gly Leu Ala Pro  
 405            410            415  
 Met Arg Leu Leu Ser Thr Leu Glu Ala Trp Leu Pro Ala Lys Glu Gln  
 420            425            430  
 Leu His Ser Ser Pro Lys Val Val Ser Ser Ala Gln Gln Gln Asn Gly  
 435            440            445  
 Ile His Trp Tyr Ala Asn Ala Leu Tyr Lys Val Lys Asp Tyr Val Leu  
 450            455            460  
 Pro Gln Ser Trp Arg His Asp  
 465            470

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 221 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Cys Gly Pro Gly Arg Gly Xaa Gly Xaa Arg Arg His Pro Lys Lys Leu

1            5            10            15

Thr Pro Leu Ala Tyr Lys Gln Phe Ile Pro Asn Val Ala Glu Lys Thr

20            25            30

Leu Gly Ala Ser Gly Arg Tyr Glu Gly Lys Ile Xaa Arg Asn Ser Glu

35            40            45

Arg Phe Lys Glu Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys

50            55            60

- 43 -

Asp Glu Glu Asn Thr Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys  
 65              70              75              80  
 Asp Lys Leu Asn Xaa Leu Ala Ile Ser Val Met Asn Xaa Trp Pro Gly  
 85              90              95  
 Val Xaa Leu Arg Val Thr Glu Gly Trp Asp Glu Asp Gly His His Xaa  
 100              105              110  
 Glu Glu Ser Leu His Tyr Glu Gly Arg Ala Val Asp Ile Thr Thr Ser  
 115              120              125  
 Asp Arg Asp Xaa Ser Lys Tyr Gly Xaa Leu Xaa Arg Leu Ala Val Glu  
 130              135              140  
 Ala Gly Phe Asp Trp Val Tyr Tyr Glu Ser Lys Ala His Ile His Cys  
 145              150              155              160  
 Ser Val Lys Ala Glu Asn Ser Val Ala Ala Lys Ser Gly Gly Cys Phe  
 165              170              175  
 Pro Gly Ser Ala Xaa Val Xaa Leu Xaa Xaa Gly Gly Xaa Lys Xaa Val  
 180              185              190  
 Lys Asp Leu Xaa Pro Gly Asp Xaa Val Leu Ala Ala Asp Xaa Xaa Gly  
 195              200              205  
 Xaa Leu Xaa Xaa Ser Asp Phe Xaa Xaa Phe Xaa Asp Arg  
 210              215              220

**(2) INFORMATION FOR SEQ ID NO:22:**

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 167 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: peptide  
 (v) FRAGMENT TYPE: internal  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:  
 Cys Gly Pro Gly Arg Gly Xaa Xaa Xaa Arg Arg Xaa Xaa Xaa Pro Lys  
 1              5              10              15  
 Xaa Leu Xaa Pro Leu Xaa Tyr Lys Gln Phe Xaa Pro Xaa Xaa Xaa Glu  
 20              25              30  
 Xaa Thr Leu Gly Ala Ser Gly Xaa Xaa Glu Gly Xaa Xaa Xaa Arg Xaa  
 35              40              45  
 Ser Glu Arg Phe Xaa Xaa Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile  
 50              55              60  
 Phe Lys Asp Glu Glu Asn Xaa Gly Ala Asp Arg Leu Met Thr Xaa Arg

- 44 -

65            70            75            80  
Cys Lys Xaa Xaa Xaa Asn Xaa Leu Ala Ile Ser Val Met Asn Xaa Trp  
85            90            95  
Pro Gly Val Xaa Leu Arg Val Thr Glu Gly Xaa Asp Glu Asp Gly His  
100            105            110  
His Xaa Xaa Xaa Ser Leu His Tyr Glu Gly Arg Ala Xaa Asp Ile Thr  
115            120            125  
Thr Ser Asp Arg Asp Xaa Xaa Lys Tyr Gly Xaa Leu Xaa Arg Leu Ala  
130            135            140  
Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu Ser Xaa Xaa His Xaa  
145            150            155            160  
His Xaa Ser Val Lys Xaa Xaa  
165

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number  
WO 01/64238 A3(51) International Patent Classification<sup>7</sup>: A61K 38/17.  
31/472, 31/496, 31/553, 31/7076, 48/00, A61P 19/00.  
35/00LESER-REIFF, Ulrike [DE/DE]: Weidenweg 6, 82377  
Penzberg (DE). BURTSCHER, Helmut [US/US]: Am  
Aehrenanger 10, 82392 Habach (DE).

(21) International Application Number: PCT/US01/06450

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 28 February 2001 (28.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/186,058 29 February 2000 (29.02.2000) US(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 60/186,058 (CIP)  
Filed on 29 February 2000 (29.02.2000)

Published:

— with international search report

(71) Applicant (for all designated States except US): CURIS,  
INC. [US/US]; 61 Moulton Street, Cambridge, MA 02138  
(US).(88) Date of publication of the international search report:  
7 February 2002

(72) Inventors; and

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.(75) Inventors/Applicants (for US only): ZEHENTNER,  
Barbara [DE/DE]; Bachstrasse 8, 84174 Viecht (DE).

WO 01/64238 A3

(54) Title: METHODS AND COMPOSITIONS FOR REGULATING ADIPOCYTES

(57) Abstract: The present application relates to a method for modulating the formation and/or maintenance of adipocyte tissue by ectopically contacting adipocyte cells, especially adipocyte stem/progenitor cells, *in vitro* or *in vivo*, with a hedgehog therapeutic or ptc therapeutic in an amount effective to alter the growth state of the treated cells, e.g., relative to the absence of administration of the hedgehog therapeutic or ptc therapeutic.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/06450

|                                     |           |            |            |            |             |
|-------------------------------------|-----------|------------|------------|------------|-------------|
| A. CLASSIFICATION OF SUBJECT MATTER |           |            |            |            |             |
| IPC 7                               | A61K38/17 | A61K31/472 | A61K31/496 | A61K31/553 | A61K31/7076 |
|                                     | A61K48/00 | A61P19/00  | A61P35/00  |            |             |

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, PAJ, WPI Data, MEDLINE, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No |
|------------|---|----------------------|
| X          | WO 99 00117 A (ONTOGENY)<br>7 January 1999 (1999-01-07)<br>page 98 -page 101  | 24                   |
| A          |   | 1-23, 25,<br>26      |
| A          | BLAKE PEPINSKI R ET AL: "Identification<br>of a palmitic acid-modified form of human<br>sonic hedgehog"<br>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN<br>SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE,<br>MD, US,<br>vol. 273, no. 22,<br>29 May 1998 (1998-05-29), pages<br>14037-14045, XP002094956<br>ISSN: 0021-9258<br>--- |                      |
|            | -/-   |                      |

Further documents are listed in the continuation of box C

Patent family members are listed in annex

° Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

13 November 2001

22/11/2001

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/06450

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |   |                       |
|--|---|-----------------------|
| Category   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
| P,X  | ZEHENTNER BARBARA K ET AL: "BMP-2 and sonic hedgehog have contrary effects on adipocyte-like differentiation of C3H10T1/2 cells."<br>DNA AND CELL BIOLOGY,<br>vol. 19, no. 5, May 2000 (2000-05), pages<br>275-281, XP002182604<br>ISSN: 1044-5498<br>the whole document<br>----- | 1-26                  |
| P,A  | WO 00 51628 A (BIOGEN)<br>8 September 2000 (2000-09-08)<br>page 76 -page 78<br>-----  | 1-26                  |

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1, 8-18, 21 and 23-26 partially relate to a compound defined by reference to a desirable characteristic or property, namely being a tpc therapeutics binding to patched or mimicking hedgehog mediated patched signal transduction or being an antisense construct inhibiting the signal transduction of patched or being a PKA inhibitor.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds mentioned in the description on page 64 line 30 to page 67 line 6 (PKA inhibitors) or on page 68 line 28 to page 69 line 15 (antisense constructs).

The term "small organic molecules" used in claim 9 covering so many possible compounds and being not further defined in the description than as a possible PKA inhibitor or as an agonist or antagonist of hedgehog protein the search for this claim has been limited to the definition indicated above.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**INTERNATIONAL SEARCH REPORT**

## Information on patent family members

International Application No

PCT/US 01/06450

| Patent document cited in search report | Publication date |                | Patent family member(s)               | Publication date                       |
|--|------------------|----------------|---------------------------------------|--|
| WO 9900117                             | A 07-01-1999     | AU<br>WO       | 8173098 A<br>9900117 A2               | 19-01-1999<br>07-01-1999               |
| WO 0051628                             | A 08-09-2000     | AU<br>EP<br>WO | 3616000 A<br>1119368 A2<br>0051628 A2 | 21-09-2000<br>01-08-2001<br>08-09-2000 |